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1.1 Transition Metal-Catalyzed Direct C–H Bond Functionalization 
The selective construction of heterocyclic structural motifs is of key importance for many state 
of the art applications of synthetic organic chemistry. Heteroaromatic compounds with 




Figure 1.1: Examples of naturally occurring and bioactive heterocycles. 
 
The de novo synthesis of naturally occurring molecules containing heteroatoms on large scale 
is a challenging task and a perpetual driving force for the development of new synthetic 
methodologies. Especially the chemo- and site-selective formation of C–C bonds remains as 
an ongoing inspiration of synthetic organic chemists. As a result, considerable progress was 
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made on transition metal-catalyzed C–C coupling reactions during the past decades.[5-9] In this 
context, it is important to mention that in 2010 the Nobel prize in chemistry was awarded jointly 
to R. F. Heck, E. Negishi and A. Suzuki for their significant contributions to the development 
of palladium-catalyzed cross-coupling reactions.[10] 
In these transformations, the palladium catalyst promotes the reaction between an aryl- or 
vinyl(pseudo)halide 1 and an organometallic reagent 2 to the cross-coupled product 3 (Scheme 
1.1). Other metals are also known to achieve these transformations by their catalytic mode of 
actions in reactions, for example nickel or copper. Although these reactions are very efficient, 
they feature a significant disadvantage, namely that prefunctionalized starting materials are a 





Scheme 1.1: Palladium-catalyzed cross-coupling reactions. 
 
With respect to ecological and economical aspects of organic synthesis, new concepts for more 
sustainable transition metal-catalyzed direct C–H functionalizations have been conceived.[13,14] 
The direct C–H functionalization has the advantage that the prefunctionalization of the starting 
materials is not required, which is accompanied with a significant reduction of waste material 
4. The Scheme 1.2 shows the three different strategies that are widely used for the 
transformations in transition metal-catalyzed direct C–H functionalizations.[15] The direct 
cleavage of C–H bonds and their transformation into C–Het bonds has become a compelling 
research area in modern chemistry geared to achieving complex target structures. These 
protocols offer appealingly short routes to natural products, pharmaceuticals, and 
agrochemicals. 
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Scheme 1.2: Strategies for the transition metal-catalyzed direct C–H functionalizations. 
 
In analogy to traditional cross-coupling chemistry, Scheme 1.2a shows the coupling between 
5 with an unactivated C–H bond and an aryl- or vinyl(pseudo)halide and halides 6. The reaction 
demonstrated in (Scheme 1.2b) works inversely: The C–H bond in an aryl- or vinyl-substrate 
is functionalized with an organometallic reagent 7. For these kind of reactions, however, the 
use of an oxidant is mandatory. The Scheme 1.2c describes the dehydrogenative coupling 
between substrates 5 through activation of two C–H bonds and the formal generation of 
dihydrogen. However, an oxidant is also needed for this type of reactions. Although a number 
of transformations in which a C–H bond is functionalized with participation of a transition 
metal-activated ligand via a transition metal-induced radical-chain mechanism are known, 
Shilov classifies only specific types of reactions as "true C–H activation".[16] In these reactions, 
the metal is directly involved in the cleavage of the C–H bond and a M–C –bond is formed. 
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Different mechanistic pathways, four of which are shown in Scheme 1.3 as the traditionally 
most generally accepted ones, can take place for these processes.[17-20] 
 
Scheme 1.3: Different mechanisms for transition metal-catalyzed C–H activation. 
 
The first pathway shown in Scheme 1.3a is the oxidative addition of a C–H bond to the metal 
center. This process can occur for electron-rich and low-valent late transition metals, such as 
rhenium, iron, ruthenium, osmium, iridium and platinum. If late- or post-transition metals are 
employed in high oxidation stages, including palladium(II), platinum(II), platinum(IV), 
mercury(II), the mechanism is frequently shifted towards an electrophilic substitution (Scheme 
1.3b). However, early group 3 and 4 transition metals as well as lanthanides cannot undergo 
oxidative addition. For these metals –bond metathesis (SBM) usually takes place (Scheme 
1.3c). C–H activation can also proceed via 1,2-addition to unsaturated Π=X bonds (Scheme 
1.3d). As a novel mode of action, an increasing mode of C–H activation, many of reactions 
proceeds via "base-assisted" C–H activation.[19] For instance, a carboxylate-ligand on the 
transition metal can act as base to promote the abstraction of the proton, along with an 
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electrophilic activation of the C–H bond by the metal. Proton abstraction by the carboxylate 
and C–M bond formation take place simultaneously. Such transition states 10 have been 
described as "concerted-metalation-deprotonation" (CMD)[20] or "amphiphilic metal-ligand 
activation" (AMLA)[17] and the mechanism can be generalized as shown in Scheme 1.4.[19,21-23] 
 
 
Scheme 1.4: Mechanism for the carboxylate-assisted C–H activation. 
 
Various calculations showed that a six-membered transition state, where the carboxylate is still 
bound to the transition metal, is favored over a four-membered transition state as for example, 
shown in the differences in energy between the potential transition-states of the iridium-
catalyzed C–H activation in benzene (Figure 1.2).[35b,35c] 
 
 
Figure 1.2: Differences in energy between a 4-membered and 6-membered TS. 
Nevertheless, in case of hydroxyl- or alkoxyl-ligands only 4-membered transition states are 
possible. This transition state appears to be a SBM (Scheme 1.3c). However, calculations by 
Goddard III et al. revealed that, in contrast to SBM, the M–O bond is based on a different 
orbital than the newly formed H–O bond.[25,26]  Herein, a four-membered transition state was 
proposed and mechanistic pathway is termed as "internal electrophilic substitution" (IES)[26]. 
In this context, theoretical calculations have offered new insight into the mechanism of base-
assisted C–H metalation. Based on computational studies, Davies and Macgregor described 
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such reaction as an "ambiphilic metal-ligand activation" (AMLA)[35a] whereas Fagnou used the 
term "concerted-metalation-deprotonation" (CMD)[36]. Both proposals favor a similar six-
membered transition state, however, Davies and Macgregor suggested an agostic interaction 
between the metal center and the C–H bond (Figure 1.3). An activation or strained model was 
used to compare the performance of hydroxide and acetate, whether the later can access the 
both four-membered and six-membered transition states (Scheme 1.4).[35b] Although the 
computed barriers of >40kcal mol-1 are rather high for different processes involved, the 
different transition state geometries show the domination by interaction with base.[35c] This can 
be rationalized as base(acetate)-assisted-intermolecular electrophilic substitution-type (BIES) 
C−H metalation event.[51b,55] 
 
Figure 1.3: Proposed transition state for base-assisted C–H activation. 
 
 
1.2 Site-Selectivity and Directing Groups in C–H Bond Functionalization 
 
The main challenge in C–H activation chemistry is the chemo- and site-selective cleavage of 
specific C–H bonds. The selective conversion of methane to methanol, for instance, is of great 
importance with respect to the potential use of methanol as a fuel.[27] However, the 
chemoselective oxidation of alkanes is still a challenging task, as alcohols and aldehydes tend 
to be more reactive than the hydrocarbons themselves thus resulting in overoxidation. Radical-
based reactions, on the other side, are often not selective enough and lead to product mixtures. 
Scheme 1.5a shows the early catalytic system which was developed by Shilov for the selective 
methane activation.[16] 
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Scheme 1.5: Methane activation by Shilov and Periana. 
 
Besides the selective C–H activation of aliphatic compounds, the selective functionalization of 
aromatic and heteroaromatic C–H bonds is of significant importance, as an ample number of 
fine chemicals consists of aromatic moieties. On the one hand, C–H activation on aromatic 
system might be accelerated due to the precoordination of the aromatic –system to the 
transition metal.[29-31] On the other hand, the site-selective C–H bond cleavage of functionalized 
arenes and heteroarenes remains a challenging task. 
In the early 1970s, work by Shaw and Gaunt highlighted the importance of stoichiometric 
amounts of NaOAc for successful cyclometalation of N, N-dimethylaminomethylferrocene 
(13) (Scheme 1.6).[32] Subsequently, Reutov and co-workers found that carboxylic acids are 
competent additives for the same transformation.[33,34] More importantly, a transition state of 
concerted carboxylate-assisted intermolecular deprotonation (15)[19,32-34] was specifically 
proposed. 
The most common way to achieve site-selectivity in direct C–H bond activation on arenes is 
the use of a directing group, which is usually placed in the ortho-position to the C–H bond to 
be functionalized (Scheme 1.7). The directing group bears a heteroatom with a lone pair of 
electrons and can thus coordinate to the transition metal complex [TM]. 
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Scheme 1.7: Principle of a directing group in transition metal-catalyzed C–H activation. 
 
In the past decade, a variety of different directing groups, some of which are shown in Figure 
1.4, have been successfully applied for palladium-, nickel-, rhodium-, ruthenium- or iridium-
catalyzed direct C–C and C–heterobond reactions.[14,15,30–32]  
 
 
Figure 1.4: Different directing-groups in transition-metal catalyzed C–H activation. 
 
C–H bonds are ubiquitous in nature, a feature which on the one hand facilitates their usage as 
starting material for elaboration of more complex structures. However, on the other hand, this 
makes controlling the site-selectivity of C–H functionalization a great challenge. In 
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electrophilic aromatic substitution, it has been well established that electron-donating 
substituents direct incoming electrophiles to the ortho- (17b) and para-positions (17c), whereas 
electron-withdrawing substituents lead to the meta- position (17a) (Scheme 1.8).  
 
 
Scheme 1.8: Site-selectivity in electrophilic aromatic substitution. 
 
Based on pioneering work by Lewis,[37] in 1993 Murai et al. described the first example of a 
directed catalytic C–H bond functionalization of aromatic ketones 20 (Scheme 1.9). This 
reaction can also be considered as a hydroarylation of olefin 21. 
 
 
Scheme 1.8a: Hydroarylation by Lewis. 
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Herein the carbonyl-functionality served as the directing group for the ruthenium-catalyst. 
Further intermediate developments showed that also other directing groups and other 
ruthenium catalysts can be used for these hydroarylations, with recent advances from the 
groups of Genet and Ackermann.[38-43] 
 
Scheme 1.9: Hydroarylation by Murai. 
 
1.3 Ruthenium-Catalyzed Direct Arylations with Organometallic Reagents 
 
A ruthenium-catalyzed[41b] chelation-assisted approach was developed based on the use of 
arylboronates[41c] as arylating agents.[41] Thereby, a regioselective ruthenium-catalyzed 
arylation of substrates bearing an oxygen-containing directing group was achieved. A variety 
of aromatic ketones were efficiently arylated in pinacolone using aryl boronates 25 with both 
electron-donating, as well as electron-withdrawing substituents (Scheme 1.10). 
 
 
Scheme 1.10. Ruthenium-catalyzed arylation of ketone in pinacolone. 
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Mechanistic studies revealed that pinacolone acts here not only as the solvent, but also as an 
oxidizing agent. Additionally, inter- and intramolecular competition experiments with 
deuterium-labeled ketones provided evidence for a pre-coordination of the ruthenium catalyst 
by the oxygen of the aryl ketone.[41d] Thus, a mechanism was elaborated consisting of (a) 
coordination, (b) oxidative addition to yield an ortho-metalated ruthenacycle, (c) insertion of 




Scheme 1.11. Proposed mechanism for ruthenium-catalyzed arylations of ketones 24. 
 
An extension of this reaction to the functionalization of C(sp3)–H bonds was more recently 
reported. Thus, pyrrolidines 35 were efficiently arylated with substituted arylboronates in 
pinacolone, yielding, however, often mixtures of diastereomers (Scheme 1.12).[41f] 
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Scheme 1.12. Ruthenium-catalyzed functionalization of a C(sp3)–H bond in pyrrolidine 35. 
 
Jun and coworkers used a related approach for a ruthenium-catalyzed arylation of 
aldimines.[41g] Here, a pyridyl-substituent allowed for the selective arylation with arylboronates 
39. Methyl vinyl ketone (40) as additive led to high isolated yields of the corresponding ketones 
(Scheme 1.13). 
 
Scheme 1.13. Ruthenium-catalyzed direct arylation of aldimine 38. 
 
A catalytic system comprising [RuCl2(6-C6H6)]2 and PPh3 was developed by Oi, Inoue and 
coworkers for direct arylations of pyridine derivatives using aryl bromides as the electrophiles 
in NMP as the solvent (Scheme 1.14).[41h] 
 
 
Scheme 1.14. Ruthenium-catalyzed direct arylation of pyridine 43 with bromide 4. 
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The same protocol proved applicable to directed arylations of imines, imidazolines and 
oxazolines as pronucleophilic starting materials in NMP (Scheme 1.15).[41i] Transformations 
of the later substrates should prove useful, since 2-oxazolinyl substituents 46 can be easily 
converted into a variety of valuable functionalities.[41j] 
 
Scheme 1.15. Ruthenium-catalyzed direct arylation with heteroaryl bromide 47. 
 
Also alkenyl C–H bonds were directly functionalyzed with aryl bromides 47 using this catalytic 





Scheme 1.16. Ruthenium-catalyzed direct arylation of alkene 49. 
 
A phosphine ligand-free ruthenium-catalyzed direct arylation with aryl bromides as 
electrophiles 4 was disclosed. Notably, the use of inexpensive RuCl3·(H2O)n as catalyst 
allowed for economically attractive C–H functionalizations of pyridine 43, oxazoline 46 and 
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Scheme 1.17. Ruthenium-catalyzed phosphine free direct arylation of pyridine 43. 
 
Among aryl halides, chlorides are the most useful simple class of electrophilic substrates, due 
to their lower cost and wide diversity of commercially available compounds.[41] The direct 
arylations with aryl chlorides were until recently only generally applicable in palladium-
catalyzed intramolecular transformations.[41n] However, a broadly applicable Intermolecular 
C–H arylation of various arenes with aryl chlorides was accomplished by Ackermann with a 
ruthenium complex derived from secondary phosphine oxide (SPO) (1-Ad)2P(O)H as preligand 
(Scheme 1.18).[41o] Thereby, pyridine and ketimine derivatives were efficiently C–H arylated 
with functionalized electron-deficient, and electron-rich, thus for an oxidative addition 
electronically deactivated, aryl chlorides. 
 
 
Scheme 1.18. Ruthenium-catalyzed direct arylation with aryl chlorides 54 and 55. 
 
Importantly, tosylates 61 are more stable towards hydrolysis than triflates. Thus, protocols for 
traditional cross-coupling reactions were developed by the group of Ackermann using 
ruthenium complex derived from heteroatom-substituted secondary phosphine oxide (HASPO) 
preligand 59[41p] allowed for C–H arylations with various tosylates 58.[41q]. Selective mono- or 
diarylation reactions could be achieved through the judicious choice of the corresponding 
electrophile (Scheme 1.19). Thus, while aryl chlorides 60 gave rise to diarylated products, the 
use of aryl tosylates 61 cleanly afforded the corresponding monoarylated derivatives. 
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Scheme 1.19. Selective ruthenium-catalyzed direct arylations through choice of electrophile. 
 
Direct arylations of pronucleophiles with inexpensive aryl chlorides 60 proceeded with high 
efficacy and excellent diastereoselectivity using either ruthenium carbenes or a ruthenium 
complex derived from air-stable secondary phosphine oxide preligand (1-Ad)2P(O)H as 
catalyst (Scheme 1.19).[41r] 
 
1.3 Transition Metal-Catalyzed Oxidative C–H functionalization with 
Alkenes and Alkynes  
 
1.3.1 Transition Metal-Catalyzed Oxidative C–H Alkenylation 
 
Palladium-catalyzed oxidative cross-coupling reactions were discovered by Fujiwara and 
Moritani in the late 1960s.[44] Recent years have witnessed its wide application in the 
preparation of numerous synthetically and practically useful heterocycles, such as 
isoquinolines, isoquinolones, isocoumarins, -pyrones and 2-pyridines.[47] In 1979, Hong et al. 
reported rhodium-catalyzed styrene synthesis using simple arenes and ethylene in the presence 
of CO.[48] In 2007, Satoh and Miura reported the rhodium-catalyzed oxidative alkenylation of 
easily accessible benzoic acid using acrylates, acryl amides or nitriles as alkenylating reagent. 
The oxidant was stoichiometric amounts of Cu(OAc)2∙H2O in the presence of catalytic 
Cu(OAc)2·H2O.
[49] Later, Glorius and coworkers reported the rhodium-catalyzed alkenylations 
of acetanilides,[50] acetophenones and benzamides.[51] In contrast, Ackermann reported 
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independently C–H alkenylation of acetanilide 69, benzamide 70, carbamates 71, and sulfonic 
acid derivatives 72 (Scheme 1.20) with inexpensive ruthenium(II) catalysts.[51b-51e,174] 
 
 
Scheme 1.20: Selected examples of ruthenium(II)-catalyzed oxidative alkenylations. 
 
1.5 Transition Metal-Catalyzed Oxidative Alkyne Annulation 
 
Larock et al. in 1991 reported the efficient palladium-catalyzed alkyne annulation with 
substituted haloarenes.[52] Thus, a number of synthetically valuable protocols have been 
developed based on the Larock-type heterocyle synthesis (Scheme 1.21)[53] 
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Scheme 1.21: Larock alkyne annulation. 
 
It has become a challenging research target to combine transition metal-catalyzed C–H bond 
metalation and alkyne annulation in a one pot fashion. Various procedures (Scheme. 1.22) have 
been reported with rhodium as the catalyst and Cu(OAc)2·H2O as the oxidant.
[54] 
Later, the Ackermann group as well as the group of Lee and Sahoo accomplished the 
ruthenium(II)-catalyzed direct C–H olefinations of benzamide 79, carboxylic acids 80, phenol 
81, phosphates 83 and sulfoximines 84.[57a-57c]  
 
Scheme 1.22: Selected examples of ruthenium(II)-catalyzed oxidative annulations. 
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1.5 Transition Metal-Catalyzed Alkenylation and Alkyne Annulation by 
C–H/N–O Cleavage  
 
To the development of oxidative alkenylation and alkyne annulations subsequently utilized C–
H/N–O cleavages. The advantage of this method is that the substrate itself acts as an 'internal 
oxidant' via N–O cleavage. Thus external oxidants such as Cu(OAc)2·H2O are no longer 
needed. Fagnou and coworkers initiated the rhodium(III)-catalyzed C–H alkyne annulation 
with hydroxamic acid esters substrates. Later, the Fagnou group as well as the Glorius group 
accomplished the rhodium(III)-catalyzed direct C–H olefinations of benzhydroxamic acid 
esters with "oxidizing directing group" methods.[55-57]  
Versatile ruthenium(II)-catalyzed alkyne annulations were discovered by the research group of 
Ackermann as well as explored by the groups of Li and Wang in 2011.[58-59] Oximes 88 proved 
to be effective internal oxidants. In 2012, Ackermann and co-workers reported the first cationic 
ruthenium(II) catalysts for alkyne annulations with oximes through C–H/N–O clevages 
(Scheme 1.23). Ruthenium(II)-catalyzed oxidative C–H bond alkenylation of N-




Scheme 1.23: Ruthenium(II)-catalyzed annulation by C–H/N–O bond functionalization. 
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1.6 Transition Metal-Catalyzed C–O Formations by C–H Activation  
 
Oxygenated aromatic molecules are key intermediates in organic synthesis and important 
structural components of useful pharmaceuticals, agrochemicals, polymers, and biologically 
active compounds.[62] For instance, phenol is a central commodity chemical in industry, which 
is largely produced in a three step synthesis (cumene process) starting from benzene and 
propylene. Although during recent years transition metal-catalyzed coupling of halogenated or 
boronated arenes (91) to phenol (92) have been discovered,[63-65] direct C–H oxygenation 
should be the optimal choice considering the atom-economy aspect of oxygenation reactions 
and its importance in further transformations in organic synthesis (Scheme 1.24). 
 
 
Scheme 1.24: Selected examples of metal-mediated phenol synthesis 92. 
 
Jintoku and Fujiwara in the early 1990’s, reported the palladium-catalyzed transformation of 
benzene (93) and molecular oxygen to phenol 92 (Scheme 1.24).[66] The palladium precursor 
was modified by the addition of 1,10-phenanthroline and dissolved in a mixture of benzene and 
acetic acid. The reaction proceeded at 180 °C under an atmosphere of oxygen (15 atm) and 
carbon monoxide (15 atm). The acetylated phenol (95) was monitored as a side product. 
Early examples of palladium-catalyzed ligand-directed C(sp2)–H bond oxygenation were 
reported by Crabtree and Sanford using PhI(OAc)2 as the stoichiometric oxidant (Scheme 
1.25).[67,174] A variety of pyridine derivatives (96) and other well decorated nitrogen-based 
substituents served as excellent DG, delivering ortho-acetoxylated products (97) in excellent 
yields. However, simple ketones and aldehydes did not undergo ortho-acetoxylation under 
these conditions, presumably because these are weakly-coordinating ligands for palladium. 
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 Scheme 1.25: Palladium-catalyzed C(sp2)–H bond oxygenation. 
 
Based on their mechanistic studies,[71,72] Sanford and coworkers proposed the catalytic cycle 
for palladium-catalyzed ortho-acetoxylation as shown in Scheme 1.26. First, ligand-directed 
C–H activation generates a cyclopalladated intermediate 98. Second, two-electron oxidation of 
the palladacycle generates the palladium(IV) species 99. Third, reductive elimination releases 
the product 100 and regenerates the palladium(II) catalyst.[73,74] 
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Scheme 1.26: Proposed mechanism for palladium-catalyzed ortho-acetoxylation 100. 
 
Oxgenations reactions have been studied thoroughly using inorganic peroxides, such as Oxone 
and K2S2O8.
[71] Yet, molecular oxygen is the optimal oxygen source considering the atom-
economy aspect. Recently, the group of Yu described a palladium(II)-based catalytic system 
that fetched the regioselective ortho-hydroxylation of potassium benzoates with the 
environmentally friendly molecular oxygen as the oxidant (Scheme 1.27).[73] The reaction rates 
were significantly increased in presence of stoichiometric benzoquinone (BQ) and thereby 
converted substrates (101) into desired ortho-hydroxylated product 102 in satisfying yield with 
atmospheric O2. They confirmed that the oxygen-atom incorporated with labeling experiments. 
into the hydroxylated product originated from molecular oxygen18O2. 
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Scheme 1.27: Palladium-catalyzed C(sp2)–H bond oxygenation. 
 
Recently, ruthenium-catalyzed hydroxylations of C–H bonds have been developed. Previous 
reports illustrated the RuO4-mediated hydroxylation of unactivated tertiary C(sp
3)–H bonds in 
hydrocarbons (103).[74-75] Du Bois and coworkers disclosed the C(sp3)–H hydroxylation with 
catalytic RuCl3·nH2O using KBrO3 as the stoichiometric oxidant, allowing the oxygenation of 
the weakest C–H bonds in substrates 103 (Scheme1.28).[76] Thus, this method is largely limited 
to tertiary alkyl C–H bonds.  
 
Scheme 1.28: Ruthenium-catalyzed C(sp3)–H bond oxygenation. 
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During the past few years a tremendous development in the ruthenium-catalyzed direct 
hydroxylation of stronger C(sp2)–H bonds in (hetro)arenes has been witnessed.[62] Rao and 
coworkers disclosed ruthenium-catalyzed ortho-hydroxylation with benzoic acid using K2S2O8 
or HIO3 as the oxidant,
[77] while Ackermann and coworkers employed the well-defined 
ruthenium(II)–biscarboxylate complex [Ru(O2CMes)2(p-cymene)] as well as inexpensive 
RuCl3∙nH2O in the hydroxylation reactions using hypervalent iodine reagents as the oxidant.
[78] 
The acidic reaction medium turned out to be crucial for chelation-assisted ortho-hydroxylations 
on (hetro)arene 43 with ester 107, amide 105, or even weakly-coordinated ketone 109 as the 
directing groups.[79-80] While previous studies had focused on arenes bearing electron-
withdrawing directing groups, the group of Ackermann[81] independently explored ruthenium-
catalyzed carbamate 111 as well as weakly co-ordinating aldehyde 113 ortho-hydroxylation 
with excellent site-selectivities. This mode of reaction could be used in further post-synthetic 
functionalizations of electron-rich phenol 111 and aldehyde 113 to respective valuable 
heterocycles (Scheme. 1.29).[82] 
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Scheme 1.29: Selected examples of Ruthenium(II)-catalyzed C(sp2)–H bond hydroxylation. 
 
 
Whilst previous studies on ruthenium(II)-catalyzed C(sp2)–H bond oxygenation of arenes 
bearing electron-withdrawing or electron-donating directing groups are limited to 
acetoxylation and hydroxylations of aromatics[78-81] the group of Sanford reported 
benzoxylation of 2-phenylpyridines with benzoate iodonium salts in the presence of a 
palladium catalyst.[83] In 2009, Cheng’s group demonstrated benzoxylation of 2-phenyl-
pyridines with benzoic acids in the presence of a rhodium catalyst.[84] A very recent report from 
the group of Jeganmohan showed the use of aryl-carboxylic acids 101 in ruthenium(II) 
catalysis to achieve the aryloxylation[87] of acetanilides 113 using inorganic oxidants (Scheme 
1.30).[88]  
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1.7  Transition Metal-Catalyzed C–N Bond Formations  
 
Aromatic amines are of significant importance owing to their widespread existence in natural 
products and artificial organic compounds.[89,90] Because of their unique properties, they have 
found broad applications in the prepration of various materials, such as agrochemicals, 
pharmaceutical agents, dyes, pigments, and polymers[91,92] As a consequence, developing 
practical and efficient preparations of amines has always been one of the central research topics 
in both academic and industrial areas.[62,93-97] 
As many efforts have been devoted to their synthesis, substantial achievements have been made 
over the past decades, and a large amount of different catalytic systems have been successfully 
established. The Ullmann–Goldberg condensation 121,[97-101] Chan–Lam coupling 124,[102-106] 
and Buchwald–Hartwig amination 124,[107-111] reactions are among the classic methodologies, 
which provide increasingly viable and practical tools for C–N bond formation (Scheme1.31). 
However, in all these cases, prefunctionalization of the arenes, such as for aryl halides, pseudo 
halides (4), or boronic acids (122) is necessary and the accompanying generation of undesired 
stoichiometric byproducts (hydrogen halides or the corresponding salts) cannot be avoided. 
Nowadays, with economic and environmental considerations becoming increasingly important, 
it is highly desirable to explore new strategies to circumvent those inherent limitations. 
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Scheme 1.31: Early examples of metal-catalyzed C(sp2)–H bond amination. 
 
Transition-metal-catalyzed direct C–H functionalization opens a new avenue for diverse C–N 
bond construction in a step and atom-economical way, without the requirement of 
prefunctionalization of the C–H coupling partners. With the assistance of various directing 
groups with different coordination abilities, the cyclometalation of numerous transition-metal 
catalysts can regioselectively occur on the ortho-position through the C–H activation process. 
Subsequently, a variety of amino sources have been successfully employed as effective 
coupling partners to install a nitrogen-containing functional group. In general, there are two 
approaches to fulfill the transformation. The first employs simple neutral amines, amides, or 
sulfonamides as effective aminating reagents. In this process, external oxidants are always 
required to facilitate the formation of the C–N bond. The second strategy utilizes preactivated 
amino sources, including N-chloroamine, N-hydroxycarbamate, O-acylhydroxylamine, 
nitrosobenzene, N-fluorobenzenesulfonimide (NFSI), azides, and 1,4,2-dioxazol-5-one, under 
redox-neutral conditions (Scheme 1.32).[19,46,112-118] 
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Scheme 1.32: Directing group assisted ortho- C–H amination. 
 
A more detailed mechanistic consideration is illustrated in Scheme 1.32a. Starting from the 
reactive metallacycle species 126, a variety of amidating reagents can coordinate to the metal 
center to form 128a, 128b, or 128c. Several classical amidating reagents were selected to 
describe the following different catalytic cycles. In general, there are two kinds of possible key 
intermediates involved in the above amidation process. One is a nitrene intermediate whereas 
the other is an imido intermediate. For the first case, organic azide and 1,4,2-dioxazol-5-one 
are the most widely used amino source, which release compound 128bb, although some 
primary amines could also deliver the nitrene intermediate 128ba, which subsequently 
proceeded through a stepwise nitrenoid transfer pathway to yield product 127 from 128ba. For 
the second type, some secondary amines in the presence of external oxidant and base could 
generate 128bc by direct metalation. The oxidative addition of secondary N-benzoate 
alkylamine to the metal center followed by reductive elimination yields 127. Finally, 
protonolysis by another molecule of the starting material 125 or acid would afford the final 
aminated product 127 and regenerate the reactive species 126. 
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Scheme 1.32a: Catalytic cycles for transition-metal-catalyzed ortho- C–H aminations. 
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Scheme 1.33: Selected examples of copper mediated C–H amination. 
 
In 2006, Yu’s group rendered the stoichiometric direct C–H amination of 2-phenylpyridine (43) 
with amine (130).[119] One equivalent of copper(II)_acetate was used as the catalyst and air 
acted as the oxidant (Scheme 1.33). However, in this preliminary work, only one example was 
provided without any substrate scope exploration. Later, a similar system was demonstrated by 
Chatani, albeit with lower efficiency. [120] Subsequently, several other groups developed 
different catalytic systems independently. Four years later, Li and co-workers developed an 
amidation of 2-arylpyridine derivatives 43 with amides by using a catalytic amount of CuBr in 
combination with tert-butyl peroxide (TBP) as the oxidant under neat conditions. This is a 
ligand and base-free transformation.[121] Satisfying yields were achieved for the secondary 
amides. However, when primary amides or TsNH2 were utilized, comparatively lower yields 
were obtained. Simultaneously, Nicholas’ group reported that a catalytic amount of Cu(OAc)2 
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mediated the amidation of 2-phenylpyridine (43) by using molecular oxygen as the terminal 
oxidant. A broad range of primary N-reagents, such as sulfonamides, carboxamides, and 
anilines, could all participate in the reaction, providing the expected amination products in 
moderate to good yields.[122] A trace amount of DMSO was added at high reaction temperatures 
of 160 °C to enable high catalytic turnover. In 2014, Shen reported a copper-catalyzed C–H 
amidation of N-pyrimidyl/pyridyl indoles 137 and arylpyridines 43 under aerobic conditions 
by using phthalimide as an aminating reagent.[123] Once again, the high reaction temperature of 
150 °C is the main limitation of this strategy. The Bolm group disclosed a rapid access to N-
arylated sulfoximines by copper-mediated C–H amination of 2-arylpyridines with 
sulfoximines. A stoichiometric amount of copper salt was required to ensure the efficiency 
when oxygen was used as the oxidant.[124]. Very recently, Li, Chen and coworkers presented a 
copper(I)bromide-catalyzed intermolecular dehydrogenative amidation of arenes with amides 
by using air as the terminal oxidant. A wide range of amides such as N-aryl amides, N-alkyl 
amides, benzamide derivatives, imides, and lactams all proved to be good coupling 
partners.[125]  
 
Scheme 1.34: Selected examples of rhodium(III)_catalyzed C–H bond amination. 
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Besides free amines which were explored using copper catalysts[119-125] N-chloroamine 143,[119-
120] N-aroyloxyamide 142 are another kind of efficient preactivated amino source. In 2013, the 
Glorius group reported a rhodium(III)-catalyzed C–H amidation using electron-deficient 
aroyloxycarbamates 139 as an efficient electrophilic nitrogen source (Scheme 1.34).[126] Both 
pyridine 43 and O-methyl hydroxamic acids served as efficient directing groups to give access 
to N-carbamate protected arylamines 140 under mild reaction conditions. The group of Yi, Xu 
and co-workers extended this type of preactivated amino reagent to include N-(2,4,6-
trichlorobenzoyloxy)amides, which proved to be effective coupling partners for the 
rhodium(III)_catalyzed direct regioselective C2-amidation of indoles bearing an N-2-pyrimidyl 
directing group 146.[127] 
 
Scheme 1.35: Selected examples of rhodium(III)_catalyzed C–H bond amination. 
 
The group of Chang disclosed the amidation of 2-phenylpyridine (43) with tosyl azide 149 
(TsN3) which was efficiently catalyzed by a cationic Cp*Rh(III)
_species and which was 
generated in situ by treating [RhCp*Cl2]2 with a silver salt (Scheme 1.35).
[128] Besides pyridine 
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43, quinoline 135, pyrazole 51, and oxime 117 as well as purine 160 could also be used as good 
chelation groups to promote the amidation with moderate to good yields. In addition, the 
reaction could be scaled up.[129] Since then, TsN3 149 has become a popular amidating reagent 
for various amidation processes. For instance, Zhou, Li et al. developed a rhodium-catalyzed 
direct C2-amidation of indoles bearing a 2-pyrimidyl unit as a directing group through C–H 
activation by using sulfonyl azides 149-153 as the amine source.[130] In their work, ten 
equivalents of water were added as an additive to enhance the efficiency. Recently, our group 
also made some contributions to this area. 
 
Scheme 1.36: Selected examples of Iridium(III)_catalyzed C–H bond amination. 
 
Besides rhodium catalysis, it is reasonable to investigate the catalytic ability of iridium, which 
is in group 9 and just below rhodium in the periodic table.[131] Among others Chang’s group 
continued to explore [Cp*Ir(III)]-catalyzed C–H aminations by using organoazides 165-
167.[132-141] Because the catalyst precursor, [IrCp*Cl2]2 is structurally and electronically 
comparable the previously used [RhCp*Cl2]2 (Scheme 1.35).
[121-125] They succeeded in the 
iridium–catalyzed intermolecular C–H amidation of arene assisted by various conventional 
directing groups, including benzamide 138, removable carbamate 163, ketoxime 117, pyridine 
43, pyrazole 51, oxazoline 46, benzoxazole 175, isoquinoline 176, and acyl anilide 113. 
(Scheme 1.36)[132-141] Bolm and co_workers extended this methodology in mechanochemistry 
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under solvent-free conditions in a ball mill.[133] Furthermore, by adding an acid additive to 
accelerate the rate-determining, product-releasing step, they succeeded in a remote 
regioselective C–H amidation of quinoline N-oxides 164 at the 8-position under mild 
conditions.[134,135] In addition, by the combination of acetic acid and lithium carbonate as 
additives, iridium was able to catalyze the direct C–H amidation of weakly coordinating esters 
107 and ketones 109 with various sulfonyl azides 149-153. Moreover, carboxylic acid 101 
could also be utilized as a traceless directing group in the Ir-catalyzed direct C–H amidation 
with sulfonyl azide 149. (Scheme 1.36).[136,137] Subsequent protodecarboxylation of the ortho-
amidated benzoic acid 174 product could be mediated by Pd(OAc)2 under heating. The two 
tandem reactions were compatible to enable a convenient one-pot, two-step process for the 
preparation of meta-substituted (N-sulfonyl)aniline derivatives, which are not easily accessible 
by other ways. Wu and Cui showed that 1,2,3-triazole 177 and nitrone 178 could be efficient 
directing groups for the iridium-catalyzed amidation of azide 149.[138,139] It was noteworthy that 
the regio-selectivity and reactivity could be greatly improved by installation of N-oxide motif 
on the triazole group. After the reaction, the N-oxide 164 could be readily reduced by 
PCl3.
[132,136] Huestis and Chen developed a benzylic primary amine directed 
orthosulfonamidation of aryl C–H bonds with sulfonyl azides 149 by using a commercially 
available iridium(III) complex as the catalyst.[141] 
Later, they used phosphoryl azides 166 to synthesize phosphoramidates by Ir(III)-catalyzed 
intermolecular C–H amidation with the assistance of NaOAc as the additive.[142,143] Both 
benzamide 138 and ketone 109 proved to be suitable substrates for the transformation. In the 
meantime, Zhu’s group independently applied phosphoryl azides 166 in the direct C–H 
phosphoramidation of 2-arylpyridines 43 and 1-arylpyazoles 51.[144] In this transformation 
AgOAc was used as the additive to enhance the efficacy. Recently, Lu and co-workers 
disclosed an iridium-catalyzed C–H amination of benzamides 138 by using alkyl azides 151 as 
the primary alkylamine source 130. A wide range of alkyl azides, including linear, branched, 
and cyclic alkyl azides were suitable coupling partners. Even biologically relevant molecules, 
such as amino acids, peptides, steroids, sugars, and thymidine derivatives could also be 
installed with high efficiency and complete chiral retention.[145] It was found that the CsOAc 
additive was vital for success and governed both the reactivity and the regioselectivity for this 
transformation. The group of Chang and Li group independently developed Ir(III)-catalyzed 
regioselective direct C7-amidation and amination of indolines 179 with various organoazides 
149, such as sulfonyl, acyl, aryl, and alkyl azides 149-153 (Scheme 1.37).[146,147] In Chang’s 
work, easily removable N-protecting groups such as N-Boc or N-Cbz could readily be 
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employed as efficient directing groups. Li showed that the 7-aminoindoline product could be 
oxidized by MnO2 to afford 7-aminoindole in situ in a one-pot operation.
[147] 
 
Scheme 1.37: Ruthenium(II)_catalyzed C–H bond amidation. 
 
Compared with rhodium and iridium, ruthenium is significantly less expensive (rhodium 800 
USD, iridium 700 USD, ruthenium 40 USD per troy oz) and it has been used more and more 
in transition-metal-catalyzed direct C–H functionalizations.[7,15,30,32,45] The groups of Sahoo[150] 
and Jiao[151] reported the ruthenium-catalyzed intermolecular ortho C–H amidation of weakly 
co-ordinating acyclic aromatic ketones with sulfonyl azides 149 (Scheme 1.37). At the same 
time, Chang’s group[152] also described the ruthenium-catalyzed intermolecular C–H amidation 
by using sulfonyl azides 150 as the amino source. In Chang’s work, not only weakly 
coordinating ketones 109, but also benzamide 138 and various heterocycles could act as 
efficient directing groups to promote the transformation. Kim and co-workers successfully 
extended the substrate scope to cyclic ketones 109 including xanthones and chromones.[153] A 
wide range of sulfonyl azides 151 were suitable for the amidation. However, benzoyl azide and 
phenyl azide 152 show no reactivity under the standard reaction conditions. 
Ackermann et al.[154] reported a ruthenium(II)-catalyzed direct amidation of arenes displaying 
heteroaromatic groups with a broad range of alkyl and aryl sulfonyl azides 149. Pyrazole 51, 
pyrimidine 137, and pyridine 43 proved to be efficient DGs to provide satisfying yields. Later, 
Ding, Luo and co-workers[155] demonstrated that benzothiazole 175 also could facilitate the 
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ruthenium(II)-catalyzed direct amidation of sulfonyl azides 149. Furthermore, Liang’s 
group[156] studied the mechanism by employing ruthenium-catalyzed amidation of 2-
phenylpyridine (43) with 4-methylbenzenesulfonyl azide as a model reaction. Two ruthenium 
intermediates were isolated and fully characterized by X–ray crystallography. A ruthenium–
imido species was proposed to explain the formation of the azacyclopropane analog. The Zhu’s 
group[157] developed a ruthenium-catalyzed regioselective direct C7-amidation of indoline 179 
with sulfonyl azides 149. The N-acyl group was employed to accomplish the C–H amidation 
process. Sahoo demonstrated ruthenium-catalyzed sulfoximine 180 directed intermolecular C–
H amidation of methyl-phenyl sulfoximine (MPS) 180 with sulfonyl azides 152 or N–OTs 
phthalimide 183. Stoichiometric KOAc or Ag2O as base additives were required to enhance to 



















Transition-metal-catalyzed C–H bond functionalizations are attractive tools for improving the 
atom- and step-economy of organic synthesis.[7,19,30,32,41] In recent years, ruthenium(II)-
complexes have been identified as powerful catalysts for the direct transformation of otherwise 
unreactive C–H bonds into C–C bonds.[41] On the contrary, ruthenium(II)_catalyzed C(sp2)–
heteroatom bond forming processes continue to be scarce.[154] 
The mono-selective C‒H amination of arenes received considerable attention, as a key 
structural frameworks in drug discovery.[165,166] In this context, it should take advantage of the 
less expensive ruthenium for the demanding direct amination of heteroarenes (43 and 51) in a 
broadly applicable and highly selective fashion (Scheme 1.38). 
Herein, we disclose the heteroatom-assistance in directed C–H bond amidations, in which the 
versatile ruthenium(II)-catalysts overrode the inherent substrate-controlled heteroatom 
oxidation by chelation-controlled aromatic C–H activation.[113] It is noteworthy that the acetate-
assistance leading to pyridine-amidated products can be easily converted to other useful 
building blocks in organic synthesis.[160-162]  
 
Scheme 1.38: Ruthenium-catalyzed C–H amidation with pyrazoles 51. 
 
 
Scheme 1.39: Ruthenium(II)-catalyzed C–H amidation with pyridine 43. 
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It is a challenging project for C–H nitrogenations with weakly co-ordinating directing 
groups[7,39,163,164] Amines are readily available ready to be transformed into valuable 
heterocycles like indoles, quinolines and quinoxalines, which are very useful synthons for 
industries.  
Aminophenones 185 are key motifs in natural product synthesis,[165,166] medicinal chemistry, 
crop protection, or material sciences, and they represent versatile intermediates in organic 
synthesis.[167] As a consequence, methods that allow for the efficient prepration for well-
decorated aminophenones continue to be in high demand in organic chemistry.[168]  It should 
take advantage of the less expensive ruthenium for the demanding direct amination of ketones 
184.The transformative nature of our C–H activation platform provides a step-economical 
access to decorated primary aminophenones as a key intermediate in the synthesis of various 
bioactive heterocycles.  
 
Scheme 1.40: Envisioned facile access to primary aminophenones 185. 
 
Although the Ackermann group has developed weakly coordinated ketones for site-selective 
C–H oxygenations, heteroarenes are doubtless much more challenging as a substrate in C–H 
oxygenations.[79-82] Ruthenium(II)-catalyzed C–H oxygenations by 2-pyridyloxyarene and 
sulfoximine benzamides assistance has proven thus far elusive. Taking advantage of the unique 
characteristics of ruthenium catalysis, the formyl group could possibly serve as a directing 
group rather than a substrate in the ruthenium-catalyzed C–H oxygenations. 
Whilst previous studies of ruthenium(II)-catalyzed C(sp2)–H bond oxygenation of arenes 
bearing electron-withdrawing or electron-donating directing groups are limited to 
acetoxylation and hydroxylations of aromatics.[78-81]  
The catalytic direct oxygenation of otherwise unreactive C(sp2)–H bonds was shown to be the 
most step-economical approach to substituted phenols.[169] Although ruthenium-catalyzed  
direct C(sp2)–H bonds direct oxygenation of arenes were reported, these notable progresses 
were mainly focused on oxygenation of electron-deficient substrates bearing electron- 
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withdrawing directing groups.[170-172] Therefore, a ruthenium-catalyzed C(sp2)–H bond 
oxygenation of phenol derivatives envisioned (Scheme 1.41). The major limitation in the 
synthesis of heteroarene-containing products is largely due to the facile N_oxidation of these 
heterocycles by hyper-valent iodine(III) reagents in ruthenium(II) catalyzed oxygenation 
reactions. In addition, despite their significant practical importance, reports of ruthenium-
catalyzed C–H oxygenations of substrates displaying removable directing groups for C–C bond 
formation is well established.[173-174] 
 
 
Scheme 1.41: Removable auxiliary assistance for ruthenium(II) catalyzed oxygenations. 
 
In spite of these significant advances, the use of non–removable and non–modifiable DGs and 
the lack of generality limit the broad synthetic application of this transformation and 
unfortunately continue to be scarce. In addition, highly chemoselective functionalization in the 
presence of a variety of C–H bonds remains elusive. The incorporation of easily removable and 
robust DGs can overcome some of these limitations.[176-178] For instance, we have devised 
reaction conditions for step-economical direct oxygenation via use of phenyl-methyl-
sulfoximine as reusable auxiliary.[180-185]  
 
Scheme 1.42: Reusable auxiliary assistance for ruthenium(II) catalyzed oxygenations 180. 
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In the transition metal-catalyzed alkenylations, directing groups were usually introduced to 
achieve site-selective C–H functionalization.[38-43] Recently, major progress in the development 
of ruthenium-catalyzed oxidative C–H alkenylation reactions has been done by the Ackermann 
research group and others.[88,186-189] The previously described alkenylations with oximes and 
N-methoxybenzamides require external oxidant. To perform the reaction at a reduced 
temperature and to avoid a second transition metal, it was decided to use a dioxygen as a trigger 
and air or molecular oxygen as the terminal oxidant.[190] Herein, the well-studied reaction 
between arenes and activated alkenes should serve as a modelsystem.[191-195] However, the 
commonly applied DGs are usually difficult to remove or modify under mild conditions. 
Herein, we devise ruthenium(II)-catalyzed oxidative alkenylations with 2-aryloxypyridines 
186 as a preparative approach to the synthetically valuable alkenylated phenols 94.[196-199]  
 
 









Results and Discussion 
- 41 - 
 
3 Results and Discussions  
3.1 Ketone-assisted ruthenium(II)-catalyzed C–H imidation: access to 
primary aminoketones by weak coordination 
It is a challenging project to perform C–H amination with weakly coordinating directing 
groups.[160-164] The Ackermann group has made great achievements by utilizing ketones for site-
selective ruthenium(II)-catalyzed C–H oxygenations, as well as the formyl group assisted C–
H oxygenations.[210] But the direct access to aminophenones has unfortunately proven elusive 
thus far. Aminophenones 185 are key structural motifs in natural product syntheses, medicinal 
chemistry, crop protection, or material sciences,[165] and they represent versatile intermediates 
in organic synthesis.[167] As a consequence, methods that allow for the efficient preparation of 
decorated aminophenones 185 continue to be in high demand.[92,168] The development of new 
chemical transformations based on the catalytic functionalization of otherwise inert C–H bonds 
has the potential to dramatically simplify the synthesis of complex molecules.[14,15] For 
instance, transition metal-catalyzed C–H amidations have emerged as an increasingly viable 
alternative to the palladium-catalyzed aminations of aryl halides. Particularly, ruthenium(II)-
complexes have in recent years been identified as powerful tools for C–H nitrogenations, 
largely exploiting strongly coordinating directing groups that are difficult to remove or 
modify.[179-181] Herein we disclose the first direct access to aminophenones via versatile 
ruthenium(II)-catalyzed C–H activation. 
 
3.1.1 Optimization of ruthenium(II)–catalyzed imidation of ketones  
It is known that acetophenone is very prone to –oxidation, thus substrate 184a was the best 
substrate for the optimization. The previously used organic azides 149 were declined as the 
nitrogen source. The results summarized in entries 1-10 (Table 1) showed that the 1,4-dioxane 
was the best reaction medium and AgSbF6 was found to be most suitable for this 
transformation, giving the desired product 192 in 34% yield. The dimeric complex [RuCl2(p-
cymene)]2 outperformed [Ru(O2CMes)2(p-cymene)], [Ru2(hp)4Cl] and [Ru2(OAc)4Cl] (entries 
8_12, Table 1). Typical [Cp*CoI2(CO)], [Cp*Rh (Cl)2]2 and Pd(OAc)2 catalysts failed in 
delivering the desired product 192 (entries 13_15, Table 1), highlighting the challenging nature 
of the ketone-assisted C–H nitrogenation. 
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Table 1: Screening of catalysts and solvents. 
 
Entry Catalyst Additive Solvent Time (h) Yield (%)a 
1 [RuCl2(p-cymene)]2 --- toluene 22 8 
2 [RuCl2(p-cymene)]2 AgSbF6 t-AmOH 22 NR 
3 [RuCl2(p-cymene)]2 AgSbF6 DME 22 NR 
4 [RuCl2(p-cymene)]2 AgSbF6 t-AmOH 22 NR 
5 [RuCl2(p-cymene)]2 AgSbF6 H2O 22 8 
6 [RuCl2(p-cymene)]2 AgSbF6 DCE 22 23 
7 [RuCl2(p-cymene)]2 AgSbF6 1,4-dioxane 22 34 
8 RuCl3·(H2O) n AgSbF6 1,4-dioxane 22 16 





































16 [RuCl2(p-cymene)]2 AgSbF6 1,4-dioxane 24 78b 
17 [RuCl2(p-cymene)]2 AgSbF6 1,4-dioxane 22 63 
a Reaction conditions: 184a (0.5 mmol), 183a (1.2 mmol), catalyst (5.0 mol %), solvent (2.0 mL), under N2, 
100 °C, 24 h, isolated yield, b Cu(OAc)2·H2O (0.5 equiv). 
 
As the next step, optimization studies to identify the optimal additive and ratio of reagents 
for the efficient direct amidation of arene 184 with pthalimide 183 were performed. The 
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Table 2: Effect of acetates on C–H imidation 
 
 
Entry Additive (0.5 equiv) Solvent Yield a 
1 Cu(OAc)2·H2O 1,4-dioxane 54 
2 Cu(OAc)2·H2O 1,4-dioxane 78 
3 LiOAc 1,4-dioxane 25 
4 CsOAc 1,4-dioxane 34 
5 NaOAc 1,4-dioxane 23 
6 NaOAc 1,4-dioxane 14 
7 NH4OAc 1,4-dioxane 16 
8 KOAc 1,4-dioxane 18 
a Reaction conditions: 184a (0.5 mmol), 183a (0.6 mmol), catalyst (5.0 mol %), solvent (2.0 mL), under N2, 
100 °C, 22 h, isolated yield, isolated yield; Cu(OAc)2·H2O (0.5 equiv). 
 
With the dimeric complex [RuCl2(p-cymene)]2 as the catalyst, stoichiometric amount of 
Cu(OAc)2·H2O as additive and 1,4-dioxane as solvent, the desired product 192 was formed 
in 54% yield entry 1 (Table 2). Different additives were tested (Table 2, entries 3_8) and 
notably, the lower loading of Cu(OAc)2·H2O (entry 2) was found to be the optimal condition 
for the ruthenium(II)-catalyzed C–H bond imidation reaction.  
 
3.1.2      Scope of ruthenium(II)-catalyzed imidation of ketones 184 
 
With the optimized catalytic conditions in hand (Table 2, entry 2), the C–H imidation scope 
with well decorated ketones 184 and pthalimide 183 was investigated (Scheme. 1.44). The 
ruthenium(II)-catalyzed C–H bond imidation reaction gave the best results when the para-
substituted arylketone 184 was bearing both an electron_withdrawing groups, such as 
trifluoromethyl, fluoro, chloro and bromo substituents (Scheme 1.44) as well as 
electron_donating groups, such as methoxy and tert-butyl groups 184 (Scheme 1.44), thus 
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showing robustness of the versatile synthetic methodology which should prove instrumental 





Scheme 1.44: Scope of ruthenium(II)-catalyzed imidation of ketones 184. 
The naphthalene substituted aryl-ketones 184k and 184l were employed in the ruthenium(II)-
catalyzed C–H bond imidation reactions with excellent positional selectivity of C–H bond 
functionalization protocol in these products 192ka and 192la. Yet, the robust ruthenium(II) 
catalyst was not limited to carbocyclic aromatic compounds. Indeed, the C–H imidation of 
thiophene 192ja proved viable as well, occurring with good site-selectivity (Scheme 1.44). 
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3.1.2 Scope of ruthenium(II)-catalyzed imidation of meta-substituted ketones 184 
 
Afterwards we investigated the site-selectivity of the ruthenium(II)-catalyzed C–H bond 
imidation reactions using meta-substituted arylketones 192m (Scheme 1.45). The steric factor 
was found important for controlling the site-selectivities. High levels of site-selectivity were 
observed within the reaction and functional groups like methoxy and trifluoromethyl 
substituents were well imidated to deliver products 192 (Scheme 1.45). It is noteworthy that 




Scheme 1.45: Scope of ruthenium(II)-catalyzed imidation of meta-substituted ketones 184. 
3.1.2 Scope of ruthenium(II)-catalyzed C–H imidation with phthalimides 
 
Moreover, this catalytic system could be applied to differently substituted phthalimides 183. 
Chloro, methyl and electron rich tert-butyl groups were well tolerated to give imidated products 
in acceptable yields 192aa-192ac (Scheme 1.46).  
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Scheme 1.46: Scope of ruthenium(II)-catalyzed C–H imidation with phthalimides 183. 
 
3.1.3 Facile acess to primary aminopheneones 185 
 
The synthetic utility of the ruthenium(II)-catalyzed amidation protocol was reflected by 
providing efficient access to the synthetically useful primary aminophenones. Furthermore, we 
were delighted to find that the versatile imidated products could be very easily transformed to 
free anilines by deprotedtion of pthalimido group thereby, yielding the desired ortho-
aminophenones 185. Useful functional groups, such as, fluoro, chloro, or bromo groups, were 
well tolerated by ruthenium catalyst (Scheme 1.47). 
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Scheme 1.47: Facile access to primary aminopheneones 185. 
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Scheme 1.48: Diversification of products 193-198. (a) 4, ArCOCH2Br, DMF, 100 °C, 16 h. 
(b) 4, ArCCH, InCl3 (20 mol %), CH3CN, 90 °C, 24 h. 
 
3.1.4  Mechanistic Studies  
 
To shed light on the course of this new ruthenium(II)-catalyzed amidation protocol, a set of 
experiments were performed. 
 
3.1.4.1 Competition experiments 
 
First, the intermolecular competition experiment between para-substituted ketones 184c/184e 
highlighted electronic effects, while meta-substituted ketones 184p/184m showed primarily 
the influence on site-selectivity of the C–H bond functionalization. The results of the electron-
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rich and electron-deficient arenes are presented herein. The competition between para-
(trifluoromethyl)-substituted arene 184e and para-methoxy-substituted arene 184c indicated 
that the electron-rich arene reacted faster, (Scheme 1.49a). Also in the second reaction between 
para-methyl-substituted arene 184b and para-fluoro-substituted arene 184f, a significant larger 
amount of the electron-rich amidated product was observed (Scheme 1.49b). Finally, the third 
experiment to reveal the high level of positional-selectivity between meta-fluoro-substituted 
arene 184p and meta-methoxy-substituted arene 184n was conducted and revealed the similar 
reactivity profile (Scheme 1.49c). These experiments clearly showed that electron-rich ketones 
reacted faster than electron-deficient ones. 
 
Scheme 1.49: Competition experiments between ketones 184. 
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3.1.4.1 Studies with isotopically labelled compounds 
 
In consideration of the unique selectivity features displayed by competition experiments by the 
ketone-assisted ruthenium(II)-catalyzed C–H amidation, we performed experiments with 
isotopically labelled substrates 184b (Scheme 1.50). As C–H and C–D bonds differ in their 
bond strength and energy, this approach is of great importance for determining the kinetics of 
reactions involving C–H bond cleavages.[212] In presence of pthalimide 183a, 54% hydrogen 
of ketone 184b was replaced by deuterium and 76% of hydrogen on the amidated product 
184ba was replaced by deuterium, using CD3OD as the co-solvent. Thus the C–H bond 
cleavage is most likely reversible and thus not the turnover determining step of the catalytic 
cycle. Finally, a competition experiment between 184a and [D]n-184a revealed a low kinetic 
isotope effect (KIE) of 1.8 (Scheme 1.51).  
 
 
Scheme 1.50: Studies with isotopically labeled co-solvent 184a. 
 
 
Scheme 1.51: Independent KIE experiment. 
Results and Discussion 
- 51 - 
 
3.1.4.3 Plausible catalytic cycle 
 
Summarizing the information, a reaction mechanism can be plausibly proposed for the 
ruthenium(II)-catalyzed C–H amidation (Scheme 1.52). First, the catalytically active cationic 
ruthenium species 193 is formed by abstraction of one chloride-ligand assisted by AgSbF6. 
Then the coordination of in-situ generated ruthenium(II)-carboxylate complex 193 by ketone 
184 to generate complex 195 and carboxylic acid. Second, the cyclometalated intermediate 195 
is subsequently coordinated by amidating reagent 183. Thereafter, N–O bond cleavage delivers 
the cationic complex 197, which finally regenerates the catalytically active species 193, thereby 
liberating the desired amidated product 192 (Scheme 1.52). Here, it is proposed that the acetate 
facilitates the C‒H bond cleavage, which serves as a catalytic proton shuttle from the transition 
state of the BIES process to the insoluble base.[51b,55] 
 
 
Scheme 1.52: Plausible mechanism of ruthenium(II)-catalyzed C–H amidation. 
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3.2  Ruthenium(II)_Catalyzed C–H Amidation of Heteroarenes 
 
Aromatic amines are widely found in pharmaceuticals, agrochemicals and natural products,[92] 
and amino groups can be readily transformed into many valuable functional groups, such as 
amides, acids, nitriles, or azides among others.[209] Hence, it is important to develop new 
methods to introduce the group onto an aromatic ring. 
 
3.2.1 Optimization of ruthenium(II)-catalyzed C–H nitrogenation of heteroarenes 
 
At the outset of the studies, a variety of reaction conditions were screened for the envisioned 
ruthenium(II)_catalyzed C–H nitrogenation of arenes 43 with organic azide 149 as a suitable 
nitrogen source.  The optimal reaction conditions for this direct amidation in the most efficient 
and selective way was established. Attempted reactions in THF, t-AmOH, DME, toluene, 
DMF, NMP or water, gave only traces of the amidated product 168aa (Table 3, entries 3-7). 
Yet, switching  the solvent to DCE dramatically increased the yield (entriy 9). Even the 
carboxylate assistance did not change the efficacy (entry 12). Among a set of representative 
ruthenium complexes, the dimeric ruthenium(II)_complex [RuCl2(p-cymene)]2 was then shown 
to be the best ruthenium source in combination with AgSbF6 (entry 9). The best conditions 
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Table 3: Optimization of ruthenium(II)-catalyzed C–H nitrogenation of pyridine 43a 
 
 
Entry [Ru] Additive Solvent Time (h) Yield (%)a 
1 [RuCl2(p-cymene)]2 AgSbF6 THF 22 41 
2 [RuCl2(p-cymene)]2 AgSbF6 t-AmOH 22 31 
3 [RuCl2(p-cymene)]2 AgSbF6 DME 22 22 
4 [RuCl2(p-cymene)]2 AgSbF6 toluene 22 38 
5 [RuCl2(p-cymene)]2 AgSbF6 DMF 22 NR 
6 [RuCl2(p-cymene)]2 AgSbF6 NMP 22 NR 
7 [RuCl2(p-cymene)]2 AgSbF6 NMP·H2O 22 26 
8 [RuCl2(p-cymene)]2 AgSbF6 H2O 22 23 
9 [RuCl2(p-cymene)]2 AgSbF6 DCE 22 54 
10 RuCl3·(H2O) n AgSbF6 DCE 22 16 
11 [RuBr2(p-cymene)]2 AgSbF6 DCE 22 64 
12 [Ru(O2CMes)2(p-cymene)] KO2CMes DCE 22 34 
13 [RuCl2(p-cymene)]2 AgBF4 DCE 22 37 
14 [RuCl2(p-cymene)]2 (2.5) mol % AgSbF6 DCE 22 42 
15 [RuCl2(p-cymene)]2 AgSbF6 DCE 22 84b 
16 [RuCl2(p-cymene)]2 AgSbF6 DCE 22 63c 
17 [RuCl2(p-cymene)]2 AgSbF6 DCE 22 54d 
a Reaction conditions: 43a (0.5 mmol), 149a (0.75 mmol), catalyst (5.0 mol %), DCE (2.0 mL), under N2,  
100 °C, 22 h, isolated yield, b NaOAc (0.5 equiv); c NaOAc (1.0 equiv) d NaOAc (0.3 equiv). 
 
 
Next, optimization studies to identify the optimal acetate source and ratio of reagent for the 
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Table 4: Effect of acetates on C–H amidation. 
 
Entry Acetate (0.5 equiv) Solvent Yield (%)a 
1 Cu(OAc)2·H2O DCE 52b 
2 Cu(OAc)2·H2O DCE 63 
3 LiOAc DCE 45 
4 CsOAc DCE 54 
5 NaOAc DCE 63 
6 NaOAc DCE 84 
7 NH4OAc DCE 46 
8 KOAc DCE 58 
a Reaction conditions: 43a (0.5 mmol), 149a (0.75 mmol), catalyst (5.0 mol %), solvent (2.0 mL), under N2, 100 
C, 22 h, isolated yield, isolated yield; b Cu(OAc)2·H2O (1.0 equiv). 
 
With the dimeric complex [RuCl2(p-cymene)]2 as the catalyst stoichiometric amounts of 
Cu(OAc)2·H2O as additive and 1,4-dioxane as solvent, the desired product 168a was formed 
in 52% yield (Table 4, entry 1). Different additives were tested (entries 2-5) and notably 
NaOAc (entry 6) was found to be the best. 
 
3.2.2  Scope of Ruthenium(II)-catalyzed amidation of pyridines 43. 
 
Under the optimized conditions the direct amidation of various substitutes hetero-arenes 43 
was explored (Scheme 1.53). Notably, a variety of functional groups on the arenes 43 were 
well tolerated by the effective catalytic system to furnish the corresponding amidated products 
168, even bearing sterically hindered substituent  (Scheme 1.53).  
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Scheme 1.53: Scope of ruthenium(II)-catalyzed amidation of pyridines 43. 
 
Then, we evaluated the versatility of the C–H amidation with para-methyl-substituted 
heteroarenes and 76% yield of the amidated product were isolated. Generally, the catalytic 
system showed high chemoselectivity, exclusively  yielding the mono-amidated products 
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3.3  Ruthenium(II)-Catalyzed C–H Oxygenations of phenols 94. 
 
In recent years, a number of DGs for the C–H oxygenation reaction catalyzed by ruthenium(II)-
complexs have been explored.[62] However, the transformation of these directing groups in a 
number of cases remains a major problem, whereas the methods that exploited removable 
directing groups are scarce.[174,175] First, it should be examined if the carboxylate assistance 
could promote the direct oxygenation of substrates forming six membered ruthenacycle as an 
intermediate as well. Successful solution of this problem could open the way for a novel 
strategy of using removable DGs. Therefore, we developed ruthenium-catalyzed twofold C–H 
functionalization with arenes and heteroarenes using easily cleavable pyridin-2-yloxy directing 
groups 186.[175] Based on these studies we became interested in developing a C–H oxygenation 
reaction with a reusable directing groups.[59,158]  
 
3.3.1 Optimization of ruthenium(II)-catalyzed C–H oxygenation of phenols 94. 
 
Initially, we selected 2-(o-tolyloxy)-pyridine (186a) and para-methylbenzoic acid (101a) as 
the substrates to test the reaction conditions (Table 5). While additives were found to be 
mandatory for of ruthenium(II)-catalyzed acyloxylations with carboxylic acids, they proved to 
be effective for the desired C–O bond formation of product 187aa (Table 5, entries 2-7). 
Among a variety of additives that were examined AgSbF6 proved to be superior, which can be 
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Table 5: Optimization of ruthenium(II)-catalyzed oxygenation of phenol 186a. 
 
 
Entry Catalyst Additive Solvent  Yield (%)a 
1 [RuCl2(p-cymene)]2 -- DCE  NR 
2 [RuCl2(p-cymene)]2 KOAc DCE  NR 
3 [RuCl2(p-cymene)]2 Ag2CO3 DCE  28 
4 [RuCl2(p-cymene)]2 AgPF6 DCE  24 
5 [RuCl2(p-cymene)]2 AgBF4 DCE  42 
6 [RuCl2(p-cymene)]2 KPF6 DCE  53b 
7 [RuCl2(p-cymene)]2 AgSbF6 DCE  78c 
8 [RuCl2(p-cymene)]2 AgSbF6 DCE  43c 12h 
9 RuCl3(H2O) n AgSbF6 DCE    55c, d 
10 [Ru(O2CMes)2(p-cymene)] KO2CMes DCE  34 
11 [Ru2(hp)4Cl] AgBF4 DCE  46 
12 [Ru2(OAc)4Cl] AgSbF6 DCE  42 
13 [RuCl2(p-cymene)]2 (2.5 mol %) AgSbF6 DCE   63c 
a Reaction conditions: 186a (1.0 mmol), 101a (0.5 mmol), catalyst (5.0 mol %), K2S2O8 (1.0 mmol), solvent 
(2.0 mL), under N2, 100 °C, 18 h, isolated yield, b KPF6 (40 mol %); c K2S2O8 (1.0 mmol), d RuCl3· (H2O) n 
(10 mol %). 
 
As the next step, optimization studies were performed. to identify the optimal ratio and 
oxidant for the efficient direct C–H acyloxylation of arene 186 with carboxylic acid 101 The 
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Entry Oxidant (2.0 equiv) Solvent Yield (%)a 
1 Ag2CO3 DCE 28 
2 Ag2O DCE 32 
3 K2CO3 DCE 14 
4 Na2CO3 DCE 16 
5 Oxone DCE 55 
6 K2S2O8 DCE 78a 
7 (NH4)2S2O8 DCE 46 
8 K2S2O8 DCE 58b 
a Reaction conditions: 186a (1.0 mmol), 101a (0.5 mmol), catalyst (5.0 mol %), K2S2O8 (1.0 mmol), solvent 
(2.0 mL), under N2, 100 °C, 18 h, isolated yield, b K2S2O8 (1.0 equiv). 
 
Subsequently, a set of common sacrificial oxidants such as Ag2CO3 and Ag2O were tested 
(Table 6, entries 1 and 2), and the utilization of K2CO3, Na2CO3 as bases failed to deliver the 
good yield of product 187aa under otherwise identical reaction conditions (entries 3‒5). 
Furthermore, the application of Oxone, K2S2O8, (NH4)2S2O8 successfully implemented 
(entries 6 and 7), which revealed that the combination of the peroxydisulfate moiety and the 
potassium cation plays a crucial role for this C‒H transformation. and 2.0 equivalent of 
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3.3.2       Scope of ruthenium(II)-catalyzed C–H oxygenation with arene 186. 
With the optimized catalytic system in hand, we tested its versatility with a set of 
representative arenes 186 and carboxylic acids 101 (Scheme 1.54). When using mono-
substituted or para-di-substituted arenes 186a-186i, the C–H acyloxylations proceeded with 
excellent levels of chemoselectivity, such that the mono-oxygenated products were obtained 
in high to excellent yields 187. 
 
 
Scheme 1.54: Scheme of ruthenium(II)-catalyzed acyloxylation of arene 186. 
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The robust ruthenium(II)-catalyst proved to be tolerant of various functional groups, 
including fluoro, chloro and bromo substituents the latter of which should prove valuable for 
further functionalizations of the products 187. Interestingly, placing an additional electron-
donating substituent on the pyridyl-oxy auxiliary did not give an improved yield of the 




Scheme 1.55: Positional selectivity in ruthenium(II)-catalyzed acyloxylation of arene 186. 
 
Subsequently, the regioselectivity of the C–H acyloxylations was explored with the meta-
substituted arene 186j and a variety of carboxylic acids 101 (Scheme 1.55). The 
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regioselectivity was governed by steric interactions, thereby delivering 187ja-187jl as the 
sole products. This ruthenium(II)-catalyzed C–H acyloxylation displayed excellent 
chemoselectivity by tolerating various electrophilic functional groups, including fluoro, 
chloro, iodo and even sensitive nitro groups (Scheme 1.55). 
The cationic ruthenium(II)-catalyst was found to have a broad substrate scope for the C–H 
acyloxylations reaction. Thus, heteroaromatic acids 101m-101o, including the thiophene 
derivative 101o, were also identified as viable substrates. (Scheme 1.56). The 2,3-furyl 
substituted carboxylic acids also underwent the acyloxylation and showed the versatility of 





Scheme 1.56: Ruthenium(II)-catalyzed acyloxylation with heteroaromatic acids 186. 
 
The unique power of the C–H acyloxylations was highlighted by the successful use of alkyl 
carboxylic acids 101p-101s, which have hitherto proven to be particularly challenging 
substrates (Scheme 1.57). 
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Scheme 1.57: Ruthenium(II)-catalyzed acyloxylation with aliphatic carboxylic acids 101. 
 
3.3.3     Mechanistic studies  
 
To shed light on the course of this new ruthenium(II)-catalyzed oxygenation protocol, a set 
of experiments were performed to elucide its mechanistic aspects. 
 
3.3.3.1    Competition experiments 
 
First, the intermolecular competition experiment between ortho-substituted arenes 186g 
highlighted electronic effects. The results of the electron-rich and electron-deficient arenes 
are presented herein. The competition between ortho-methyl-substituted arene 186a and 
ortho-fluoro-substituted arene 186g indicated that the electron-rich arene reacted faster 
(Scheme 1.58a). Also in the second reaction between meta-methyl-substituted arene 186j 
and meta-fluoro-substituted arene 187k a significant larger amount of the electron-rich 
amidated product was observed (Scheme 1.58b). The third experiment to reveal the high 
level of positional-selectivity between aliphatic carboxylic acid 101r and aromatic 
carboxylic acid 101b was conducted and revealed a similar profile (Scheme 1.58c). Finally, 
the fourth experiment between para-methyl-substituted carboxylic acid 101b and para-nitro-
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substituted arene 101g was conducted (Scheme 1.58d). Overall, these experiments clearly 
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Scheme 1.58: Competition experiments with arenes 187a. 
 
3.3.3.2     Studies with isotopically labeled compounds 
 
In consideration of the unique selectivity features displayed by competition experiments by 
the removable auxiliary-assisted ruthenium(II)-catalyzed C–H oxygenation, we performed 
experiments with isotopically labelled substrates (Scheme 1.59). In presence of carboxylic 
acid 101b, 89% hydrogen of arene 186b was replaced by deuterium and 31% hydrogen on 
the oxygenated product 187 was changed to deuterium using CD3OD as a co-solvent. These 
results suggest that the C–H bond cleavage is most likely reversible and thus not the turnover 
determining step of the catalytic cycle.  
 
 
Scheme 1.59: Reversible H/D exchange in presence of D2O 
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3.3.3.3     Plausible catalytic cycle 
 
Based on these mechanistic studies, a plausible catalytic cycle was proposed for this 
ruthenium(II)-catalyzed C–H oxygenation (Scheme 1.60). After reversible and fast C–H 
bond ruthenation on arene 187 by the cationic ruthenium carboxylate species 199, the 
resulting cationic ruthenium complex 199 undergoes coordination and insertion of aryl 
carboxylic acid 101, and thus affords the intermediate 201. Finally, the desired oxygenated 
product is formed and the cationic ruthenium(II)-carboxylate catalyst is regenerated after β-
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3.4    Reusable auxiliary assistance for ruthenium(II)-catalyzed C–H 
oxygenation of sulfoximines  
 
Recently, the independent studies from Bolm and Sahoo revealed the synthetic utility of the 
well-established reusable sulfoximines[158,159] which have been employed for the efficient C–
H oxidation of arenes.[165] In recent years, the group of Ackermann developed number of 
directing groups for the C–H oxygenation reaction catalyzed by ruthenium(II)-complex.[62] 
A ruthenium(II)-catalyzed intermolecular C–H oxygenation assisted by removable auxiliary 
provided step-economical access to synthetically meaningful salicylic acid derivatives. The 
first iodine(III)- and silver-free C–H oxygenation strategy occurred by ruthenium(II)-
catalysis with ample scope and high functional group tolerance to efficiently deliver densely 
substituted arenes employing the readily available benzoic acids as coupling partners 
exploiting removable auxiliary assistance in oxygenations.  
 
3.4.1   Optimization of ruthenium(II)-catalyzed C–H oxygenation of sulfoximines 
 
With the promising success with removable directing group in ruthenium(II)-catalyzed 
acyloxylations we became interested in developing a novel  methodology for the RDG  in 
C–O forming reactions. Initially, we selected N-(o-methylbenzoyl) 180 and para-
methylbenzoic acid 101a as substrates to test the reaction conditions (Table 7). 
Additives proved to be effective for the desired C–O bond formation of 189 (Table 7). 
Among a variety of additives that were examined KPF6 proved to be superior, which can be 
rationalized by the in-situ generation of a cationic ruthenium(II)species (entries 7-11). The 
direct C–H oxygenation of arene 180 with carboxylic acid 101 were performed. The results 
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Table 7: Optimization of ruthenium(II)-catalyzed oxygenation of 180. 
 
 
Entry Catalyst Additive Solvent Time (h) Yield (%)a 
1 [{RuCl2(p-cymene)}2] AgSbF6 DME 24 21 
2 [{RuCl2(p-cymene)}2] AgSbF6 t-AmOH 24 8 
3 [{RuCl2(p-cymene)}2] AgSbF6 1,4-dioxane 24 16 
4 [{RuCl2(p-cymene)}2] AgSbF6 toluene 24 NR 
5 [{RuCl2(p-cymene)}2] AgSbF6 DMF 24 NR 
6 [{RuCl2(p-cymene)}2] AgSbF6 NMP 24 NR 
7 [{RuCl2(p-cymene)}2] AgSbF6 DCE 24 26 
8 [{RuCl2(p-cymene)}2] AgSbF6 DCE 24 23 
9 [{RuCl2(p-cymene)}2] AgBF6 DCE 24 24 
10 [{RuCl2(p-cymene)}2] AgPF6 DCE 24 16 
11 [{RuCl2(p-cymene)}2] KPF6 DCE 24 81
a 
12 [RuCl3·nH2O] KPF6 DCE 24 23
b 
13 [MnBr(CO)5] KPF6 DCE 24 NR 
14 ---- KPF6 DCE 24 NR 
15 [{RhCp*Cl2}2] KPF6 DCE 24 NR
 
16 [Cp*Co(CO)I2] KPF6 DCE 24 NR
 
a Reaction conditions: 180a (0.5 mmol), 101a (0.60 mmol), catalyst (5.0 mol %), (NH4)2S2O8 (1.0 mmol), 
solvent (2.0 mL), under N2, 100 °C, 24 h, isolated yield, b (NH4)2S2O8 (1.5 mmol). 
Next step, optimization studies to identify the optimal oxidant source for the efficient 
direct amidation of arene 180 with carboxylic acid 101 were performed. The results are 
summarized in Table 8. 
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Table 8: Exploring oxidants 
 
 
Entry Oxidant (2.0 equiv) Solvent Yield (%)a 
1 K2S2O8 DCE 11
 
2 PhI(OAc)2 DCE NR 
4 KHSO5 DCE 16 
5 Ag2O DCE NR 
6 PhI(TFA)2 DCE NR
 
7 Oxone DCE 16 
8 (NH4)2S2O8 DCE 81 
9 (NH4)2S2O8 DCE 54
b 
10 (NH4)2S2O8 DCE 38
c 
a Reaction conditions: 180a (0.5 mmol), 101a (0.6 mmol), catalyst (5.0 mol %), (NH4)2S2O8 (1.0 mmol), 
solvent (2.0 mL), under N2, 100 °C, 18 h, isolated yield, b KPF6 (0.3 equiv), c KPF6 (0.2 equiv).  
 
A set of common sacrificial oxidants K2S2O8, PhI(OAc)2, KHSO5, Ag2O, PhI(TFA)2, oxone 
and (NH4)2S2O8 were tested and (NH4)2S2O8 was identified as the optimal reaction oxidant 
(entries 1-7). 
 
3.4.2     Scope of ruthenium(II)-catalyzed C_H oxygenation of arene 180. 
 
With an optimized catalytic system in hand, we then tested its versatility with a set of 
representative arenes 180 and carboxylic acids 101 (Scheme 1.62). When using mono-
substituted or para-substituted arenes180c the C–H oxygenation proceeded with excellent 
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levels of chemoselectivity, such that the mono-oxygenated products were obtained in high 
to excellent yield 189cb (Scheme 1.62). 
 
 
Scheme 1.62: Scope of ruthenium(II)-catalyzed acyloxylation of acids 101. 
 
The robust ruthenium(II) catalyst proved to be tolerant of various functional groups, 
including fluoro, chloro, and bromo substituents, the latter of which should prove valuable 
for further functionalization of the products 189 (Scheme 1.62). To our delight, thiophene-
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3-carboxylic acid was successfully installed as a coupling partner 101o to give product 189ao 




Scheme 1.63: Scope of ruthenium(II)-catalyzed acyloxylation of arene 180. 
 
High levels of positional selectivity were observed with para-substituted arenes 180c as well. 
Substitutions on the aromatic moiety N–aroyl MPS 180 were likewise tolerated under the 
optimized reaction conditions. The widely applicable ruthenium(II) catalyst was not limited to 
aromatic substrates. Indeed, the C–H oxygenation of para- and meta- substitueted products 
180db proved viable, occurring with excellent levels of positional control (Scheme 1.63). 
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Scheme 1.64. Reusability of directing group. 
Finally, hydrolysis of the oxygenated products with aqueous HCl readily cleaved the removable 
DG in a traceless fashion. Thus, the desired ortho-hydroxy carboxylic acids 102a (71%) and 
102b (73%) were obtained respectively, with the recovery of the DG (Scheme 1.64). The 
synthetic utility of the ruthenium(II)-catalyzed oxygenation protocol was reflected by 
providing efficient access to the synthetically useful salicylic acid derivatives 190a and 190b 
(Scheme 1.64). 
 
3.4.3    Mechanistic studies 
To shed light on the course of this ruthenium(II)-catalyzed oxygenation protocol a set of 
experiments were performed. 
 
3.4.3.1   Competition experiments 
 
First, intermolecular competition experiment between para-substituted arenes 180c 
highlighted electronic effects on site-selectivity of the C–H bond functionalization. The 
competition between para-methyl-substituted arene 180c and the un-substituted arene 180b, 
showed that the electron-rich arene reacted faster. (Scheme 1.65a). Also in the second reaction 
between para-methyl-benzoic acid 189cb and para-nitro-benzoic acid 189ca, a significant 
larger amount of the electron-rich oxygenated product was observed (Scheme 1.65b). The third 
experiment was conducted to reveal the high level of positional-selectivity between aliphatic 
carboxylic acid 101x and aromatic carboxylic acid 101b and revealed the challenging nature 
of aliphatic carboxylic acids (Scheme 1.65c). These experiments clearly showed that the 
electron-rich arenes reacted faster than the electron-deficient ones. 
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Scheme 1.65: Competition experiments between arenes 180 and acids 101. 
 
 
3.4.3.3    Plausible catalytic cycle 
 
Based on these mechanistic studies a plausible catalytic cycle was proposed for this 
ruthenium(II)-catalyzed C–H oxygenation (Scheme 1.66). After reversible and fast C–H bond 
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ruthenation on arene 180 with the cationic ruthenium carboxylate species 198, the resulting 
cationic ruthenium complex 202 undergoes coordination and insertion of aryl carboxylic acid 
203, and thus affords the intermediate 204. Finally, the desired oxygenated product is formed 
and the cationic ruthenium(II)-carboxylate catalyst is regenerated after reductive elimination. 
The operationally simple protocol featured high catalytic efficacy and excellent functional 
group tolerance. These observations, and particularly the preferential transformation of 
electron-rich arenes, can be rationalized in terms of a base-assisted intramolecular electrophilic 
substitution-type (BIES)[51b,55] C–H metalation event to be operative.  
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3.5    Ruthenium(II)-catalyzed C–H alkenylation of arenes bearing 
removable directing group with O2 as the oxidant 
 
Oxidative alkenylation by twofold C–H activation[15,19] represents the most efficient and step-
economical strategy for the assembly of selectively substituted olefins.[39,164] Based on 
pioneering studies by Fujiwara and Moritani,[44-46] tremendous progress has been made in 
metal-catalyzed cross-dehydrogenative olefinations, most notably in palladium catalysis.[213] 
In contrast, versatile ruthenium(II)-complexes[62] have only recently emerged as powerful 
catalysts for oxidative C–H functionalizations. Despite these indisputable advances, 
ruthenium(II)-catalyzed oxidative alkenylations using chelation assistance have been thus far 
limited to the use of antibacterial copper(II) or expensive silver(I) salts as the oxidants.[32,42] 
Thereby, undesired metal waste is generated, which contradicts the sustainable nature of C–H 
activation technology. A notable elegant exception was developed by Milstein and co-workers, 
which indicated the potential of ruthenium catalysis.[214] Unfortunately, the catalyst was 
severely limited to rather harsh reaction conditions, such as high pressure reactions with CO at 
8 atm and a reaction temperature of 180 °C. Moreover, mixtures of regioisomeric products 
which were difficult to separate were largely obtained when using substituted arenes. In 
contrast, we have very recently identified the beneficial effect of carboxylates for aerobic 
alkyne annulations. We then became interested in developing the first ruthenium(II)-catalyzed 
positional selective alkenylations with O2 as the sole oxidant. 
 
3.5.1    Optimization studies 
 
Initially, we selected 2-(o-tolyloxy)pyridine 186 and ethyl acrylate 63 as the substrates to test 
the reaction conditions (Table 9). While carboxylate additives were found to be mandatory for 
ruthenium-catalyzed direct arylations with aryl halides, 4 and proved to be effective for the 
desired oxidative C–H bond alkenylation of 205 (entries 1–3). To our delight, the coupled 
product 205 was isolated in 68% yield when using the well defined ruthenium catalyst 
[Ru(O2CMes)2(p-cymene)] 198 (10 mol %) and 3.0 mmol of 63 (entry 5). Importantly, this 
alkenylation product was also obtained in 32% yield with PEG as the solvent. Molecular 
dioxygen served as the sacrificial oxidant (entry 6). Furthermore, control experiments verified 
that no desired product was observed in the absence ruthenium-catalyst. Lowering the amount 
of acrylate as a coupling partner in this solvent-free transformation resulted in lower isolated 
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yields (entries 4-7).  The well-defined ruthenium(II)-carboxylate catalyst outcompeted the 
RuCl3·H2O, Rul3·H2O and [Ru2(hp)4Cl] in delivering the alkenylated product in exceedingly 
good yields in ruthenium(II)-oxidase catalysis (entries 8-11).  
 
Table 9: Optimization of ruthenium(II)-catalyzed C–H alkenylation. 
 
Entry Catalyst Additive Solvent Time (h) Yield (%)a 
1 [Ru(O2CMes)2(p-cymene)] CsOAc PEG 18 32 
2  [Ru(O2CMes)2(p-cymene)] CsOAc CH3OH:PEG 
(1:1) 
18 28 
3  [Ru(O2CMes)2(p-cymene)] CsOAc t-BuOH 18 34 
4 [Ru(O2CMes)2(p-cymene)] ----- H2O 18 18 
5 [Ru(O2CMes)2(p-cymene)] CsOAc acrylate 18 54
[a] 
6 [Ru(O2CMes)2(p-cymene)] CsOAc acrylate 18 26
[b] 
7 [Ru(O2CMes)2(p-cymene)] CsOAc acrylate 18 68[c] 
8 RuCl3.H2O (10 %) CsOAc acrylate 18 36
[c] 
9 Rul3.H2O (10 %) CsOAc acrylate 18 NR 
10 ---- CsOAc acrylate 18 NR 
11 [Ru2(hp)4Cl] (5 %) CsOAc acrylate 18 41 
a Reaction conditions: 186a (0.5 mmol), 63a (2.5 mmol), catalyst (10.0 mol %), under O2, 120 °C, 18 h, 
isolated yield b 63a (1.0 mmol); c 63a (1.5 mmol). 
 
With the optimized conditions in hand, we explored the versatility of this C–H 
monoalkenylation reaction (Scheme 1.67). Gratifyingly, substrates with both electron-
donating (products 205aa-205fa) and electron-withdrawing substituents 205ha at the ortho 
and para position of the phenyl ring were viable and furnished the desired products 205ia in 
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high isolated yields, thus indicating the general applicability of phenoxylpyridine substrates 
205la. 
3.5.2     Scope of ruthenium(II)-catalyzed C–H alkenylation of phenol derivatives 186. 
 
Scheme 1.67: Scope of aerobic ruthenium(II)-catalyzed C–H alkenylation of phenol 
derivatives 186 
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Notably, halogen substituents at the ortho and para position of the phenyl ring in substrates 
168g and 168h were also tolerated under this catalytic system (Scheme 1.67). This could 
provide a versatile synthetic handle for further functionalization of the products 205ha. 
Furthermore, oxidative alkenylations with naphthol derivative 205la, respectively, delivered 
the desired alkenylated products with excellent site selectivity. Importantly, the catalytic C–H 
bond functionalizations occurred with excellent diastereoselectivities, delivering the E 
diastereomers as the sole products in all cases. The site-selectivity of the oxidative C–H bond 
functionalization with meta-substituted phenol derivatives 168j was largely controlled by steric 
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4 Summary and Outlook  
Phenols and amines are key structural motifs of numerous bioactive compounds of relevance 
to agrochemicals and drug discovery, among others. Transition metal-catalyzed direct 
functionalization processes of otherwise inert C‒H bonds emerged as a more sustainable 
alternative to the classically used cross-coupling reactions for the synthesis of substituted 
phenol and derivatives. For this reason, the research was focused on the development of novel 
methods for efficient and selective direct C‒H transformations to construct C‒O and C‒N bond 




Scheme 1.68: Facile access to primary aminopheneones 185. 
 
 
Scheme 1.69: Removable auxiliary assistance for ruthenium(II) catalyzed oxygenations 186. 
 
The first part of this thesis described an efficient and generally applicable method for the 
ruthenium(II)-catalyzed oxidative C‒N bond formation of ketone 184 accomplished with 
different nitrogen sources (Scheme 1.68). The high activity of the catalytic system was not 
restricted to aromatic carboxalic acids 101 as coupling partners, but enabled the first 
ruthenium(II)-catalyzed direct C‒N formation of 2-phenylpyridine 43. An in situ generated 
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cationic ruthenium(II)-catalyst promoted the highly chemo- and mono-selective C‒H 
funtionalization in excellent yields with a broad substrate scope. Here, electron-donating and -
withdrawing groups on the arene of both ketone and aromatic azide 149 based reagents were 
compatible with this transformation to set the stage after removal of the pthalimido group for 




Scheme 1.70: Reusable auxiliary assistance for ruthenium(II)-catalyzed oxygenations. 
A straight forward synthesis starting from benzoic acid derivatives 101 by applying C‒O bond 
formation approach as the key reaction and subsequent removal of the DG group provides the 




Scheme 1.71: Ruthenium(II)-catalyzed oxidative alkenylation 
We then became interested in developing the first ruthenium(II)-catalyzed positional selective 
alkenylations with O2 as the sole oxidant. Use of the versatile ruthenium oxidase catalysis by 
direct dioxygen-coupled turnover include: a) an unparalleled broad substrate scope in aerobic 
alkenylations, b) sustainable aerobic C–H activations that produce H2O as the only by-product, 
c) exceedingly mild reaction conditions, and d) oxidative olefinations with weakly coordinating 
or removable directing groups. 
Experimental Section 
- 80 - 
 
5 Experimental Section 
 
5.1 General Remarks 
All reactions involving moisture- or air-sensitive reagents or products were conducted under 
an atmosphere of nitrogen, using standard Schlenk techniques and pre-dried glassware. 
Syringes for handling of dry solvents or liquid reagents were evacuated and purged with 
nitrogen threefold prior to use. Analytical data of substances that are known in the literature 




All solvents for reactions were purified using a MBRAUN Solvent Purification System 800 
(MB SPS 800) or were dried, degassed, distilled and stored under an inert atmosphere (argon 
or nitrogen) according to following standard procedures. 
 
t-Amyl alcohol (t-AmOH) was dried over Na for 5 h and distilled under ambient pressure. 
 
t-Butyl alcohol (t-BuOH) was dried over Na and distilled under ambient pressure and stored 
over molecular sieves (4 Å). 
 
1,2-Dichloroethane (DCE) was dried over CaH2 for 8 h and distilled under ambient pressure. 
 
1,2-Dimethoxyethane (DME) was dried over Na for 12h and distilled over Na/benzophenone 
under ambient pressure. 
 
1,4-Dioxane was dried over CaH2 and distilled under reduced pressure. 
 
Methanol (MeOH) was dried over Mg(OEt)2 for 3 h and distilled under ambient pressure. 
 
N-Methyl-2-pyrrolidone (NMP) was stirred for 6 h over CaH2 and subsequently distilled 
under reduced pressure. 
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Tetrahydrofuran (THF) was purified using a MB SPS 800 and distilled under ambient 
pressure. 
 
Toluene (PhMe) was dried over Na and distilled over Na/benzophenone under ambient 
pressure. 
 
Water (H2O) was degassed for 2 h and ultrasonicated. 
 




Following pressures were measured on the used vacuum pumps and are not corrected: 
membrane pump vacuum (MPV): 5.0 mbar, oil pump vacuum (OPV): 0.1 mbar. 
 
5.1.3 Melting Point 
 





Analytical TLC was performed on 0.25 mm silica gel 60F plates (Macherey-Nagel) with 254 
nm fluorescent indicator from Merck. Plates were visualized under ultraviolet light. 
Chromatographic purification of products was accomplished by flash column chromatography 
on Merck silica gel, grade 60 (0.040–0.063 mm and 0.063–0.200 mm, 70–230 mesh ASTM). 
 
5.1.5 Nuclear Magnetic Resonance Spectroscopy 
 
Nuclear magnetic resonance (NMR) spectra were recorded at 300, 400, 500, 600 MHz 
(1H-NMR), at 75, 126 MHz (13C-NMR, APT) and at 282 MHz (19F-NMR) respectively, on 
Bruker Avance III HD 400 and 500, or Varian Mercury 300, Inova 500 and 600 instruments. 
Chemical shifts are reported as δ-values in ppm relative to the residual proton peak of the 
deuterated solvent or its carbon atom, respectively. 
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CDCl3 7.26 ppm 77.16 ± 0.06 ppm 
DMSO-d6 2.50 ppm 39.52 ± 0.06 ppm 
 
For the characterization of the observed signal multiplicities, the following abbreviations were 
used: s (singlet), d (doublet), t (triplet), q (quartet), hept (heptet), m (multiplet). Coupling 
constants J are reported in Hertz (Hz). 
 
5.1.6 Infrared Spectroscopy 
 
Infrared spectra were recorded using a Bruker Alpha-P ATR FT-IR spectrometer. Liquid 
samples were measured as a film, and solid samples were measured neat. The analysis of the 
spectra was carried out using the software from Bruker OPUS 6. The absorption is given in 
wave numbers (cm‒1) and the spectra were recorded in the range of 4000–400 cm‒1. 
 
5.1.7 Mass Spectrometry 
 
EI- and EI-HRMS spectra were measured on a Time-of-Flight mass spectrometer AccuTOF 
from Joel. ESI-mass spectra were recorded on an Ion-Trap mass spectrometer LCQ from 
Finnigan or on a Time-of-Flight mass spectrometer microTOF from Bruker. ESI-HRMS 
spectra were recorded on a Bruker APEX IV mass spectrometer. The ratio of mass to charge 




Chemicals obtained from commercial sources (purity > 95%) were used without further 
purification. The following compounds were synthesized by known literature procedures: 




5.2 General Procedures 
General Procedures 
- 83 - 
 
 
5.2.1 Representative procedure A: Ruthenium(II)−catalyzed C−H omidations with 
weakly coordinating ketones 192: A suspension of 2,2-dimethyl-1-phenylpropan-1-one 
(184), (81.0 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183), (190 
mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) 
and Cu(OAc)2∙H2O (49.0 mg, 0.50 equiv) in 1,4-dioxane (2.0 mL) was stirred in a sealed tube 
under N2 at 100 °C for 24 h. At ambient temperature, the reaction mixture was diluted with 
CH2Cl2 (20 mL) and passed through celite with CH2Cl2 (100 mL). The organic layer was dried 
over Na2SO4. After evaporation of the solvent in vacuo, the crude product was purified by 
column chromatography on silica gel (n-hexane/EtOAc: 10:1) to yield 192 (120 mg, 78%) as 
a colorless solid. 
 
5.2.2 Representative procedure B: Ruthenium(II) catalyzed C–H imidations with weakly 
coordinating ketones: A suspension of 2,2-dimethyl-1-phenylpropan-1-one (184), (81.0 mg, 
0.50 mmol), 5-methyl-1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183), (200 mg, 
0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and 
Cu(OAc)2·H2O (49.0 mg, 0.50 equiv) in 1,4-dioxane (2.0 mL) was stirred in a sealed tube 
under N2 at 100 °C for 24 h. At ambient temperature, the reaction mixture was diluted with 
CH2Cl2 (20 mL) and passed through celite with CH2Cl2 (100 mL). The organic layer was dried 
over Na2SO4. After evaporation of the solvent in vacuo, the crude product was purified by 
column chromatography on silica gel (n-hexane/EtOAc: 10:1) to yield 192 (120 mg, 70%) as 
a colorless solid. 
 
5.2.3 Representative procedure C: Access to primary aminoketones: A suspension of 2-(2-
ivaloylphenyl)isoindoline-1,3-dione (192), (307 mg, 1.0 mmol) and hydrazine (2.0 mL), was 
stirred at ambient temperature for 4 h. At ambient temperature, the reaction mixture was diluted 
with CH2Cl2 (20 mL) and passed through celite with CH2Cl2 (50 mL). The organic layer was 
dried over Na2SO4. After evaporation of the solvent in vacuo, the crude product was purified 
by column chromatography on silica gel (n-hexane/EtOAc: 5:1) to yield 185 (122 mg, 69%) as 
an orange liquid. 
 
5.2.4 Representative procedure D Access indoles and quinolines: A suspension of ortho-
aminoketone (185), (88.5 mg. 0.5 mmol), 2-bromo-1-phenylethan-1-one (149 mg, 1.5 equiv), 
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and anhydrous DMF (2.0 mL) was added and stirred at 100 °C for 16 h. At ambient 
temperature, the reaction mixture was diluted with Et2O (20 mL) and passed through celite 
with Et2O (100 mL). The organic layer was dried over Na2SO4. After evaporation of the solvent 
in vacuo, the crude product was purified by column chromatography on silica gel (n-
hexane/EtOAc: 5:1) to yield 193 (112 mg, 81%) as a yellow solid. 
 
5.2.5 Representative procedure E Access indoles and quinolines: A suspension of ortho-
aminoketone (185), (88.5 mg. 0.50 mmol), 2-bromo-ethynylbenzene (77.0 mg, 1.5 equiv), 
InCl3 (14.8 mg, 20 mol %) and anhydrous CH3CN (2.0 mL) was added and stirred at 90 °C for 
24 h. At ambient temperature, the reaction mixture was diluted with EtOAc (20 mL) and passed 
through celite with CH2Cl2 (100 mL). The organic layer was dried over Na2SO4. After 
evaporation of the solvent in vacuo, the crude product was purified by column chromatography 
on silica gel (n-hexane/EtOAc: 5:1) to yield 194a (124 mg, 94%) as a yellow solid. 
 
5.2.6 Representative Procedure E1: Ruthenium-catalyzed C–H amidation of pyridines 43 
: In a 20 mL flame-dried screw-capped sealed tube, 2-phenylpyridine (43), (71 mg, 0.50 mmol), 
4-methyl benzenesulfonyl azide (149), (183 mg, 2.0 equiv), [RuCl2(p-cymene)]2 (15.0 mg, 5.0 
mol %), AgSbF6 (34.0 mg, 20.0 mol %), NaOAc (21 mg, 0.5 equiv) in DCE (2.0 mL) were 
stirred at 100 °C for 24 h. At ambient temperature, the reaction mixture was diluted with H2O 
(75 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic layers were 
washed with brine (50 mL) and dried over Na2SO4. After filtration and evaporation of the 
solvents in vacuo, the crude product was purified by column chromatography on silica gel (n-
hexane/EtOAc: 4:1) to yield 168 (113 mg, 70%) as a colorless solid. 
 
5.2.7 Representative procedure F: Ruthenium-catalyzed oxidative oxygenation of 
substituted pyridines 186: A suspension of 2-(o-tolyloxy)pyridine (186), (185.4 mg, 1.00 
mmol), p-toluic acid (101a), (68.4 mg, 0.50 mmol), [{RuCl2-(p-cymene)}2] (7.6 mg, 2.5 mol 
%), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol) in DCE (2.0 mL) was stirred 
in a sealed tube under N2 at 100 °C for 18 h. At ambient temperature, the reaction mixture was 
diluted with 20 mL CH2Cl2 (20 mL) and passed through celite with CH2Cl2 (100 mL). The 
organic layer was dried over Na2SO4. After evaporation of the solvent under reduced pressure, 
the crude product was purified by column chromatography on silica gel (n-hexane/EtOAc: 
10:1) to yield 187 (124.8 mg, 78%) as a colorless solid. 
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5.2.8 Representative procedure G: Ruthenium(II)−catalyzed C−H oxygenation of arenes 
180: A suspension of sulfoximine benzamide (180), (137 mg, 0.50 mmol), carboxylic acid 
(101a), (82.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 5.0 mol %), KPF6 (46.0 mg, 
50 mol %) and (NH4)2S2O8 (114 mg, 1.00 mmol) in DCE (2.0 mL) was degassed with N2 five 
times and stirred in a sealed tube under N2 at 110 °C for 24 h. At ambient temperature, the 
reaction mixture was diluted with CH2Cl2 (20 mL) and passed through Celite with CH2Cl2 (150 
mL). The organic layer was dried over Na2SO4. After evaporation of the solvent in vacuo, the 
crude product was purified by column chromatography on silica gel (n-hexane/EtOAc: 10:3) 
to yield 189 (164 mg, 81%) as a colorless solid. 
 
5.2.9 Representative procedure H: Remove and reuse of sulfoximine 202: N-[2-(4-
Methylbenzoyloxy-4-methoxy)]-S-methyl-S-phenylsulfoximine (189) (211 mg, 0.50 mmol) 
was dissolved in aqueous HCl (12 N, 5.0 mL) and stirred at 80 °C for 48 h. The reaction mixture 
was extracted with CH2Cl2, and aqueous layer was basified with 40% NaOH and extracted with 
CH2Cl2. The organic layer was washed with brine, dried over Na2SO4, and concentrated under 
vacuum to give sulfoximine 202 (130 mg, 74%) as a colorless liquid dried over Na2SO4, and 
concentrated under vacuum to give the corresponding 4-methoxy-2-hydroxy benzoic acid 190a 
(139 mg, 71%). 
 
5.2.10 Representative Procedure I: Aerobic ruthenium(II)-catalyzed oxidative 
alkenylation with O2 as oxidant 186: A suspension of 2-(aryloxy)pyridine (186) (0.50 mmol, 
1.0 equiv), acrylate (63) (2.5 mmol, 5.0 equiv), Ru(O2CMes)2(p-cymene)] (28.0 mg, 0.05 
mmol, 10.0 mol %) and CsOAc (288 mg, 1.50 mmol) were placed in a pre-dried 25 mL Schlenk 
tube. The flask was evacuated and flushed with O2 three times. The reaction mixture was stirred 
at 120 °C for 18 h under O2 (1 atm). At ambient temperature, the reaction mixture was diluted 
with saturated aq. NH4Cl (10 mL) and extracted with EtOAc (3 x 25 mL). The combined 
organic layers were dried over Na2SO4. After filtration and evaporation in vacuo, the product 









Scheme 1.71: H/D-Exchange experiments of weakly co-ordinating ketone 184. 
 
5.3.1 Procedure J: H/D-Exchange experiments of weakly co-ordinating ketone (Scheme 
1.50). A suspension of 2,2-dimethyl-1-phenylpropan-1-one (184) (81.0 mg, 0.50 mmol), 1,3-
dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183) (190 mg, 0.60 mmol), [{RuCl2(p-
cymene)}2] (15.3 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2∙H2O (49.0 mg, 
0.50 equiv) in 1,4-dioxane:CD3OD (5:1, 2.0 mL) was stirred in a sealed tube under N2 at 100 
°C for 24 h. At ambient temperature, the reaction mixture was diluted with CH2Cl2 (20 mL) 
and passed through celite with CH2Cl2 (100 mL). The organic layer was dried over Na2SO4. 
After evaporation of the solvents in vaccuo, the crude product was purified by column 
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5.3.2 Ruthenium-Catalyzed H/D Exchange in Substrates 186b with D2O as the cosolvent. 
 
 
Scheme 1.72 H/D-Exchange experiments of arene 186. 
 
5.3.3 Procedure K: H/D-Exchange experiments of 2-phenoxypyridine (Scheme 1.59): A 
suspension of 2-phenoxypyridine 186b (171 mg, 1.0 mmol), p-toluic acid 101b (68.4 mg, 0.5 
mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol%), AgSbF6 (34.4 mg, 20 mol%) and K2S2O8 
(270 mg, 2.0 mmol) in DCE:D2O (1.8:0.2, 2 0 mL) was stirred in a sealed tube under N2 at 100 
°C for 18 h. At ambient temperature, the reaction mixture was diluted with 20 mL CH2Cl2 and 
passed with celite with 100 mL CH2Cl2. The organic layer was dried over Na2SO4. After 
evaporation of the solvents in vaccuo, the crude product was purified by column 
chromatography on silica gel (n-hexane/EtOAc: 10:1) to yield [D]n-187bd 73% and [D]n-
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6 Analytical Data: 
 
Synthesis of 2-(2-Pivaloylphenyl)isoindoline-1,3-dione (192aa) 
 
 
The representative procedure A was followed using 2,2-dimethyl-1-phenylpropan-1-one (184a) (81.0 
mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 0.60 mmol), 
[{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2∙H2O (49.0 
mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 192aa (120 mg, 
78%) as a white solid.  
 
M. p.: 125_126 °C. 
 
1H-NMR (400 MHz, CDCl3): δ = 7.90 (dd, J = 7.3, 0.6 Hz, 2H), 7.77 (dd, J = 7.2, 1.2 Hz, 2H), 7.68 
(ddd, J = 7.7, 1.6, 0.5 Hz, 1H), 7.58–7.52 (dd, J = 7.2, 1.3 Hz, 1H), 7.45 (td, J = 7.6, 1.3 Hz, 1H), 7.35 
(ddd, J = 7.9, 1.3, 0.5 Hz, 1H), 1.30 (s, 9H). 
 
13C-NMR (100 MHz, CDCl3): δ = 209.7 (Cq), 167.5 (Cq), 137.8 (Cq), 134.3 (CH), 131.9 (Cq), 130.6 
(CH), 130.2 (CH), 129.4 (Cq), 127.9 (CH), 126.9 (CH), 123.7 (CH), 44.4 (Cq), 28.4 (CH3).  
 
IR (ATR): 2943, 1720, 1650, 1372, 1060, 982, 830, 509 cm-1.  
 
MS (EI) m/z (relative intensity) 307 (65) [M+], 192 (100), 161 (55), 142 (35). 
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Synthesis of 2-(5-Methyl-2-pivaloylphenyl)isoindoline-1,3-dione (192ba) 
 
 
The representative procedure A was followed using 2,2-dimethyl-1-(p-tolyl)propan-1-one (184b) (88.0 
mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 0.60 mmol), 
[{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2∙H2O (49.0 
mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 192ba (118 mg, 
74%) as a white solid.  
 
M.p.: 136_137 °C. 
 
1H-NMR (500 MHz, CDCl3): δ = 7.83 (dd, J = 7.6, 0.5 Hz, 1H), 7.70 (d, J = 8.6, Hz, 2H), 7.55 (d, J = 
7.9 Hz 2H), 7.4 (td, J = 7.6, 1.3 Hz, 1H), 7.36–7.32 (m, 1H), 2∙54 (s, 3H), 1.31 (s, 9H). 
 
13C-NMR (126 MHz, CDCl3): δ = 209.5 (Cq), 167.5 (Cq), 145.5 (Cq), 137.8 (Cq), 134.8 (CH), 132.2 
(Cq), 130.5 (CH), 129.4 (Cq), 127.7 (CH), 124.1 (CH), 123.5 (CH), 44.4 (Cq), 28.4 (CH3), 22.1 (CH3). 
 
IR (ATR): 2953, 1725, 1675, 1378, 1110, 824, 531 cm-1.  
 
MS (EI) m/z (relative intensity) 321 (40) [M+], 281 (100), 184 (65), 165 (45).  
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Synthesis of 2-(5-Methoxy-2-pivaloylphenyl)isoindoline-1,3-dione (192ca) 
 
 
The representative procedure A was followed using 1-(4-methoxyphenyl)-2,2-dimethylpropan-1-one 
(184c) (96.0 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 
0.60 mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and 
Cu(OAc)2·H2O (49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) 
yielded 192ca (119 mg, 63%) as a white solid.  
 
M. p: 186_187 °C.  
 
1H-NMR (600 MHz, CDCl3): δ = 7.89 (dd, J = 5.4, 3.1 Hz, 1H), 7.85 (dd, J = 5.4, 3.1 Hz, 1H), 7.74 
(ddd, J = 5.6, 3.0, 1.7 Hz, 2H), 7.69 (d, J = 8.7 Hz, 1H), 6.94 (dd, J = 8.7, 2.6 Hz, 1H), 6.86 (d, J = 2.6 
Hz, 1H), 3.84 (s, 3H), 1.29 (s, 9H).  
 
13C-NMR (126 MHz, CDCl3): δ = 208.6 (Cq), 167.8 (Cq), 161.0 (Cq), 134.3 (CH), 134.3 (CH), 132.6 
(Cq), 132.0 (CH), 131.5 (Cq), 129.8 (Cq), 128.6 (CH), 124.0 (CH), 123.5 (CH), 55.6 (CH3), 44.4 (Cq), 
28.5 (CH3).  
 
IR (ATR): 2962, 1719, 1259, 1084, 1012, 792, 644 cm-1.  
 
MS (EI) m/z (relative intensity) 337 (65) [M+], 289 (100), 161 (55), 142 (45).  
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Synthesis of 2-[(5-(tert-Butyl)-2-pivaloylphenyl)]isoindoline-1,3-dione (192da) 
 
The representative procedure A was followed using 1-[4-(tert-butyl)phenyl)]-2,2-dimethylpropan-1-
one (184d) (109 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 
0.60 mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and 
Cu(OAc)2·H2O (49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) 
yielded 192da (114 mg, 63%) as a white solid. 
 
M.p.: 164_165 °C.  
 
1H-NMR (500 MHz, CDCl3): δ = 7.88 (dd, J = 5.5, 3.0 Hz, 2H), 7.74 (dd, J = 5.5, 3.1 Hz, 2H), 7.64 
(dd, J = 8.2, 0.4 Hz, 1H), 7.44 (dd, J = 8.2, 0.7 Hz, 1H), 7.32 (d, J = 2.0 Hz, 1H), 1.33 (s, 9H), 1.30 (s, 
9H). 
 
13C-NMR (126 MHz, CDCl3): δ = 209.5 (Cq), 167.7 (Cq), 154.3 (Cq), 134.7 (Cq), 134.0 (CH) 132.0 
(Cq), 129.3 (CH), 127.3 (CH), 126.9 (CH), 124.9 (CH), 123.6 (Cq), 45.0 (Cq), 34.9 (Cq), 31.0 (CH3), 
28.4 (CH3). 
 
IR (ATR): 2956, 1717, 1685, 1378, 1117, 1088, 964, 736 cm-1. 
 
MS (EI) m/z (relative intensity) 363 (45) [M+], 187 (100), 214 (65), 105 (35). 
 
HR-MS (ESI) m/z for C23H26NO4 [M+H+]   calcd.: 364.0734. 
found: 364.0709. 
Analytical Data 
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The representative procedure A was followed using 2,2-dimethyl-1-[(4-
(trifluoromethyl)phenyl)]propan-1-one (184e) (115 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-
methylbenzenesulfonate (183a) (190 mg, 0.60 mmol), [{RuCl2-(p-cymene)}2] (14.0 mg, 5.0 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O (49.0 mg, 0.50 equiv). Isolation by column 




1H-NMR (300 MHz, CDCl3): δ = 7.93–7.89 (m, 2H), 7.80–7.75 (m, 3H), 7.73–7.68 (m, 1H), 7.64 (dt, 
J = 1.9, 0.7 Hz, 1H), 1.31 (s, 9H). 
 
13C-NMR (126 MHz, CDCl3): δ = 208.6 (Cq), 166.9 (Cq), 141.0 (CH), 134.0 (Cq), 132.6 (q, 2JC-F = 35 
Hz, Cq), 132.4 (CH), 131.0 (q, 1JC-F = 272 Hz, Cq), 127.3 (CH), 126.0 (Cq), 125.2 (q, 3JC-F = 4 Hz, CH), 
124.8 (q, 3JC-F = 4 Hz, CH), 121.2 (CH), 44.5 (Cq), 28.3 (CH3). 
 
19F-NMR (283 MHz, CDCl3) δ = -63.0 (s). 
 
IR (ATR): 2973, 1714, 1379, 1292, 1115, 1076, 884, 702 cm-1. 
 
MS (EI) m/z (relative intensity) 341 (45) [M+], 287 (100), 226 (70), 134 (45). 
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Synthesis of 2-(5-Fluoro-2-pivaloylphenyl)isoindoline-1,3-dione (192fa) 
 
 
The representative procedure A was followed using 1-(4-fluorophenyl)-2,2-dimethylpropan-1-one 
(184f) (90.0 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 0.60 
mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O 
(49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 192fa 
(107 mg, 66%) as a white solid. 
 
M.p.: 137–138 °C.  
 
1H-NMR (300 MHz, CDCl3): δ = 7.89 (ddd, J = 5.5, 2.9, 0.4 Hz, 2H), 7.77 (d, J = 0.4 Hz, 1H), 7.77–
7.74 (m, 1H), 7.70 (ddt, J = 8.6, 5.9, 0.4 Hz, 1H), 7.18 (dd, J = 2.6, 0.4 Hz, 1H), 7.16–7.08 (m, 1H), 
1.30 (s, 9H). 
 
13C-NMR (126 MHz, CDCl3): δ = 208.4 (Cq), 166.9 (Cq), 163.0 (q, 1JC-F = 238 Hz, Cq), 161.7 (CH), 
133.7 (q, 4JC-F = 4 Hz, Cq), 131.7 (CH), 131.5 (q, 3JC-F = 10 Hz, CH), 128.6 (q, 3JC-F = 10 Hz, Cq), 123.8 
(CH), 117.8 (q, 2JC-F = 22 Hz, CH), 114.8 (q, 2JC-F = 22 Hz, CH), 44.5 (Cq), 28.5 (CH3). 
 
19F-NMR (283 MHz, CDCl3) δ = -107.7 (s). 
 
IR (ATR): 2971, 1736, 1658, 1325, 1120, 821, 536 cm-1. 
 
MS (EI) m/z (relative intensity) 325 (65) [M+], 221 (100), 148 (60), 139 (50). 
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The representative procedure A was followed using 1-(4-chlorophenyl)-2,2-dimethylpropan-1-one 
(184g) (98.0 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 
0.60 mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and 
Cu(OAc)2·H2O (49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) 
yielded 192ga (116 mg, 68%) as a white solid. 
 
M.p.: 126_127 °C. 
 
1H-NMR (400 MHz, CDCl3): δ = 7.86 (dd, J = 1.8, 0.6 Hz, 1H), 7.84 (dd, J = 8.0, 0.6 Hz, 1H), 7.73–
7.68 (m, 2H), 7.55 (ddd, J = 7.6, 1.5 Hz, 1H), 7.46 (td, J = 7.6, 1.3 Hz, 1H), 7.34 (ddd, J = 7.9, 1.3, 0.5 
Hz, 1H), 1.29 (s, 9H). 
 
13C-NMR (126 MHz, CDCl3): δ = 209.7 (Cq), 166.6 (Cq), 141.1 (Cq), 137.6 (Cq), 134.4 (CH), 133.6 
(Cq), 130.8 (CH), 130.1 (CH), 129.2 (CH), 127.1 (Cq), 125.0 (CH), 44.5 (Cq), 28.4 (CH3). 
 
IR (ATR): 2990, 1836, 1725, 1429, 1185, 970, 715, 534 cm-1. 
 
MS (EI) m/z (relative intensity) 341 (65) [M+], 281 (100), 162 (55), 139 (45). 
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The representative procedure A was followed using 1-(4-bromophenyl)-2,2-dimethylpropan-1-one 
(184h) (120 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 0.60 
mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O 
(49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 192ha 




1H-NMR (500 MHz, CDCl3): δ = 7.91–7.87 (m, 2H), 7.78–7.75 (m, 2H), 7.58 (dd, J = 8.4, 1.9 Hz, 1H), 
7.56–7.52 (m, 2H), 1.29 (s, 9H).  
 
 
13C-NMR (126 MHz, CDCl3): δ = 208.6 (Cq), 166.9 (Cq), 136.3 (Cq), 134.4 (CH), 133.2 (CH), 131.6 
(CH), 131.0 (Cq), 130.7 (Cq), 128.0 (CH), 124.0 (CH), 123.8 (Cq), 44.5 (Cq), 28.4 (CH3). 
 
 
IR (ATR) 2930, 1820, 1735, 1502, 1112, 725, 435 cm-1. 
 
 
MS (EI) m/z (relative intensity) 385 (40) [79Br, M+], 388 (40) [81Br, M+], 217 (100), 138 (60), 140 (50). 
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The representative procedure A was followed using 1-(4-iodophenyl)-2,2-dimethylpropan-1-one (184i) 
(144 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 0.60 
mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O 
(49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 192ia (115 
mg, 53%) as a white solid. 
 
M.p.: 108_109 °C. 
 
 
1H-NMR (500 MHz, CDCl3): δ = 7.91–7.88 (m, 2H), 7.79 (dd, J = 8.2, 1.7 Hz, 1H), 7.76 (dd, J = 6.5, 
2.1 Hz, 2H), 7.71 (d, J = 7.3 Hz, 1H), 7.40 (d, J = 8.2 Hz, 1H), 1.28 (s, 9H). 
 
13C-NMR (126 MHz, CDCl3): δ = 208.7 (Cq), 167.0 (Cq), 138.9 (CH), 137.0 (Cq), 136.8 (CH), 134.4 
(CH), 131.6 (Cq), 130.4 (Cq), 128.0 (CH), 123.8 (CH), 95.6 (Cq), 44.5 (Cq), 28.4 (CH3). 
 
 
IR (ATR): 2958, 1713, 1676, 1367, 952, 712, 529 cm-1. 
 
 
MS (EI) m/z (relative intensity) 433 (25) [M+], 328 (100), 276 (55), 115 (35). 
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The representative procedure A was followed using 2,2-dimethyl-1-(naphthalen-2-yl)propan-1-one 
(184k) (106 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 0.60 
mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O 
(49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 192ka 
(123 mg, 69%) as a white solid. 
 
M.p.: 113_114 °C. 
 
1H-NMR (500 MHz, CDCl3): δ = 8.16 (s, 1H), 7.92– (dd, J = 7.2, 1.2 Hz, 3H), 7.88–7.85 (m, 1H), 7.84 
(s, 1H), 7.77 (dd, J = 7.3, 1.2 Hz, 2H), 7.59 (dd, J = 7.3, 1.2 Hz, 2H), 1.39 (s, 9H).  
 
13C-NMR (126 MHz, CDCl3): δ = 209.5 (Cq), 167.8 (Cq), 134.4 (Cq), 134.3 (CH), 133.5 (Cq), 132∙0 
(Cq), 131.6 (Cq), 129.6 (CH), 128.5 (CH), 128.1 (CH), 128.0 (CH), 127.7 (CH), 127.4 (CH), 126.7 (Cq), 
123.7 (CH), 44.6 (Cq), 28.7 (CH3). 
 
IR (ATR): 2923, 1718, 1687, 1466, 1171, 1074, 832, 747 cm-1. 
 
 
MS (EI) m/z (relative intensity) 357 (25) [M+], 308 (100), 276 (55), 115 (35). 
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The representative procedure A was followed using 2,2-dimethyl-1-(naphthalen-1-yl)propan-1-one 
(184l) (106 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 0.60 
mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O 
(49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 192la (100 




1H-NMR (500 MHz, CDCl3): δ = 8.16 (dd, J = 6.3, 0.7 Hz, 2H), 7.94–7.91 (m, 2H), 7.89–7.83 (m, 2H), 
7.78–7.75 (m, 2H), 7.61–7.57 (m, 2H), 1.39 (s, 9H). 
 
 
13C-NMR (126 MHz, CDCl3): δ = 209.5 (Cq), 167.8 (Cq), 134.5 (Cq), 134.3 (CH), 133.5 (Cq), 132.0 
(Cq), 131.6 (Cq), 129.7 (CH), 128.5 (CH), 128.1 (CH), 128.0 (CH), 127.7 (CH), 127.4 (CH), 126.8 (Cq), 
123.7 (CH), 44.6 (Cq), 28.7 (CH3). 
 
 
IR (neat): 2926, 1869, 1726, 1518, 1327, 1248, 1057, 892 cm-1. 
 
MS (EI) m/z (relative intensity) 357 (55) [M+], 318 (100), 221 (55), 108 (35). 
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The representative procedure A was followed using 2,2-dimethyl-1-(3-tolyl)propan-1-one (184m) (115 
mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 0.60 mmol), 
[{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2∙H2O (49.0 
mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 192ma (104 




1H NMR (500 MHz, CDCl3): δ = 7.88 (dd, J = 5.4, 3.1 Hz, 2H), 7.74 (dd, J = 5.5, 3.1 Hz, 2H), 7.45 (s, 
1H), 7.32 (d, J = 7.2 Hz, 1H), 7.22 (d, J = 7.3 Hz, 1H), 2.43 (s, 3H), 1.28 (s, 9H). 
 
 
13C NMR (126 MHz, CDCl3): δ = 210.0 (Cq), 167.6 (Cq), 138.2 (Cq), 137.8 (Cq), 134.3 (CH), 131.9 
(CH), 131.2 (Cq), 130.0 (CH), 127.4 (CH), 126.6 (Cq), 123.7 (CH), 44.4 (Cq), 28.3 (CH3), 21.4 (CH3). 
 
 
IR (ATR): 2953, 1736, 1358, 1106, 1086, 982, 838, 509 cm-1. 
 
MS (EI) m/z (relative intensity) 321 (45) [M+], 280 (100), 189 (55), 145 (40). 
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The representative procedure A was followed using 1-(3-methoxyphenyl)-2,2-dimethylpropan-1-one 
(184n) (96.0 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 
0.60 mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and 
Cu(OAc)2·H2O (49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) 




1H-NMR (300 MHz, CDCl3): δ = 7.90 (dd, J = 5.4, 3.0 Hz, 1H), 7.88 (dd, J = 5.4, 3.0 Hz, 1H), 7.72 
(ddd, J = 5.3, 2∙8, 1.6 Hz, 2H), 7.59 (d, J = 8.6 Hz, 1H), 6.95 (dd, J = 8.4, 2∙3 Hz, 1H), 6.86 (s, 1H), 
3.82 (s, 3H), 1.27 (s, 9H). 
 
13C-NMR (126 MHz, CDCl3): δ = 208.6 (Cq), 167.9 (Cq), 161.0 (Cq), 134.3 (CH), 134.0 (CH), 132∙6 
(Cq), 132∙0 (CH), 131.9 (Cq), 129.8 (Cq), 123.6 (CH), 123.6 (CH), 55.6 (CH3), 44.4 (Cq), 28.5 (CH3). 
 
 
IR (neat): 2981, 1664, 1219, 1120, 1027, 735, 656 cm-1. 
 
MS (EI) m/z (relative intensity) 337 (65) [M+], 264 (100), 236 (60), 193 (50), 152 (30). 
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The representative procedure A was followed using 2,2-dimethyl-1-[(3-
(trifluoromethyl)phenyl)]propan-1-one (184n) (124 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-
methylbenzenesulfonate (183a) (190 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O (49.0 mg, 0.50 equiv). Isolation by column 




1H-NMR (500 MHz, CDCl3): δ = 7.93–7.89 (m, 3H), 7.80–7.76 (m, 3H), 7.53 (s, 1H), 1.33 (s, 9H).  
 
13C-NMR (126 MHz, CDCl3): δ = 208.2 (Cq), 166.8 (Cq), 138.0 (Cq), 134.6 (CH), 132.0 (q, 2JC-F = 35 
Hz, Cq), 130.6 (q, 1JC-F = 272 Hz, Cq), 127.4 (q, 3JC-F = 4 Hz, CH), 126.3 (CH), 125.2 (CH), 124.0 (q, 
3JC-F = 4 Hz, CH), 123.8 (Cq), (q, 4JC-F = 2 Hz, Cq), 44.5 (Cq), 28.4 (CH3). 
 
19F-NMR (283 MHz, CDCl3): δ = -62.8 (s). 
 
IR (ATR): 2964, 1895, 1325, 1263, 1126, 1054, 823, 728 cm-1. 
 
MS (EI) m/z (relative intensity) 375 (45) [M+], 287 (100), 226 (70), 134 (45). 
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The representative procedure A was followed using 1-(3-fluorophenyl)-2,2-dimethylpropan-1-one 
(184p) (90.0 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 
0.60 mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and 
Cu(OAc)2·H2O (49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) 




1H-NMR (300 MHz, CDCl3): δ = 7.82 (ddd, J = 5.5, 2.9, 0.4 Hz, 2H), 7.70 (d, J = 0.4 Hz, 2H), 7.71–
7.69 (m, 2H), 7.16 (s, 1H), 1.30 (s, 9H). 
 
13C-NMR (126 MHz, CDCl3): δ = 208.3 (Cq), 166.8 (Cq), 163.8 (q, 1JC-F = 243 Hz, Cq), 161.7 (CH), 
134.1 (CH), 133.6 (q, 4JC-F = 4 Hz, Cq), 131.6 (q, 3JC-F = 9 Hz, Cq), 128.5 (q, 3JC-F = 9 Hz, CH), 128.5 
(CH), 117.8 (q, 2JC-F = 23 Hz, CH), 114.8 (Cq), 44.5 (Cq), 28.5 (CH3). 
 
19F-NMR (283 MHz, CDCl3): δ = -107.8 (s). 
 
IR (ATR): 2969, 1782, 1257, 1127, 1028, 985, 844, 744 cm-1. 
 
MS (EI) m/z (relative intensity) 325 (55) [M+], 223 (100), 118 (65), 142 (50). 
 
 






- 103 - 
 




The representative procedure A was followed using 2,2-dimethyl-1-(3-[(chloromethyl)phenyl)]propan-
1-one (184q) (115 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 
mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and 
Cu(OAc)2·H2O (49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) 




1H-NMR (300 MHz, CDCl3): δ = 7.97–7.83 (m, 2H), 7.76 (dd, J = 5.5, 3.1 Hz, 2H), 7.62 (d, J = 6.3 
Hz, 1H), 7.52 (dd, J = 8.5, 0.7 Hz, 1H), 7.30 (d, J = 8.5 Hz, 1H), 1.30 (s, 9H). 
 
13C-NMR (126 MHz, CDCl3): δ = 208.2 (Cq), 167.1(Cq), 138.9 (Cq), 134.4 (CH), 133.9 (Cq), 131.7 
(CH), 131.3 (Cq), 130.6 (CH), 127.8 (CH), 127.0 (Cq), 123.8 (CH), 44.6 (Cq), 28.4 (CH3). 
 
IR (ATR): 2970, 1722, 1676, 1357, 1089, 734, 688 cm-1. 
 
MS (EI) m/z (relative intensity) 341 (45) [M+], 284 (100), 168 (65), 135 (50). 
 
 









- 104 - 
 





The representative procedure A was followed using 2,2-dimethyl-1-(thiophen-3-yl)propan-1-one (184j) 
(84.0 mg, 0.50 mmol), 1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183a) (190 mg, 0.60 
mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O 
(49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 192ja 
(101 mg, 59%) as a white solid. 
M.p.:118_119 °C. 
 
1H-NMR (400 MHz, CDCl3): δ = 7.92 (ddd, J = 5.5, 3.2, 0.3 Hz, 2H), 7.78–7.75 (m, 2H), 7.46 (d, J = 
5.8 Hz, 1H), 7.34 (d, J = 5.8 Hz, 1H), 1.29 (s, 9H). 
 
13C-NMR (101 MHz, CDCl3): δ = 202.9 (Cq), 166.4 (Cq), 135.5 (CH), 135.2 (Cq), 134.5 (CH), 131.9 
(Cq), 126.0 (CH), 124.0 (Cq), 123.7 (CH), 44.5 (Cq), 27.4 (CH3). 
 
IR (ATR): 2975, 1713, 1673, 1377, 759, 718, 530 cm-1. 
 
MS (EI) m/z (relative intensity) 313 (35) [M+], 256 (100), 157 (60), 172 (55), 104 (30), 43 (10). 
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The representative procedure B was followed using 2,2-dimethyl-1-phenylpropan-1-one (184a) (82.0 
mg, 0.50 mmol), 5-methyl-1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183b) (199 mg, 0.60 
mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O 
(49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 192ab 




1H-NMR (500 MHz, CDCl3): δ = 7.76 (dd, J = 7.6, 0.5 Hz, 1H), 7.69–7.64 (m, 2H), 7.55–7.51 (m, 2H), 
7.43 (td, J = 7.6, 1.3 Hz, 1H), 7.36–7.32 (m, 1H), 2.50 (s, 3H), 1.29 (s, 9H). 
 
13C-NMR (126 MHz, CDCl3): δ = 209.5 (Cq), 167.5 (Cq), 167.4 (Cq), 145.5 (Cq), 137.8 (Cq), 134.8 
(CH), 132.2 (Cq), 130.5 (CH), 129.4 (Cq), 129.2 (Cq), 128.3 (CH), 127.7 (CH), 126.8 (CH), 124.1 (CH), 
123.5 (CH), 44.4 (Cq), 28.4 (CH3), 22.1 (CH3). 
 
IR (ATR): 2979, 1704, 1678, 1379, 1086, 965, 740 cm-1. 
 
MS (EI) m/z (relative intensity) 321 (55) [M+], 281 (100), 286 (65), 256 (50), 193 (35). 
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Synthesis of 5-(tert-Butyl)-2-(2-pivaloylphenyl)isoindoline-1,3-dione (192ac) 
 
 
The representative procedure B was followed using 2,2-dimethyl-1-phenylpropan-1-one (184a) (85.0 
mg, 0.50 mmol), 5-(tert-butyl)-1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183c) (224 mg, 
0.60 mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and 
Cu(OAc)2·H2O (49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) 




1H-NMR (400 MHz, CDCl3): δ = 7.93 (dd, J = 1.7, 0.7 Hz, 1H), 7.82–7.75 (m, 2H), 7.68 (ddd, J = 7.7, 
1.5, 0.5 Hz, 1H), 7.54 (dd, J = 7.6, 1.5 Hz, 1H), 7.46–7.42 (m, 1H), 7.33 (ddd, J = 7.8, 1.3, 0.5 Hz, 1H), 
1.37 (s, 9H), 1.30 (s, 9H). 
 
13C-NMR (101 MHz, CDCl3): δ = 209.8 (Cq), 167.9 (Cq), 167.5 (CH), 159.0 (Cq), 137.8 (Cq), 132.1 
(Cq), 131.4 (CH), 130.6 (CH), 130.2 (CH), 129.5 (Cq), 129.2 (CH), 127.8 (CH), 126.9 (Cq), 123.5 (Cq), 
120.9 (CH), 44.4 (Cq), 35.8 (Cq), 31.1 (CH3), 28.4 (CH3). 
 
IR (ATR): 2915, 1821, 1632, 1259, 1105, 1026, 862, 749 cm-1. 
 
MS (EI) m/z (relative intensity) 363 (35) [M+], 284 (100), 286 (60), 256 (50), 193 (30), 43 (10). 
 






- 107 - 
 




The representative procedure B was followed using 2,2-dimethyl-1-phenylpropan-1-one (184a) (85.0 
mg, 0.50 mmol), 5-chloro-1,3-dioxoisoindolin-2-yl-4-methylbenzenesulfonate (183d) (210 mg, 0.60 
mmol), [{RuCl2(p-cymene)}2] (14.0 mg, 5.0 mol %), AgSbF6 (34.4 mg, 20 mol %) and Cu(OAc)2·H2O 
(49.0 mg, 0.50 equiv). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 192ad 
(115 mg, 68%) as a white solid. 
 
M.p.: = 174_175 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 7.91 (dd, J = 7.2, 1.5 Hz, 2H), 7.79 (dd, J = 7.3, 1.3 Hz, 2H), 7.62 (d, 
J = 7.3 Hz, 1H), 7.52 (dd, J = 7.5, 1.3 Hz, 1H), 7.33–7.23 (m, 1H), 1.30 (s, 9H).  
 
13C-NMR (126 MHz CDCl3): δ = 208.2 (Cq), 167.1 (Cq), 166.5 (Cq), 138.8 (Cq), 134.4 (CH), 134.0 
(Cq), 132.8 (Cq), 131.5 (CH), 131.2 (Cq), 130.6 (CH), 128.8 (CH), 127.5 (CH), 127.0 (Cq), 123.8 (CH), 
44.6 (Cq), 28.4 (CH3).  
 
IR (ATR): 2872, 1729, 1635, 1345, 1023, 721, 635 cm-1. 
 
MS (EI) m/z (relative intensity) 341 (45) [M+], 306 (100), 307 (60), 291 (50), 276 (35), 57 (10). 
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The representative procedure C was followed using a suspension of 2-(2-pivaloylphenyl)isoindoline-
1,3-dione (192aa) (307 mg, 1.0 mmol) and hydrazine (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5:1) yielded 185a 1-(2-aminophenyl)-2,2-dimethylpropan-1-one (120 
mg, 69%) as a orange liquid. 
 
1H-NMR (500 MHz, CDCl3): δ = 7.76 (dd, J = 8.1, 1.5 Hz, 1H), 7.20–7.14 (m, 1H), 6.68 (ddd, J = 8.6, 
2.0, 0.4 Hz, 2H), 5.63 (s, 2H), 1.37 (s, 9H).  
 
13C-NMR (126 MHz, CDCl3): δ = 209.5 (Cq), 149.4 (Cq), 132.4 (CH), 130.3 (CH), 118.8 (Cq), 117.8 
(CH), 115.2 (CH), 44.8 (Cq), 29.0 (CH3). 
 
 
IR (ATR): 3472, 3341, 2953, 1620, 1465, 970, 805, 519 cm-1. 
 
MS (EI) m/z (relative intensity) 177 (55) [M+], 120 (100), 149 (65), 149 (55), 92 (25), 57 (10). 
 
HR-MS (ESI) m/z for C11H16NO [M+H+]    calcd.:178.1259.  
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The representative procedure C was followed using a suspension of 2-(5-methyl-2-
pivaloylphenyl)isoindoline-1,3-dione (192ba) (321 mg, 1.0 mmol) and hydrazine (2.0 mL). Purification 




1H-NMR (600 MHz, CDCl3): δ = 7.72 (d, J = 7.3 Hz, 1H), 6.48 (dd, J = 7.2, 1.3 Hz, 1H), 6.42 (dd, J = 
6.8, 1.2 Hz, 1H), 5.81 (s, 2H), 2.23 (s, 3H), 1.37 (s, 9H). 
 
 
13C-NMR (126 MHz, CDCl3): δ = 208.7 (Cq), 143.4 (Cq), 131.0 (CH), 130.8 (Cq), 118.0 (CH), 116.5 
(CH), 115.8 (Cq), 44.6 (Cq), 29.0 (CH3), 21.4 (CH3). 
 
 
IR (ATR): 3474, 3347, 2965, 1618, 1547, 1475, 1183, 970 cm-1. 
 
 
MS (EI) m/z (relative intensity) 190 (35) [M+], 134 (100), 135 (60), 106 (55), 77 (25), 43 (10). 
 
 
HR-MS (ESI) m/z for C12H17ClNO [M+H+]    calcd.: 191.1301.  
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The representative procedure C was followed using a suspension of 2-(5-methoxy-2-
pivaloylphenyl)isoindoline-1,3-dione (192ca) (337 mg, 1.0 mmol) and hydrazine (2.0 mL). Purification 




1H-NMR (600 MHz, CDCl3): δ = 7.83 (d, J = 7.3 Hz, 1H), 6.18 (dd, J = 7.2, 2.3 Hz, 2H), 6.1 (s, 2H), 
3.77 (s, 3H), 1.37 (s, 9H).  
 
 
13C-NMR (126 MHz CDCl3): δ = 207.3 (Cq), 163.0 (Cq), 153.3 (Cq), 133.3 (CH), 111.6 (Cq), 103.1 
(CH), 100.3 (CH), 55.1 (CH3), 44.3 (Cq), 29.1 (CH3). 
 
 
IR (ATR): 3421, 2935, 1747, 1527, 1436, 1417, 1183 cm-1. 
 
 
MS (EI) m/z (relative intensity) 206 (35) [M+], 150 (100), 151 (60), 122 (55), 107 (30), 95 (10). 
 
 
HR-MS (ESI) m/z for C18H18NO2 [M+H+]    calcd.: 207.1223  
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The representative procedure C was followed using a suspension of 2-(5-fluoro-2-
pivaloylphenyl)isoindoline-1,3-dione (192da) (325 mg, 1.0 mmol) and hydrazine (2.0 mL). Purification 
by column chromatography on silica on silica gel (n-hexane/EtOAc: 5:1) yielded 185d (144 mg, 74%) 
as a yellow liquid. 
 
 
1H-NMR (500 MHz, CDCl3): δ = 7.88–7.79 (m, 1H), 6.36–6.26 (m, 2H), 6.00 (s, 2H), 1.37 (s, 9H). 
 
 
13C-NMR (126 MHz, CDCl3): δ = 208.4 (Cq), 166.2 (Cq), 164.2 (Cq), 133.5 (CH), 116.5 (Cq), 114.7 
(CH), 103.3 (CH), 44.6 (Cq), 29.0 (CH3). 
 
 
19F NMR (282 MHz, CDCl3): δ = _106.6. 
 
 
IR (ATR): 3487, 3361, 2928, 1681, 1254, 1142, 783, 541 cm-1. 
 
 
MS (EI) m/z (relative intensity) 195 (45) [M+], 195 (100), 165 (65), 142 (50), 112 (30), 86 (10). 
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The representative procedure C was followed using a suspension of 2-(5-chloro-2-
pivaloylphenyl)isoindoline-1,3-dione (192ea) (342 mg, 1.0 mmol) and hydrazine (2.0 mL). Purification 




1H-NMR (500 MHz, CDCl3): δ = 7.72 (d, J = 8.7 Hz, 1H), 6.65 (dd, J = 7.1, 1.3 Hz, 1H), 6.57 (dd, J = 
8.7, 2.1 Hz, 1H), 5.82 (s, 2H), 1.36 (s, 9H). 
 
 
13C-NMR (126 MHz CDCl3): δ = 208.6 (Cq), 151.0 (Cq), 138.4 (Cq), 132.0 (CH), 117.0 (CH), 116.6 
(CH), 115.4 (Cq), 44.7 (Cq), 28.8 (CH3). 
 
 
IR (ATR): 3469, 3347, 3967, 1602, 1535, 1178, 953, 766 cm-1. 
 
 
MS (EI) m/z (relative intensity) 210 (10) [M+], 154 (100), 156 (70), 126 (55), 99 (30), 69 (10). 
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The representative procedure C was followed using a suspension of 2-(2-pivaloylphenyl)isoindoline-
1,3-dione (192fa) (386 mg, 1.0 mmol) and hydrazine (2.0 mL). Purification by column chromatography 
on silica gel (n-hexane/EtOAc: 5:1) yielded 185f (143 mg, 56%) as a orange liquid. 
 
 
1H-NMR (500 MHz, CDCl3): δ = 7.64 (d, J = 8.3 Hz, 1H), 6.83 (dd, J = 7.3, 1.4 Hz, 1H), 6.72 (dd, J = 
8.3, 2.0, Hz, 1H), 5.78 (s, 2H), 1.35 (s, Hz, 9H). 
 
 
13C-NMR (126 MHz CDCl3): δ = 208.8 (Cq), 150.9 (Cq), 131.8 (CH), 126.9 (Cq), 120.1 (CH), 118.3 
(CH), 117.1 (Cq), 44.8 (Cq), 28.7 (CH3). 
 
 
IR (ATR): 3462, 3254, 2915, 1578, 1364, 851, 816, 470 cm-1. 
 
 
MS (EI) m/z (relative intensity) 255 (40) [M+], 198 (100), 170 (60), 296 (50), 143 (30), 91 (10). 
 
 
HR-MS (ESI) m/z for C11H15BrNO [M+H+]    calcd.: 256.1430. 
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The representative procedure D was followed using a suspension of 1-(2-amino-4-methylphenyl)-2,2-
dimethylpropan-1-one (185b) (95.5 mg. 0.50 mmol), 2-bromo-1-(4-methoxyphenyl)ethan-1-one (170 
mg, 1.5 equiv), and anhydrous DMF (2 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 5:1) yielded 193 (130 mg, 81%) as a yellow solid. 
 
 
M.p.: 203_204 °C. 
 
 
1H-NMR (500 MHz, CDCl3): δ = 7.82 (d, J = 7.4 Hz, 2H), 7.78 (d, J = 7.4 Hz, 2H), 7.09 (s, 1H), 6.98 
(dd, J = 7.3, 1.2, Hz, 1H), 6.93–6.89 (m, 1H), 3.86 (s, 3H), 2.44 (s, 3H), 1.44 (s, 9H). 
 
 
13C-NMR (126 MHz, CDCl3): δ = 192.0 (Cq), 164.0 (Cq), 136.4 (Cq), 133.2 (Cq), 132.4 (CH), 131.7 
(Cq), 129.6 (CH), 127.1 (Cq), 124.6 (Cq), 122.7 (CH), 120.3 (CH), 113.8 (CH), 111.2 (CH), 55.6 (CH3), 
33.3 (Cq), 31.7 (CH3), 21.5 (CH3). 
 
IR (ATR): 3217, 2930, 1600, 1253, 1107, 984, 681 cm-1. 
 
MS (EI) m/z (relative intensity) 320 (45) [M+], 135 (100), 306 (65), 296 (50), 107 (30), 85 (10). 
 
HR-MS (ESI) m/z for C21H23NO2 [M+H+]    calcd.: 321.1729. 
found: 321.1736. 
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The representative procedure D was followed using a suspension of 1-(2-aminophenyl)-2,2-
dimethylpropan-1-one (185a) (88.5 mg. 0.50 mmol), 2-bromo-1-phenylethan-1-one (149 mg, 1.5 
equiv) and anhydrous DMF (2 mL). Purification by column chromatography on silica gel (n-
hexane/EtOAc: 5:1) yielded 193a (123 mg, 89%) as a yellow solid. 
 
M.p.: 203_204 °C. 
 
1H NMR (600 MHz, CDCl3): δ = 8.02 (s, 1H), 7.98 (dd, J = 8.5, 1.0 Hz, 1H), 7.81 (dd, J = 8.3, 1.4 Hz, 
2H), 7.60–7.57 (m, 1H), 7.45 (dd, J = 8.2, 1.3 Hz, 2H), 7.32–7.30 (m, 1H), 7.26–7.22 (m, 1H), 7.14 
(ddd, J = 8.2, 1.9, 1.1 Hz, 1H), 1.47 (s, 9H). 
 
 
13C NMR (126 MHz, CDCl3): δ = 193.2 (Cq), 138.6 (Cq), 136.0 (Cq), 133.6 (CH), 130.0 (CH), 129.7 
(CH), 12 
8.0 (Cq), 126.7 (Cq), 125.6 (CH), 123.5 (CH), 123.2 (CH), 119.7 (CH), 111.6 (CH), 33.4 (Cq), 31.7 
(CH3). 
 
IR (ATR): 3345, 2955, 1642, 1261, 1127, 742, 681, 595 cm-1. 
 
MS (EI) m/z (relative intensity) 276 (45) [M+], 262 (100), 247 (80), 105 (60), 234 (25), 43 (10). 
 
HR-MS (ESI) m/z for C19H20NO [M+H+]    calcd.: 277.1467. 
found: 277.1462  
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The representative procedure E was followed using a suspension of 1-(2-amino-4-methylphenyl)-2,2-
dimethylpropan-1-one (185b) (95.5 mg. 0.50 mmol), 2-bromo-ethynylbenzene (77.0 mg, 1.5 equiv), 
InCl3 (14.8 mg, 20 mol %) and anhydrous CH3CN (2.0 mL). Purification by column chromatography 




1H NMR (500 MHz, CDCl3): δ = 8.28 (d, J = 8.7 Hz, 1H), 8.12–8.10 (m, 2H), 7.99 (s, 1H), 7.75 (s, 
1H), 7.52–7.48 (m, 2H), 7.45 (dd, J = 8.2, 1.7, Hz, 1H), 7.33 (ddd, J = 8.9, 2.0, 0.6 Hz, 1H), 2∙54 (s, 
3H), 1.64 (s, 9H). 
 
13C NMR (126 MHz, CDCl3): δ = 157.0 (Cq), 156.5 (Cq), 148.5 (CH), 138.7 (CH), 131.0 (Cq), 129.7 
(Cq), 128.0 (CH), 127.5 (CH), 126.2 (Cq), 125.9 (Cq), 124.8 (CH), 119.3 (CH), 116.1 (CH), 115.4 (CH), 
36.3 (Cq), 31.2 (CH3), 28.4 (CH3). 
 
IR (ATR): 2927, 1543, 1056, 1219, 981, 786, 647 cm-1. 
 
MS (EI) m/z (relative intensity) 274 (55) [M+], 260 (100), 43 (40), 244 (35), 219 (25), 58 (10). 
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The representative procedure E was followed using a suspension of 1-(2-aminophenyl)-2,2-
dimethylpropan-1-one (185a) (88.5 mg. 0.50 mmol), 2-bromo-ethynylbenzene (77.0 mg, 1.5 equiv), 
InCl3 (14.8 mg, 20 mol %) and anhydrous CH3CN (2.0 mL). Purification by column chromatography 




1H NMR (600 MHz, CDCl3): δ = 8.42 (dd, J = 8.3, 1.3 Hz, 1H), 8.24 (dd, J = 8.4, 1.4 Hz, 2H), 8.17–
8.15 (m, 2H), 7.67 (ddd, J = 8.2, 5.3, 1.3 Hz, 2H), 7.55–7.45 (m, 3H), 1.68 (s, 9H). 
 
 
13C NMR (126 MHz, CDCl3): δ = 157.0 (Cq), 156.2 (Cq), 149.6 (Cq), 140.2 (Cq), 131.4 (CH), 129.1 




IR (ATR): 2957, 1586, 1227, 761, 691 cm-1. 
 
 
MS (EI) m/z (relative intensity) 260 (65) [M+], 258 (100), 243 (90), 115 (65), 226 (25), 53 (10). 
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The representative procedure E was followed using a suspension of 1-(2-amino-4-methoxyphenyl)-2,2-
dimethylpropan-1-one (185c) (103 mg. 0.50 mmol), 2-bromo-ethynylbenzene (77.0 mg, 1.5 equiv), 
InCl3 (14.8 mg, 20 mol %) and anhydrous CH3CN (2.0 mL). Purification by column chromatography 




1H-NMR (400 MHz, CDCl3): δ = 8.29 (d, J = 7.5 Hz, 1H), 8.12–8.08 (m, 2H), 7.68 (s, 1H), 7.55 (dd, 
J = 7.5, 1.3 Hz, 2H), 7.45–7.43 (m, 1H), 7.15 (dd, J = 7.3, 1.2 Hz, 2H), 3.96 (s, 3H), 1.64 (s, 9H). 
 
 
13C-NMR (101 MHz, CDCl3): δ = 159.4 (Cq), 157.5 (Cq), 156.3 (Cq), 151.6 (Cq), 140.5 (Cq), 129.0 
(CH), 128.7 (CH), 127.5 (CH), 123.4 (CH), 121.0 (Cq), 117.7 (CH), 114.4 (CH), 109.2 (CH), 55.5 
(CH3), 36.3 (Cq), 31.3 (CH3). 
 
 
IR (ATR): 2957, 1591, 1024, 1276, 924, 726, 689 cm-1. 
 
MS (EI) m/z (relative intensity) 290 (80) [M+], 276 (100), 290 (30), 235 (30), 191 (10). 
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and p-toluic acid (101b) (68.4 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), AgSbF6 
(34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 5/1) yielded 186ab (124 mg, 78%) as a white solid. 
 
M.p.: 90_92 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.13 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.75 (d, J = 8.0 Hz, 2H), 7.51 
(dd, J = 8.2, 5.2, Hz, 1H), 7.23 (d, J = 8.2 Hz, 1H), 7.13–7.10 (m, 3H), 6.95–6.72 (m, 1H), 6.82 (d, J = 
8, 6.2 Hz, 2H), 2.36 (s, 3H), 2.33 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.0 (Cq), 162.8 (Cq), 147.1(CH), 144.7 (Cq), 143.8 (Cq), 140.2 (Cq), 
138.9 (CH), 136.4 (Cq), 129.6 (CH), 128.6 (CH), 126.0 (Cq), 125.8 (CH), 123.3 (CH), 123.1 (CH), 118.1 
(CH), 110.6 (CH), 21.2 (CH3), 20.7 (CH3). 
 
IR (ATR): 2922, 1726, 1428, 1288, 1270, 1176, 1017, 776 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (79) [C12H10NO]+, 172 (4), 119 (100), 91 (41), 78 (7), 65 (13), 
51(5).  
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and benzoic acid (101a) (61.0 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), AgSbF6 
(34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 5/1) yielded 187aa (112 mg, 73%) as a white solid. 
 
M.p.: 98_100 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.12 (dd, J = 5.0, 1.7, 0.8 Hz, 1H), 7.81 (dd, J = 8.5, 1.1 Hz, 2H), 
7.61–7.46 (m, 2H), 7.40–7.29 (m, 2H), 7.21_7.10 (m, 3H), 6.89 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H), 6.85–
6.77 (m, 1H), 2.26 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.1 (Cq), 162.9 (Cq), 147.4 (CH), 145.3 (Cq), 144.1 (Cq), 142.8 (Cq), 
139.1 (CH), 129.9 (CH), 128.9 (CH), 126.6 (Cq), 126.2 (CH), 125.4 (CH), 123.8 (CH), 123.1 (CH), 
118.4 (CH), 110.9 (CH), 21.7 (CH3). 
 
IR (ATR): 1758, 1578, 1415, 1397, 1284, 1125, 1043, 742 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (100) [C12H10NO]+, 172 (10), 105 (100), 78 (15), 77 (60), 66 (5), 
51 (19). 
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and 4-flourobenzoic acid (101c) (70.0 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 




1H-NMR (300 MHz, CDCl3) δ = 8.10 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.81 (dd, J = 8.9, 5.4 Hz, 2H), 
7.53 (dd, J = 8.3, 5.2, Hz, 1H), 7.18 (d, J = 2.7 Hz, 3H), 6.99 (dd, J = 8.9, 8.4 Hz, 2H), 6.88 (dd, J = 
7.2, 5.0, Hz, 1H), 6.79 (d, J = 8.3, 0.9 Hz, 1H), 2.25 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 166.8 (Cq), 164.7 (Cq), 163.1 (d, 1JC-F = 250 Hz, Cq), 147.4 (CH), 143.3 
(Cq), 143.0 (d, 2JC-F = 20 Hz, CH), 139.1 (CH), 133.0 (Cq), 132.3 (CH), 133.5 (d, 3JC-F = 10 Hz, CH), 
128.4 (CH), 125.2 (d, 4JC-F = 3 Hz, Cq), 120.9 (CH), 118.0 (CH), 115.4 (d, 2JC-F = 20 Hz, CH), 110.1 
(CH), 16.4 (CH3). 
 
19F-NMR (283 MHz, CDCl3) δ = -104.6 (s). 
 
IR (neat): 1733, 1601, 1462, 1426, 1276, 1228, 1085, 850, 812 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (83) [C7H4FO2]+, 123 (100), 95 (34), 78 (6), 111 (30), 78 (10), 51 
(5), 43 (13). 
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and 4-methoxybenzoic acid (101d) (76.0 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187ad (106 mg, 63%) as a white solid.  
 
M.p.:102–104 °C.  
 
1H-NMR (300 MHz, CDCl3) δ = 8.16 (dd, J = 5.0, 2.0, Hz, 1H), 7.81–7.71 (m, 2H), 7.60 (dd, J = 8.3, 
7.2, Hz, 1H), 7.27–7.14 (m, 3H), 6.95–6.74 (m, 4H), 3.72 (s, 3H), 2.47 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 163.9 (Cq), 163.5 (Cq), 162.8 (Cq), 147.4 (CH), 143.5 (Cq), 143.2 (Cq), 
139.0 (CH), 133.0 (Cq), 132.0 (CH), 128.2 (CH), 125.2 (CH), 121.3 (Cq), 121.1 (CH), 118.0 (CH), 113.4 
(CH), 110.2 (CH), 55.4 (CH3), 16.4 (CH3). 
 
IR (ATR): 1730, 1428, 1262, 1234, 1095, 1076, 773, 747 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (40) [C12H10NO]+, 136 (12), 135 (100), 107 (10), 86 (11), 84 (19), 
77 (15) 51 (5). 
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and 3-(triflouromethyl)benzoic acid (101e) ( 95.0 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 
mol %), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol. Isolation by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 187ae (110 mg, 59%) as a yellow oil. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.16 (d, J = 4.6, 2.3 Hz, 1H), 8.09–8.01 (m, 1H), 8.01–7.95 (m, 1H), 
7.83 (dd, J = 8.3, 3.3 Hz, 1H), 7.61–7.45 (m, 2H), 7.28–7.19 (m, 3H), 6.95–6.80 (m, 2H), 2.29 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.1 (Cq), 162.9 (Cq), 147.4 (CH), 145.3 (Cq), 144.1 (CH), 142.8 
(CH), 139.1 (Cq), 128.9 (q, 2JC-F = 33 Hz, Cq), 129.9 (CH), 126.4 (Cq), 126.2 (q, 3JC-F = 4 Hz, CH), 125.4 
(Cq), 125.4 (CH), 123.8 (q, 1JC-F = 272 Hz, Cq), 123.1 (q, 3JC-F = 4 Hz, CH), 118.4 (CH), 110.9 (CH), 
21.7 (CH3).  
 
19F-NMR (283 MHz, CDCl3) δ = -62.81. 
 
IR (ATR): 1746, 1465, 1428, 1334, 1242, 1170, 906, 726 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (100) [C12H10NO]+, 173 (59), 145 (46), 126 (4), 83 (9), 78 (9) 51 
(5), 43 (20). 
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and 2-fluorobenzoic acid (101f) (70.0 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 




1H-NMR (300 MHz, CDCl3) δ = 8.16 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.70–7.61 (m, 1H), 7.61 (dd, J = 
8.3, 5.2, Hz, 1H), 7.53–7.44 (m, 1H), 7.21_7.18 (m, 3H), 7.15–7.02 (m, 2H), 6.96–6.81 (m, 2H), 2.47 
(s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 163.0 (d, 1JC-F = 272 Hz, Cq), 162.6 (Cq), 161.4 (d, 3JC-F = 4 Hz, Cq), 
147.4 (CH), 142.9 (Cq), 143.1 (Cq), 139.1 (CH), 134.9 (d, 3JC-F = 10 Hz, CH), 133.1 (Cq), 132.1 (CH), 
128.9 (CH), 125.3 (CH), 123.7 (d, 4JC-F = 4 Hz, CH), 120.9 (CH), 118.0 (d, 2JC-F = 10 Hz, Cq), 117.5 
(CH), 116.9 (d, 2JC-F = 22 Hz, CH), 110.0 (CH), 16.4 (CH3). 
 
19F-NMR (283 MHz, CDCl3) δ = -108.7. 
 
IR (ATR): 1737, 1717, 1426, 1271, 1185, 879, 816, 747 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (88) [C12H10NO]+ , 172 (5), 123 (100), 95 (26), 66 (4), 51 (6). 
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and furan-3-carboxylic acid (101m) (56.0 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 




1H-NMR (300 MHz, CDCl3) δ = 8.16–8.08 (m, 1H), 7.77–7.69 (m, 1H), 7.59 (ddd, J = 10.5, 5.3, 3.7, 
2.0 Hz, 1H), 7.35 (d, J = 5.3, 1.8 Hz, 1H), 7.29–7.14 (m, 3H), 6.97–6.80 (m, 2H), 6.59 (dd, J = 5.1, 1.8, 
Hz, 1H), 2.51 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 162.7 (Cq), 160.3 (Cq), 148.3 (CH), 147.5 (CH), 143.6 (CH), 143.4 
(Cq), 142.7 (Cq), 139.1 (CH), 133.0 (Cq), 128.4 (CH), 125.2 (CH), 121.0 (CH), 118.1 (Cq), 118.0 (CH), 
110.1 (CH), 109.8 (CH), 16.4 (CH3). 
 
IR (ATR): 2921, 2852, 1739, 1465, 1426, 1156, 1113, 771 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (100) [C12H10NO]+ , 172 (5), 119 (2), 102 (3), 96 (4), 95 (74) 78 
(11), 67 (4) 51 (5). 
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and furan-2-carboxylic acid (101n) (56.0 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187an (93 mg, 63%) as an off-white solid. 
 
M.p.: 101–103 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.10 (d, J = 4.5, 1.9 Hz, 1H), 7.65–7.46 (m, 2H), 7.21 (d, J = 5.1 Hz, 
3H), 6.97–6.75 (m, 3H), 6.47–6.36 (m, 1H), 2.62 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 162.6 (Cq), 155.8 (Cq), 147.4 (CH), 146.9 (CH), 143.4 (Cq), 142.4 (Cq), 
139.0 (CH), 133.1 (Cq), 128.5 (CH), 125.2 (CH), 120.9 (CH), 119.0 (CH), 118.0 (Cq), 111.7 (CH), 110.1 
(CH), 16.4 (CH3). 
 
IR (neat): 1724, 1464, 1427, 1289, 1273, 1095, 767, 748 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (100) [C12H10NO]+, 172 (6), 119 (2), 102 (3), 96 (4), 95 (76) 78 
(9), 67 (4) 51 (6). 
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The representative procedure F was followed using  2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 
mmol) and thiophene-3-carboxylic acid (101o) (64.0 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 
2.5 mol %), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 187ao (89 mg, 57%) as a white solid. 
 
M.p.: 95–97 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.12 (dd, J = 5.1, 2.0 Hz, 1H), 7.79–7.68 (m, 1H), 7.61–7.43 (m, 2H), 
7.33–7.18 (m, 2H), 7.14–7.02 (m, 2H), 6.91 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H), 6.81 (d, J = 8.3, 0.9 Hz, 
1H), 2.49 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 162.9 (Cq), 160.0 (Cq), 147.4 (CH), 144.8 (Cq), 140.0 (Cq), 139.1 (CH), 
136.8 (Cq), 133.6 (CH), 132.2 (Cq), 127.9 (CH), 126.0 (CH), 125.8 (CH), 123.5 (CH), 123.2 (CH), 118.3 
(CH), 110.9 (CH), 21.1 (CH3). 
 
IR (ATR): 1724, 1234, 1178, 1090, 1061, 853, 788, 420 cm-1. 
 
HR-MS (EI) m/z (relative intensity) 184 (79) [C12H10NO]+, 172 (6), 111 (100), 91 (4), 83 (12), 78 (10), 
51 (7), 43 (19). 
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and acetic acid (101p) (1 mL, 17 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), AgSbF6 (34.4 mg, 
20 mol %) and K2S2O8 (270 mg, 2.0 mmol) for 30 h. Isolation by column chromatography (n-
hexane/EtOAc: 5/1) yielded 187ap (139 mg, 57%) as a white solid.  
 
M.p.: 101–103 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.18–8.10 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H), 7.71–7.62 (m, 1H), 7.20–
7.13 (m, 2H), 7.08–7.02 (m, 1H), 6.99–6.86 (m, 2H), 2.23 (s, 3H), 1.96 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 168.3 (Cq), 162.6 (Cq), 147.5 (CH), 143.3 (Cq), 143.0 (Cq), 139.2 (CH),  
133.0 (Cq), 128.2 (CH), 125.2 (CH), 120.8 (CH), 118.0 (CH), 109.8 (CH), 20.4 (CH3), 16.3 (CH3). IR 
(neat): 2923, 1759, 1571, 1401, 1211, 1173, 1077, 768 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (100) [C12H10NO]+ , 201 (20), 172 (18), 79 (7), 78 (14), 66 (4), 51 
(7), 43 (13). 
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and butyric acid (101q) (44.5 mg, 0.50 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), AgSbF6 
(34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 5/1) yielded 187aq (87 mg, 64%) as an off-white solid. 
 
M.p.: 58–60 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.26–8.04 (m, 1H), 7.75–7.60 (m, 1H), 7.21–7.11 (m, 2H), 7.08–7.01 
(m, 1H), 6.99–6.85 (m, 2H), 2.27 (t, J = 7.4 Hz, 2H), 2.19 (s, 3H), 1.61–1.43 (m, 2H), 0.96 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 171.1 (Cq), 162.7 (Cq), 147.6 (CH), 143.2 (Cq), 139.2 (CH), 133.0 (Cq), 
128.3 (CH), 125.3 (CH), 121.0 (CH), 118.0 (CH), 109.9 (CH), 35.8 (CH2), 18.3 (CH2), 16.4 (CH3), 13.6 
(CH3).  
 
IR (ATR): 2965, 1760, 1463, 1426, 1270, 1235, 775 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (100) [C12H10NO]+, 201 (23), 172 (6), 79 (3), 71 (11), 66 (4), 51 
(5), 43 (18). 
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and cyclopentanecarboxylic acid (101r) (57.0 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol 
%), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187ar (108 mg, 73%) as a colorless oil. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.17–8.10 (m, 1H), 7.65 (ddd, J = 10.4, 6.3, 2.1 Hz, 1H), 7.19–7.13 
(m, 2H), 7.04 (dd, J = 6.2, 3.5 Hz, 1H), 6.99–6.84 (m, 2H), 2.77–2.69 (m, 1H), 2.20 (d, J = 1.8 Hz, 3H), 
1.77–1.46 (m, 8H). 
 
13C-NMR (75 MHz, CDCl3) δ = 174.1 (Cq), 162.7 (Cq), 147.6 (CH), 143.4 (Cq), 143.4 (Cq), 139.1 (CH), 
133.0 (Cq), 128.2 (CH), 125.3 (CH), 120.9 (CH), 118.0 (CH), 109.9 (CH), 43.6 (CH), 29.8 (CH2), 25.8 
(CH2), 16.4 (CH3).  
 
IR (ATR): 2955, 2871, 1755, 1463, 1462, 1271, 1119, 774 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (100) [C12H10NO]+, 201 (27), 172 (6), 144 (4), 78 (7), 69 (22), 51 
(6), 41 (10). 
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The representative procedure F was followed using 2-(o-tolyloxy)pyridine (186a) (185.4 mg, 1.0 mmol) 
and cyclopropanecarboxylic acid (101s) (43.0 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol 
%), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187as (78 mg, 58%) as a white solid. 
 
M.p.: 59–61 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.12 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.65 (dd, J = 8.3, 5.2,  Hz, 1H), 
7.16–7.11 (m, 2H), 7.07–7.00 (m, 1H), 6.97–6.86 (m, 2H), 2.19 (s, 3H), 1.54 (t, J = 7.9, Hz, 1H), 0.93–
0.85 (m, 2H), 0.82–0.73 (m, 2H). 
 
13C-NMR (75 MHz, CDCl3) δ = 172.2 (Cq), 162.7 (Cq), 147.5 (CH), 143.3 (Cq), 143.1 (Cq), 139.1 (CH), 
132.9 (Cq), 128.2 (CH), 125.2 (CH), 120.9 (CH), 118.0 (CH), 110.0 (CH), 16.4 (CH2), 12.8 (CH3), 8.8 
(CH2). 
 
IR (ATR): 2923, 2854, 1740, 1426, 1271, 1426, 1271, 1136, 774, 378 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (100) [C12H10NO]+, 201 (22), 172 (5), 78 (10), 69 (33), 66 (4), 51 
(6), 41 (22). 
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The representative procedure F was followed using 2-phenoxypyridine (186b) (171.1 mg, 1.0 mmol), 
4-methylbenzoic acid (101a) (67.5 mg, 0.5 mmol) and [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187bb (87 mg, 57%) as a white solid. 
 
M.p.: 97–99 °C.  
 
1H-NMR (300 MHz, CDCl3) δ = 8.14 (dd, J = 4.8, 2.1 Hz, 1H), 7.75 (d, J = 8.1 Hz, 1H), 7.60–7.52 (m, 
4H), 7.39–7.24 (m, 2H), 7.17 (d, J = 7.9 Hz, 2H), 6.96–6.89 (m, 1H), 6.84 (dd, J = 8.3, 0.9 Hz, 1H), 
2.44 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.0 (Cq), 162.9 (Cq), 147.4 (CH), 145.3 (Cq), 144.1 (Cq), 142.8 (Cq), 
139.1 (CH), 129.9 (CH), 128.9 (CH), 126.6 (Cq), 126.1 (CH), 125.4 (CH), 123.8 (CH), 123.1 (CH), 
118.4 (CH), 110.9 (CH), 21.7 (CH3).  
 
IR (ATR): 1738, 1472, 1455, 13857, 1244, 1144, 1015, 984, 742 cm-1. 
 
MS (EI) m/z (relative intensity) 170 (41) [C11H8NO]+, 120 (10), 119 (100), 91 (31), 78 (5), 65 (10), 51 
(4). 
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The representative procedure F was followed using 2-phenoxypyridine (186b) (171.1 mg, 1.0 mmol) 
and 4-chlorobenzoic acid (101e) (78.2 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.00 mmol) in DCE (2.0 mL). Isolation by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 187be (112 mg, 69%) as a white solid. 
 
M.p.: 116–118 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.11 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.78 (d, J = 8.6 Hz, 2H), 7.56 
(ddd, J = 8.4, 7.2, 2.0 Hz, 1H), 7.39–7.26 (m, 6H), 6.91 (dd, J = 7.2, 3.8, Hz, 1H), 6.85–6.80 (m, 1H).  
 
13C-NMR (75 MHz, CDCl3) δ = 163.3 (Cq), 162.9 (Cq), 147.5 (CH), 145.3 (Cq), 142.6 (Cq), 139.9 (Cq), 
139.3 (CH), 131.3 (CH), 128.7 (CH), 127.4 (Cq), 127.0 (CH), 125.6 (CH), 123.2 (CH), 123.2 (CH), 
118.5 (CH), 110.9 (CH). 
 
IR (ATR): 1738, 1588, 1465, 1427, 1244, 1225, 1053, 742 cm-1. 
 
MS (EI) m/z (relative intensity) 170 (82) [C11H8NO] +, 141 (35), 139 (100), 111 (36), 75 (11), 51 (8). 
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The representative procedure F was followed using 2-(4-chlorophenoxy)pyridine (186c) (205.6 mg, 1.0 
mmol), 4-methylbenzoic acid (101a) (67.5 mg, 0.5 mmol), [{RuCl-(p-cymene)}2] (7.6 mg, 2.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187ca (125 mg, 74%) as a colorless oil. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.11 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.73 (d, J = 8.2 Hz, 2H), 7.56 
(ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.37 (d, J = 2.3 Hz, 1H), 7.3 –7.21 (m, 2H), 7.1 –7.11 (m, 2H), 6.96–
6.81 (m, 2H), 2.42 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 163.8 (Cq), 162.7 (Cq), 147.4 (CH), 144.5 (Cq), 144.1 (Cq), 143.2 (Cq), 
139.4 (CH), 130.2 (CH), 130.0 (Cq), 129.1 (CH), 126.8 (CH), 125.7 (Cq), 124.3 (CH), 124.0 (CH), 118.7 
(CH), 111.0 (CH), 21.7 (CH3). 
 
IR (ATR): 1738, 1486, 1465, 1427, 1244, 1173, 1053, 862, 742 cm-1. 
 
MS (EI) m/z (relative intensity) 204 (28) [C11H7ClNO]+, 192 (4), 119 (100), 91 (34), 78 (8) 65 (12), 51 
(6). 
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The representative procedure F was followed using 2-(4-(trifluoromethyl)phenoxy)pyridine (186d) 
(239.1.6 mg, 1.0 mmol), 4-methylbenzoic acid (101a) (67.5 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 
mg, 2.5 mol %), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.00 mmol) in DCE (2.0 mL) were 
stirred in a sealed tube under N2 at 100 °C for 18 h. Isolation by column chromatography (n-
hexane/EtOAc: 5/1) yielded 187da (114 mg, 61%) as a colorless oil. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.15 (d, J = 4.6, 2.1 Hz, 1H), 7.8 –7.74 (m, 2H), 7.65–7.55 (m, 3H), 
7.45–7.38 (m, 1H), 7.25 (d, J = 2.3 Hz, 1H), 7.19 (dd, J = 8.3, 2.3 Hz, 1H), 6.97 (dd, J = 6.4, 2.8 Hz, 
1H), 6.9 (dd, J = 8.3, 2.3 Hz, 1H), 2.45 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 163.7 (Cq), 162.2 (CH), 148.3 (Cq), 147.4 (CH), 144.6 (Cq), 142.7 (Cq), 
139.5 (CH), 130.0 (CH), 129.1 (CH), 127.7 (q, 2JC-F = 33 Hz, Cq), 124.5 (q, 1JC-F = 280 Hz, Cq), 123.9 
(q, 3JC-F = 4 Hz, CH), 123.3 (CH), 121.6 (q, 4JC-F = 2 Hz, Cq), 119.1 (CH), 111.4 (CH), 21.8 (CH3).19F-
NMR (282 MHz, CDCl3) δ = -62.1 (s). 
 
IR (ATR): 1742, 1590, 1428, 1328, 1256, 1115, 1053 cm-1. 
 
HR-MS (EI) m/z (relative intensity) 238 (20) [C12H7F3NO]+, 226 (4), 119 (100), 91 (31), 78 (7), 65 
(12), 51 (6). 
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The representative procedure F was followed using 2-([1,1'-biphenyl]-4-yloxy)pyridine (186e) (247.2, 
1.0 mmol), 4-methylbenzoic acid (101a) (67.5 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol 
%), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.00 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 187ea (116 mg, 61%) as a white solid. 
 
M.p.: 101–103 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.15 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.79 (d, J = 8.2 Hz, 2H), 7.64–
7.50 (m, 5H), 7.47–7.30 (m, 4H), 7.20–7.13 (d, J = 8.0, 0.7 Hz, 2H), 6.96–6.85 (m, 2H), 2.35 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.1 (Cq), 162.9 (Cq), 147.4 (CH), 144.5 (Cq), 144.1 (Cq), 142.8 (CH), 
139.7 (Cq), 139.2 (Cq), 138.8 (CH), 129.9 (CH), 128.9 (CH), 128.6 (CH), 127.3 (CH), 127.0 (CH), 126.1 
(CH), 125.2 (CH), 123.3 (CH), 122.5 (CH), 118.5 (CH), 111.0 (CH), 21.7 (CH3). 
 
IR (ATR): 1733, 1466, 1430, 1273, 1244, 1059, 758, 746 cm-1. 
 
MS (EI) m/z (relative intensity) 246 (65) [C17H12NO]+, 234 (4), 119 (100), 102 (3), 91 (30), 78 (5) 65 
(7), 51 (3). 
 








- 137 - 
 




The representative procedure F was followed using 2-(2-methoxyphenoxy)pyridine (186f) (247.2, 1.0 
mmol) and 4-methylbenzoic acid (101a) (67.5 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol 
%), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187fa (127 mg, 76%) as a white solid. 
 
M.p.: 150–152 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.10 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.76–7.72 (m, 2H), 7.53 (ddd, J 
= 8.3, 7.2, 2.0 Hz, 1H), 7.28–7.19 (m, 1H), 7.13 (d, J = 8.0, 0.7 Hz, 2H), 6.99–6.81 (m, 4H), 3.80 (s, 
3H), 2.36 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.1 (Cq), 162.8 (Cq), 153.2 (Cq), 147.3 (CH), 144.3 (Cq), 144.1 (Cq), 
138.9 (CH), 134.6 (Cq), 129.1 (CH), 128.9 (CH), 126.2 (Cq), 125.2 (CH), 118.1 (CH), 115.6 (CH), 110.4 
(CH), 110.1 (CH), 56.4 (CH3), 21.7 (CH3). 
 
IR (ATR): 1729, 1598, 1464, 1427, 1262, 1095, 773, 746 cm-1. 
 
MS (EI) m/z (relative intensity) 200 (55) [C12H10NO2]+, 173 (4), 119 (100), 91 (35), 78 (5) 65 (10), 51 
(4). 
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The representative procedure F was followed using 2-(2,4-dimethylphenoxy)pyridine (186g) (199.2, 
1.0 mmol) and 4-methylbenzoic acid (101a) (67.5 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 
mol %), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.00 mmol. Isolation by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 187ga (98 mg, 59%) as a white solid. 
 
M.p.: 100–102 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.12 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.70 (d, J = 8.2 Hz, 2H), 7.52 
(ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.12 (dt, J = 8.1, 0.7 Hz, 2H), 6.99–7.21 (m, 2H), 6.87 (ddd, J = 7.1, 
5.0, 0.9 Hz, 1H), 6.79 (d, J = 8.3, 0.9 Hz, 1H), 2.36 (s, 3H), 2.35 (s, 3H), 2.21 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.3 (Cq), 162.9 (Cq), 147.4 (CH), 143.9 (Cq), 142.8 (Cq), 141.0 (Cq), 
138.9 (CH), 135.1 (Cq), 132.3 (Cq), 129.8 (CH), 128.9 (CH), 128.8 (CH), 126.3 (Cq), 121.5 (CH), 117.8 
(Cq), 110.1 (CH), 21.7 (CH3), 21.1 (CH3), 16.3 (CH3). 
 
IR (ATR): 1738, 1467, 1265, 1249, 1079, 863, 778, 745 cm-1. 
 
MS (EI) m/z (relative intensity) 198 (83) [C13H12NO]+, 186 (4), 143 (3), 119 (100), 91 (32), 78 (6) 65 
(12), 51 (4). 
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The representative procedure F was followed using 2-(naphthalen-1-yloxy)pyridine (186h) (221.2, 1.0 
mmol), 4-methylbenzoic acid (101a) (67.5 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187ha (126 mg, 71%) as an orange solid. 
 
M.p.: 145–147 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.07 (dd, J = 16.5, 4.6, 2.3 Hz, 2H), 7.96–7.89 (m, 1H), 7.86–7.72 (m, 
3H), 7.63–7.44 (m, 4H), 7.17 (d, J = 8.2 Hz, 2H), 7.01 (ddd, J = 9.8, 6.6, 3.1 Hz, 2H), 2.47 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.2 (Cq), 163.3 (Cq), 147.6 (CH), 144.2 (Cq), 139.7 (Cq), 139.6 (Cq), 
139.2 (CH), 132.5 (Cq), 129.9 (CH), 128.9 (Cq), 127.8 (CH), 126.5 (Cq), 126.3 (CH), 126.2 (CH), 126.0 
(CH), 125.6 (CH), 122.1 (CH), 122.0 (CH), 118.3 (CH), 110.2 (CH), 21.7 (CH3). 
 
IR (ATR): 1731, 1594, 1426, 1249, 1228, 1084, 774, 744 cm-1. 
 
MS (EI) m/z (relative intensity) 220 (65) [C15H10NO]+, 192 (6), 119 (100), 102 (3), 91 (31), 78 (8) 65 
(7), 51 (4). 
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The representative procedure F was followed using 2-(2-fluorophenoxy)pyridine (186i) (189.1, 1.0 
mmol) and 4-methylbenzoic acid (101a) (67.5 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol 
%), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187ia (115 mg, 71%) as a white solid. 
 
M.p.: 86–88 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.08 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.79 (d, J = 8.2 Hz, 2H), 7.63–
7.54 (m, 1H), 7.32–7.08 (m, 5H), 6.99–6.87 (m, 2H), 2.39 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 163.9 (Cq), 162.1 (Cq), 156.0 (d, 1JC-F = 253 Hz, Cq), 147.2 (CH), 144.8 
(Cq), 144.6 (d, 3JC-F = 4 Hz, Cq), 139.3 (CH), 133.5 (d, 2JC-F = 14 Hz, Cq), 129.0 (CH), 125.9 (Cq), 125.1 
(d, 3JC-F = 9 Hz, CH), 119.0 (d, 4JC-F = 2 Hz, CH) 118.9 (CH), 114.1 (d, 2JC-F = 20 Hz, CH), 113.9 (CH), 
110.5 (CH), 21.8 (CH3). 
 
IR (ATR): 1737, 1591, 1463, 1426, 1227, 1075, 986, 741 cm-1. 
 
19F-NMR (283 MHz, CDCl3) δ = -126.43 (s). MS (EI) m/z (relative intensity) 188 (39) [C11H7FNO]+, 
176 (5), 120 (15), 119 (100), 91 (45), 78 (11) 65 (16), 51 (8). 
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The representative procedure F was followed using 2-(2-bromophenoxy)pyridine (187j) (250.2, 1.0 
mmol) and 4-methylbenzoic acid (101a) (67.5 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol 
%), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol) in DCE (2.0 mL). Isolation by 
column chromatography (n-hexane/EtOAc: 5/1) yielded 187ja (144 mg, 75%) as a light yellow oil. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.16–8.12 (m, 1H), 7.73 (dd, J = 8.3, 2.2 Hz, 2H), 7.63–7.55 (m, 1H), 
7.48–7.36 (m, 2H), 7.27–7.20 (m, 1H), 7.19–7.13 (m, 1H), 6.98–6.92 (m, 2H), 6.89–6.83 (m, 1H), 2.38 
(s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 163.8 (Cq), 162.4 (Cq), 147.4 (CH), 146.0 (Cq), 144.4 (Cq), 142.0 (Cq), 
139.4 (CH), 134.4 (CH), 132.1 (CH), 130. (CH), 129.0 (CH), 128.4 (CH), 126.4 (CH), 125.9 (CH), 
125.0 (Cq), 118.9 (CH), 118.8 (Cq), 111.1 (CH), 21.8 (CH3). 
 
IR (ATR): 1737, 1483, 1464, 1245, 1171, 1053, 907, 742 cm-1. 
 
MS (EI) m/z (relative intensity) 248 (18) [C11H779BrNO]+, 296 (5), 340 (4), 119 (100), 91 (32), 78 (9) 
65 (8), 51 (7). 
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The representative procedure F was followed using 2-(m-tolyloxy)pyridine (186l) (185.2, 1.0 mmol) 
and 4-methylbenzoic acid (101a) (67.5 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.00 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187la (99 mg, 62%) as a white solid. 
 
M.p.: 94–96 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.17–8.11 (m, 1H), 7.75–7.69 (m, 2H), 7.65 (ddd, J = 8.2, 7.1, 2.0 Hz, 
1H), 7.28–7.14 (m, 5H), 6.93–6.87 (m, 1H), 6.81 (d, J = 8.2 Hz, 1H), 2.40 (s, 3H), 2.31 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.0 (Cq), 162.8 (Cq), 147.1 (CH), 144.7 (Cq), 143.8 (Cq), 140.2 (Cq), 
138.9 (CH), 136.5 (Cq), 129.6 (CH), 128.6 (CH), 126.0 (Cq), 125.8 (CH), 123.3 (CH), 123.1 (CH), 118.1 
(CH), 110.6 (CH), 21.3 (CH3), 20.7 (CH3). 
 
IR (ATR): 1726, 1428, 1270, 1240, 1071, 867, 746 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (79) [C12H10NO]+, 172 (4), 119 (100), 91 (41), 78 (7), 66 (13), 51 
(10). 
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The representative procedure F was followed using 2-(m-tolyloxy)pyridine (186l) (185.2, 1.0 mmol) 
and 4-fluorobenzoic acid (101c) (70.0 mg, 0.5 mmol), [{RuCl2-(p-cymene)}2] (7.6 mg, 2.5 mol %), 
AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187lc (103 mg, 64%) as a white solid. 
 
M.p.: 102–104 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.11 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.84 (dd, J = 8.9, 5.5 Hz, 2H), 
7.54 (dd, J = 8.3, 5.2, Hz, 1H), 7.25–7.18 (m, 1H), 7.12–6.95 (m, 4H), 6.89 (ddd, J = 7.2, 5.0, 0.9 Hz, 
1H), 6.81 (d, J = 8.3, 0.9 Hz, 1H), 2.30 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ =  166.7 (Cq), 165.0 (1JC-F = 270 Hz, Cq), 163.2 (2JC-F = 33 Hz, CH), 162.9 
(Cq), 147.4 (CH), 144.7 (Cq), 140.1 (Cq), 139.1 (CH), 136.9 (Cq), 132.5 (3JC-F = 10 Hz, CH), 126.1 (CH), 
125.3 (4JC-F = 3 Hz, Cq), 123.5 (CH), 118.3 (CH), 115.4 (2JC-F = 25 Hz, CH), 110.8 (CH), 21.1 (CH3). 
 
IR (ATR): 1736, 1507, 1467, 1431, 1259, 1065, 795, 778 cm-1. 
 
19F-NMR (282 MHz, CDCl3) δ = -106.7. 
 
HR-MS (EI) m/z (relative intensity) 184 (100) [C7H4FO2]+, 172 (6), 123 (60), 113 (10), 95 (32), 78 (7), 
51 (5), 43 (14). 
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The representative procedure F was followed using 2-(m-tolyloxy)pyridine 186l (185.2, 1.0 mmol) and 
4-chlorobenzoic acid 101g (77.5 mg, 0.5 mmol), [{RuCl2-(p-cymene)}2] (7.6 mg, 2.5 mol %), AgSbF6 
(34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 5/1) yielded 187lg (122 mg, 72%) as a white solid. 
 
M.p.: 104–106 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.11 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.76 (d, J = 8.5 Hz, 2H), 7.60 – 
7.41 (m, 1H), 7.35–7.27 (m, 2H), 7.20 (d, J = 8.1 Hz, 1H), 7.12–7.03 (m, 2H), 6.97–6.77 (m, 2H), 2.33 
(s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 163.3 (Cq), 162.9 (Cq), 147.4 (CH), 144.6 (Cq), 140.1 (Cq), 139.7 (Cq), 
139.2 (CH), 137.0 (Cq), 131.2 (CH), 128.5 (CH), 127.4 (Cq), 126.1 (CH), 123.6 (CH), 123.1 (CH), 118.3 
(CH), 110.8 (CH), 21.1 (CH3). 
 
IR (ATR): 1737, 1593, 1258, 1238, 1066, 1014, 748, 395cm-1. 
 
MS (EI) m/z (relative intensity) 184 (100) [C7H4ClO2]+, 172 (7), 139 (60), 113 (10), 111 (30), 78 (10), 
66 (5), 51 (7).  
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The representative procedure F was followed using 2-(m-tolyloxy)pyridine 186l (185.2, 1.0 mmol) and 
4-nitrobenzoic acid 101h (83.5 mg, 0.5 mmol), [{RuCl2-(p-cymene)}2] (7.6 mg, 2.5 mol %), AgSbF6 
(34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.00 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 5/1) yielded 187lh (108 mg, 62%) as a white solid. 
 
M.p.: 140–142 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.21– 8.14 (m, 2H), 8.10 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 8.09 (d, J = 
9.0 Hz, 2H), 7.55 (ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.27–7.19 (d, J = 8.0 Hz, 1H), 7.13–7.04 (m, 2H), 
6.98–6.79 (m, 2H), 2.42 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 162.7 (Cq), 162.3 (Cq), 150.5 (Cq), 147.4 (CH), 144.4 (Cq), 139.8 (Cq), 
139.3 (CH), 137.4 (Cq), 134.3 (Cq), 130.8 (CH), 126.1 (CH), 123.6 (CH), 123.3 (CH), 122.8 (CH), 118.5 
(CH), 110.8 (CH), 21.1 (CH3). 
 
IR (ATR): 1742, 1522, 1427, 1276, 1260, 876, 780, 712 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (100) [C12H10O]+, 172 (110), 150 (31), 120 (9), 104 (24), 92 (12) 
76 (14) 51 (6). 
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The representative procedure F was followed using 2-(m-tolyloxy)pyridine 186l (185.2, 1.0 mmol) and 
2-iodobenzoic acid 101i (124.0 mg, 0.5 mmol), [{RuCl2-(p-cymene)}2] (7.6 mg, 2.5 mol %), AgSbF6 
(34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.00 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 5/1) yielded 187li (120 mg, 56%) as a white solid. 
 
M.p.: 68–70 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.19 (dd, J = 4.9, 2.0 Hz, 1H), 8.09 (dd, J = 7.7, 1.2 Hz, 1H), 7.64–
7.50 (m, 2H), 7.29 (ddd, J = 7.7, 4.7, 2.7 Hz, 2H), 7.16–7.09 (m, 2H), 7.03–6.85 (m, 3H), 2.35 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 163.6 (Cq), 162.9 (Cq), 147.4 (CH), 144.6 (Cq), 141.3 (CH), 140.0 (Cq), 
139.2 (CH), 137.0 (Cq), 133.2 (Cq), 132.9 (CH), 131.1 (CH), 127.6 (CH), 126.1 (CH), 123.5 (CH), 123.1 
(CH), 118.4 (CH), 110.9 (CH), 94.7 (Cq), 21.1 (CH3). 
 
IR (ATR): 1745, 1428, 1274, 1236, 1187, 1082, 778, 747 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (80) [C12H10NO]+, 231 (98), 203 (24), 101 (3), 76 (15), 66 (4) 51 
(5). 
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The representative procedure F was followed using 2-(m-tolyloxy)pyridine 187l (185.2, 1.0 mmol), 
[1,1'-biphenyl]-4-carboxylic acid 101j (99.0 mg, 0.5 mmol), [{RuCl2-(p-cymene)}2] (7.6 mg, 2.5 mol 
%), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187lj (105 mg, 55%) as a white solid. 
 
M.p.: 98–100 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.17 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.66–7.57 (m, 2H), 7.53–7.46 (m, 
1H), 7.39–7.27 (m, 7H), 7.04–6.82 (m, 5H), 2.30 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 165.6 (Cq), 163.0 (Cq), 147.5 (CH), 144.8 (Cq), 143.0 (Cq), 140.7 (Cq), 
140.1 (Cq), 139.1 (CH), 136.7 (Cq), 131.4 (CH), 130.7 (CH), 129.9 (Cq), 129.5 (CH), 128.4 (CH), 127.8 
(CH), 127.1 (CH), 126.8 (CH), 125.9 (CH), 123.3 (CH), 122.8 (CH), 118.4 (CH), 110.9 (CH), 21.0 
(CH3). 
 
IR (ATR): 1749, 1465, 1427, 1232, 1191, 1032, 744, 697 cm-1. 
 
MS (EI) m/z (relative intensity) 181 (100) [C13H9O]+, 153 (27), 152 (31), 127 (5), 78 (4), 51 (3). 
 








- 148 - 
 




The representative procedure F was followed using 2-(m-tolyloxy)pyridine 186l (185.2, 1.0 mmol) and 
1-naphthoic acid 101k (86.0 mg, 0.5 mmol), [{RuCl2-(p-cymene)}2] (7.6 mg, 2.5 mol %), AgSbF6 (34.4 
mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 5/1) yielded 187lk (99 mg, 56%) as a white solid. 
 
M.p.: 91–93 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.96–8.91 (m, 1H), 8.22–8.17 (m, 1H), 8.01 (d, J = 8.3 Hz, 1H), 7.94 
(dd, J = 7.4, 1.3 Hz, 1H), 7.89–7.83 (m, 1H), 7.62–7.50 (m, 3H), 7.41–7.33 (t, J = 7.8 Hz, 2H), 7.21–
7.11 (m, 2H), 6.96–6.83 (m, 2H), 2.31 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.7 (Cq), 163.0 (Cq), 147.4 (CH), 144.9 (Cq), 140.4 (Cq), 139.2 (CH), 
136.9 (Cq), 133.9 (Cq), 133.6 (CH), 131.4 (Cq), 130.8 (CH), 128.4 (CH), 127.8 (CH), 126.2 (CH), 126.1 
(CH), 125.6 (Cq), 125.4 (CH), 124.2 (CH), 123.7 (CH), 123.4 (CH), 118.3 (CH), 111.0 (CH), 21.1 
(CH3). 
 
IR (ATR): 1737, 1496, 1466, 1421, 1234, 1171, 1058, 743 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (36) [C12H10NO]+, 155 (100), 127 (51), 101 (3), 78 (6), 66 (3) 51 
(4). 
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The representative procedure F was followed using 2-(m-tolyloxy)pyridine 186l (185.2, 1.0 mmol) and 
3-chlorobenzoic acid 101l (67.5 mg, 0.5 mmol), [{RuCl2-(p-cymene)}2] (7.6 mg, 2.5 mol %), AgSbF6 
(34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol. Isolation by column chromatography (n-
hexane/EtOAc: 5/1) yielded 187ll (128 mg, 76%) as a white solid. 
 
M.p.: 108–110 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.21–8.13 (m, 1H), 7.81–7.71 (m, 2H), 7.63–7.55 (m, 1H), 7.53–7.46 
(m, 1H), 7.30 (d, J = 7.4 Hz, 1H), 7.27–7.22 (m, 1H), 7.05 (d, J = 7.4 Hz, 2H), 7.01 (dd, J = 7.2, 5.0 
Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 2.30 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 163.0 (Cq), 162.8 (Cq), 147.3 (CH), 144.6 (Cq), 139.9 (Cq), 139.2 (CH), 
137.0 (Cq), 134.2 (Cq), 133.2 (CH), 130.6 (Cq), 129.7 (CH), 129.4 (CH), 127.9 (CH), 126.0 (CH), 123.5 
(CH), 122.9 (CH), 118.4 (CH), 110.8 (CH), 21.05 (CH3) . 
 
IR (ATR): 1741, 1431, 1261, 1193, 1100, 1058, 788, 739 cm-1. 
 
MS (EI) m/z (relative intensity) 184 (100) [C12H10NO]+, 172 (5), 139 (60), 113 (8), 111 (28), 78 (9) 51 
(5). 
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The representative procedure F was followed using 5-methyl-2-(o-tolyloxy)pyridine 186k (199.2, 1.0 
mmol) and 4-methylbenzoic acid 101a (67.5 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol 
%), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol. Isolation by column chromatography 
(n-hexane/EtOAc: 5/1) yielded 187ka (110 mg, 67%) as a colorless oil. 
 
1H-NMR (300 MHz, CDCl3) δ = 7.90 (d, J = 2.5, 0.8 Hz, 1H), 7.71 (d, J = 8.2 Hz, 2H), 7.31 (ddd, J = 
8.4, 2.5, 0.7 Hz, 1H), 7.20–7.09 (m, 5H), 6.69 (dd, J = 8.3, 0.7 Hz, 1H), 2.37 (s, 3H), 2.23 (s, 3H), 2.19 
(s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.2 (Cq), 161.0 (Cq), 146.9 (CH), 143.9 (Cq), 143.7 (Cq), 143.2 (Cq), 
139.9 (CH), 133.0 (Cq), 129.9 (CH), 128.8 (CH), 128.2 (CH), 127.0 (Cq), 126.3 (Cq), 125.1 (CH), 121.0 
(CH), 109.5 (CH), 21.7 (CH3), 17.4 (CH3), 16.4 (CH3). 
 
IR (ATR): 1732, 1464, 1269, 1231, 1085, 1070, 746, 395 cm-1. 
 
MS (EI) m/z (relative intensity) 198 (100) [C13H12NO]+, 171 (17), 142 (61), 118 (18), 111 (30), 78 (10), 
65 (8), 51 (7). 
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The representative procedure F was followed using 2-(3-fluorophenoxy)pyridine 186m (189.1, 1.0 
mmol), and 4-methylbenzoic acid 101a (68.4 mg, 0.5 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 mol 
%), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.00 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 187ma (93 mg, 58%) as a white solid. 
 
M.p.: 97-99 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.14 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.59 
(ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.31–7.23 (m, 1H), 7.18–7.12 (m, 2H), 7.08–6.81 (m, 3H), 2.41(s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 164.3 (Cq), 162.5 (Cq), 160.4 (d, 1JC-F = 280 Hz, Cq), 158.6 (CH), 147.5 
(CH), 146.1 (d, 4JC-F = 3 Hz, Cq), 144.4 (Cq), 139.5 (CH), 138.9 (d, 3JC-F = 4 Hz, Cq), 130.0 (CH), 129.0 
(CH), 126.0 (Cq), 124.3 (d, 3JC-F = 10 Hz, CH), 124.3 (CH), 118.9 (CH), 112.0 (d, 2JC-F = 20 Hz, CH), 
111.9 (d, 2JC-F = 25 Hz, CH), 110.6 (CH), 21.7 (CH3). 
 
19F-NMR (283 MHz, CDCl3) δ = -114.3. 
 
IR (ATR): 1737, 1496, 1466, 1421, 1234, 1171, 1140, 1058, 743 cm-1. 
 
MS (EI) m/z (relative intensity) 188 (45) [C11H7FNO]+, 176 (4), 120 (12), 91 (30), 78 (6), 65 (10) 51 
(4). 
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A suspension of 2-(o-tolyloxy)pyrimidine 186n (186.2, 1.0 mmol), [{RuCl2(p-cymene)}2] (7.6 mg, 2.5 
mol %), AgSbF6 (34.4 mg, 20 mol %) and K2S2O8 (270 mg, 2.0 mmol) in DCE:AcOH (3:1) (2.0 mL) 
were stirred in a sealed tube under N2 at 100 °C for 18 h. At ambient temperature, the reaction mixture 
was diluted with 20 mL CH2Cl2 (20 mL) and passed through celite with 100 mL CH2Cl2. The organic 
layer was dried over Na2SO4. After evaporation of the solvent in vaccuo, the crude product was purified 
by column chromatography on silica gel (n-hexane/EtOAc: 10:1) to yield Isolation by column 
chromatography (n-hexane/EtOAc: 5/1) yielded 187no (157 mg, 64%) as a white solid. 
 
M.p.: 96–98 °C. 
 
1H-NMR (300 MHz, CDCl3) δ = 8.71 (d, J = 4.8 Hz, 2H), 7.23–7.14 (m, 2H), 7.12–6.94 (m, 2H), 2.19 
(s, 3H), 2.06 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3) δ = 168.2 (Cq), 164.3 (Cq), 159.7 (CH), 142.7 (Cq), 142.6 (Cq), 132.6 (Cq), 
128.3 (CH), 125.7 (CH), 120.9 (CH), 116.1 (CH), 20.6 (CH3), 16.3 (CH3). 
 
IR (ATR): 2923, 2854, 1758, 1571, 1402, 1174, 1030, 876cm-1. 
 
HR-MS (EI) m/z (relative intensity) 185 (85) [C11H9N2O]+, 202 (100), 160 (12), 147 (9), 134 (15), 79 
(11), 53 (13). 
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Representative procedure H was followed using 2-(4-methylphenoxy)pyridine(186c) (93.0 mg, 0.50 
mmol), ethyl acrylate (63a) (250.0 mg, 5.0 mmol), [Ru(O2CMes)2(p-cymene)] (28.0 mg, 10.0 mol %) 
and CsOAc (288.0 mg, 1.5 mmol.). Purification by column chromatography (n-hexane/EtOAc: 15:1) 
yielded 205ca (100 mg, 68%) as a colourless solid.  
 
M.p.: = 115–117 °C.  
 
1H NMR (300 MHz, CDCl3) δ = 8.08 (ddd, , J=5.0, 2.0, 0.8 Hz, 1H), 7.76 (d, J=16.1 Hz, 1H), 7.66 
(ddd, J=8.1, 7.2, 2.0, 1H), 7.70 _ 7.63 (m, 1H), 7.52 – 7.49 (m, 1H), 7.29 – 7.24 (m, 1H), 7.16 (dd, J = 
7.7, 7.6 Hz, 1H), 6.95 – 6.90 (m, 2H), 6.40 (d, J = 16.1, Hz, 1H), 4.16 ( q, J = 7.1Hz, 2H), 2.08 (s, 3H), 
1.24 ( J = 7.1Hz, 3H).  
 
13C NMR (76 MHz, CDCl3) δ = 166.8 (Cq), 163.2 (Cq), 150.7 (Cq), 147.8 (CH), 139.6 CH), 139.2 (CH), 
133.1(CH), 132.3 (Cq), 128.3 (Cq), 125.6 (CH), 125.3 (CH), 119.7 (CH), 118.1 (CH), 110.3 (CH), 60.3 
(CH2), 16.6 (CH3), 14.2 (CH3).  
 
IR (ATR): 2975, 2929, 1699, 1629, 1422, 1243, 1175, 774 cm-1.  
 
MS (EI) m/z(relative intensity): 282 (15) [M+], 254 (10), 238 (15), 210 (10), 180 (10), 167 (15), 131 
(10), 78 (20).  
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Representative procedure H was followed using 2-{4-(trifluoromethyl)phenoxy}pyridine (186h) (118.0 
mg, 0.50 mmol), ethyl acrylate (63a) (250.0 mg, 5.0 mmol), [Ru(O2CMes)2(p-cymene)] (28.0 mg, 10.0 
mol %) and CsOAc (288.0 mg, 1.5 mmol.). Purification by column chromatography (n-hexane/EtOAc: 
15:1) yielded 205ha (86.0 mg, 53% ) as a colourless oil.  
 
1H NMR (300 MHz, CDCl3) δ = 8.22 – 8.14 (m, 1H), 7.96 – 7.86 (m, 2H), 7.77 (ddd, J = 8.3, 7.3, 2.0 
Hz, 1H), 7.66 – 7.58 (m, 1H), 7.21 (dt, J = 8.6, 0.9 Hz, 1H), 7.11 – 7.01 (m, 2H), 6.54 (d, J = 16.1 Hz, 
1H), 4.23 (q, J = 7.1 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H). 
 
13C NMR (75 MHz, CDCl3) δ = 166.4 (Cq), 162.6 (Cq), 155.3 (Cq), 147.7 (CH), 140.0 (CH), 137.4 
(CH), 127.7 (Cq), 127.6 (3JC-F = 4 Hz, CH), 127.1 (2JC-F = 33 Hz, Cq), 125.3 (3JC-F = 4 Hz, CH), 123.7 
(1JC-F = 272 Hz, Cq), 122.5 (CH), 121.4 (CH), 119.6 (CH), 112.3 (CH), 60.7 (CH2), 14.2 (CH3). 
 
19F-NMR (283 MHz, CDCl3) δ = -62.4 (s). 
 
IR (ATR): 2983, 1716, 1641, 1267, 1162, 1123, 1073, 773 cm-1.  
 
MS (EI) m/z (relative intensity): 336 (10) [M+], 308 (15), 292 (17), 264 (100), 248 (7), 236 (15), 215 
(10), 167 (13). 
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Representative procedure H was followed using 2-(2,4-dimethylphenoxy)pyridine (186k) (97.5 mg, 
0.50 mmol), ethyl acrylate (63a) (250.0 mg, 5.0 mmol), [Ru(O2CMes)2(p-cymene)] (28.0 mg, 10.0 mol 
%)  and CsOAc (288.0 mg, 1.5 mmol.). Purification by column chromatography (n-hexane/EtOAc: 
15:1) yielded 205ka (101.5 mg, 64%) as a colourless solid. 
 
M.p.: 73 – 75 °C. 
 
1H NMR (300 MHz, CDCl3) δ = 8.10 (ddd, J = 4.9, 2.0, 1.0 Hz, 1H), 7.75 (d, J = 16.1 Hz, 1H), 7.67 
(ddd, J = 8.2, 7.2, 2.0 Hz, 1H), 7.33 (d, J = 2.0 Hz, 1H), 7.11 (d, J = 2.0 Hz, 1H), 6.96 – 6.91 (m, 2H), 
6.41 (d, J = 16.1 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 2.34 (s, 3H), 2.06 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H). 
 
13C NMR (76 MHz, CDCl3) δ = 166.9 (Cq), 163.3 (Cq), 148.5 (Cq), 147.7 (CH), 139.5 (CH), 139.3 
(CH), 135.0 (Cq), 134.0 (CH), 131.8 (Cq), 127.7 (Cq), 125.7 (CH), 119.5 (CH), 118.0 (CH), 110.3 (CH), 
60.2 (CH2), 20.9 (CH3), 16.5 (CH3), 14.2 (CH3). 
 
IR (ATR): 2982, 1698, 1428, 1281, 1234, 1202, 1040, 774 cm-1. 
 
MS (EI) m/z (relative intensity): 296 (30) [M+], 268 (150), 280 (10), 268 (15), 252 (25), 224 (100), 203 
(30) 175 (25). 
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Representative procedure H was followed using 2-(2,3-dimethylphenoxy)pyridine (186e) (100.0 mg, 
0.50 mmol), ethyl acrylate (63a) (250.0 mg, 5.0 mmol), [Ru(O2CMes)2(p-cymene)] (28.0 mg, 10.0 mol 
%)  and CsOAc (288.0 mg, 1.5 mmol.). Purification by column chromatography (n-hexane/EtOAc: 
15:1) yielded 205ea (86.7 mg, 61%) as a colourless solid. 
 
M.p.: 127 –129 °C. 
 
1H NMR (300 MHz, CDCl3) δ = 8.12 – 8.09 (m, 1H), 7.74 (d, J = 16.1 Hz, 1H), 7.68 (ddd, J = 9.3, 7.2, 
2.0 Hz 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.96 – 6.92 (m, 2H), 6.38 (d, J = 16.1 
Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 2.33 (s, 3H), 2.02 (s, 3H), 1.26 (t, J = 7.0 Hz, 3H). 
 
13C NMR (76 MHz, CDCl3) δ = 167.0 (Cq), 163.4 (Cq), 150.5 (Cq), 147.8(CH), 141.1 (Cq), 139.6 (CH), 
139.5 (CH), 130.8 (Cq), 127.4 (CH), 125.8 (Cq), 124.5 (CH), 118.6 (CH), 118.0 (CH), 110.3 (CH), 60.2 
(CH2), 20.4 (CH3), 14.2 (CH3), 12.9 (CH3). 
 
IR (ATR): 2982, 1711, 1254, 1236, 1200, 1168, 1141, 782 cm-1. 
 
MS (EI) m/z (relative intensity): 296 (30) [M+], 268 (150), 252 (20), 224 (100), 203 (15), 181 (15), 115 
(10) 78 (20). 
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Representative procedure H was followed using 2-(2,3-dimethylphenoxy)pyridine (186e) (100.0 mg, 
0.50 mmol), tert-butyl acrylate (63b) (325.0 mg, 5.0 mmol), [Ru(O2CMes)2(p-cymene)] (28.0 mg, 10.0 
mol %) and CsOAc (288.0 mg, 1.5 mmol.). Purification by column chromatography (n-hexane/EtOAc: 
15:1) yielded 205eb (96 mg, 59%) as a colourless solid.  
 
M.p.: 114 –116 °C.  
 
1H NMR (300 MHz, CDCl3) δ = 8.10 (dd, J = 5.4, 2.1 Hz, 1H), 7.65 (d, J = 16.0 Hz, 2H), 7.71 – 7.65 
(m, 1H), 7.44 (d, J = 8.1 Hz, 1H), 7.07(d, J = 8.1 Hz, 1H), 6.99 – 6.85 (m, 2H), 6.31 (d, J = 16.0 Hz, 
1H), 2.02 (s, 3H), 2.02 (s, 3H), 1.45 (s, 9H).  
 
13C NMR (75 MHz, CDCl3) δ = 166.3 (Cq), 163.5 (Cq) 150.4 (Cq), 147.8 (CH), 140.8 (Cq), 139.5 (CH), 
138.4 (CH), 130.7 (Cq), 127.3 (CH), 125.9 (Cq), 124.3 (CH), 120.4 (CH), 117.9 (CH), 110.3 (CH), 80.1 
(Cq), 28.1 (CH3), 20.4 (CH3), 12.9 (CH3).  
 
IR (ATR): 2974, 1698, 1256, 1234, 1150, 987, 824, 782 cm-1.  
 
MS (EI) m/z (relative intensity): 324 (10) [M+], 268 (10), 252 (20), 224 (100), 208 (10), 194 (5), 175 
(15) 115 (7).  
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Representative procedure H was followed using 2-(o-tolyloxy)pyridine(186a) (93.0 mg, 0.50 mmol), 
ethyl acrylate (63a) (250.0 mg, 5.0 mmol), [Ru(O2CMes)2(p-cymene)] (28.0 mg, 10.0 mol %) and 
CsOAc (288.0 mg, 1.5 mmol.). Purification by column chromatography (n-hexane/EtOAc: 15:1) 
yielded 205aa (100 mg, 68%) as a colourless solid.  
 
M.p.: 115 –117 °C. 
 
1H NMR (300 MHz, CDCl3) δ = 8.08 (ddd, , J=5.0, 2.0, 0.8 Hz, 1H), 7.76 (d, J = 16.1 Hz, 1H), 7.66 
(ddd, J = 8.1, 7.2, 2.0, 1H), 7.70 –7.63 (m, 1H), 7.52 – 7.49 (m. 1H), 7.29 – 7.24 (m, 1H), 7.16 (dd, J = 
7.7, 7.6 Hz, 1H), 6.95 – 6.90 (m, 2H), 6.40 (d, J = 16.1, Hz, 1H), 4.16 ( q, J = 7.1Hz, 2H), 2.08 (s, 3H), 
1.24 ( J = 7.1Hz, 3H).  
 
13C NMR (76 MHz, CDCl3) δ = 166.8 (Cq), 163.2 (Cq), 150.7 (Cq), 147.8 (CH), 139.6 (CH), 139.2 
(CH), 133.1(CH), 132.3 (Cq), 128.3 (Cq), 125.6 (CH), 125.3 (CH), 119.7 (CH), 118.1 (CH), 110.3 (CH), 
60.3 (CH2), 16.6 (CH3), 14.2 (CH3).  
 
IR (ATR): 2975, 2929, 1699, 1629, 1422, 1243, 1175, 774 cm-1.  
 
MS (EI) m/z(relative intensity): 282 (15) [M+], 254 (10), 238 (15), 210 (10), 180 (10), 167 (15), 131 
(10), 78 (20). 
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Representative procedure H was followed using 2-(2-fluorophenoxy) pyridine(186b) (158.0 mg, 0.50 
mmol), ethyl acrylate (63a) (250.0 mg, 5.0 mmol), [Ru(O2CMes)2(p-cymene)] (28.0 mg, 10.0 mol %) 
and CsOAc (288.0 mg, 1.5 mmol.). Purification by column chromatography (n-hexane/EtOAc: 15:1) 
yielded 205ba (88.5 mg, 56%) as a yellow solid.  
 
M.p.: 75 – 77 °C.  
 
1H NMR (300 MHz, CDCl3) δ = 8.09 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.82 (d, J = 16.1 Hz, 1H), 7.73 
(ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.48 – 7.42 (m, 1H), 7.25 – 7.21 (m, 1H), 7.21 – 7.14 (m, 1H), 7.08 (dt, 
J = 8.3, 0.9 Hz, 1H), 7.01 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H), 6.49 (d, J = 16.2 Hz, 1H), 4.21 (q, J = 7.1 Hz, 
2H), 1.29 (t, J = 7.1 Hz, 3H).  
 
13C NMR (75 MHz, CDCl3) δ = 166.6 (Cq), 162.6 (Cq) , 155.5 (1JC-F = 251 Hz, Cq), 147.4 (CH) , 140.0 
(2JC-F =12.7 Hz, Cq), 139.6 (CH), 137.8 (4JC-F  = 4 Hz, CH), 130.3 (3JC-F = 2 Hz, Cq), 125.8 (3JC-F = 8.0 
Hz, CH), 122.9 (4JC-F = 3.4 Hz, CH), 121.0 (CH), 118.9 (CH), 117.8 (2JC-F = 19 Hz, CH), 110.7 (CH), 
60.6 (CH2), 14.2 (CH3) 19F-NMR (283 MHz, CDCl3): δ = -126.2 (s). ).  
 
IR (ATR): 2987, 1710, 1426, 1325, 1265, 1226, 1171, 980, 772 cm-1.  
 
MS (EI) m/z (relative intensity): 286 (10) [M+], 258 (15), 242 (15), 214 (100), 185 (20), 136 (10), 107 
(15), 78 (55).  
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Representative procedure H was followed using 2-{2-(trifluoromethyl)phenoxy}pyridine (186c) (118.0 
mg, 0.50 mmol), ethyl acrylate (63a) (250.0 mg, 5.0 mmol), [Ru(O2CMes)2(p-cymene)] (28.0 mg, 10.0 
mol %) and CsOAc (288.0 mg, 1.5 mmol.). Purification by column chromatography (n-hexane/EtOAc: 
15:1) yielded 205ca (88 mg, 58%) as a colourless solid.  
 
M.p.: 43 – 45 °C.  
 
1H NMR (300 MHz, CDCl3) δ = 8.01 (ddd, J = 5.1, 2.0, 0.8 Hz, 1H), 7.84 (dd, J = 7.9, 1.6 Hz, 1H), 
7.76 – 7.66 (m, 2H), 7.61 (d, J = 16.1 Hz, 1H), 7.36 (tt, J = 8.0, 0.9 Hz, 1H), 7.05 (dt, J = 8.3, 0.9 Hz, 
1H), 6.95 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H), 6.40 (d, J = 16.1 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 1.22 (t, J 
= 7.1 Hz, 3H).  
 
13C NMR (75 MHz, CDCl3) δ = 166.2 (Cq), 163.5 (Cq), 149.8 (q, 3JC-F = 1.7 Hz, Cq), 147.3 (CH), 139.7 
(CH), 137.5 (CH), 131. (CH), 130.9 (Cq), 128.6 (q, 3JC-F = 5.0 Hz, CH), 125.6 (CH), 125.0 (q, 2JC-F = 
31.6 Hz, Cq), 122.9 (q, 1JC-F = 273 Hz, Cq), 121.2 (CH), 118.7 (CH), 110.7 (CH), 60.5 (CH2), 14.1 (CH3). 
19F NMR (282 MHz, CDCl3) δ = -61.7 (s).  
 
IR (ATR): 2987, 1707, 1425, 1328, 1231, 1136, 1104, 778 cm-1.  
 
MS (EI) m/z (relative intensity): 336 (20) [M+], 292 (20), 264 (100), 244 (25), 196 (15), 167 (10), 51 
(15).  
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Representative procedure H was followed using 2-(naphthalen-1-yloxy)pyridine (186l) (110.5 mg, 0.50 
mmol), ethyl acrylate (63a) (250.0 mg, 5.0 mmol), [Ru(O2CMes)2(p-cymene)] (28.0 mg, 10.0 mol %) 
and CsOAc (288.0 mg, 1.5 mmol.). Purification by column chromatography (n-hexane/EtOAc: 15:1) 
yielded 205la (97.0 mg, 61% ) as a colourless solid. 
 
M.p.: 155–157 °C. 
 
1H NMR (300 MHz, CDCl3) δ = 8.06 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 8.00 (d, J = 16.1 Hz, 1H), 7.91 – 
7.79 (m,2H), 7.75 (s, 2H), 7.71 (ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.50 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.42 
(ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.03 (dt, J = 8.3, 0.8 Hz, 1H), 6.96 (ddd, J = 7.2, 5.0, 0.9 Hz, 1H), 6.54 
(d, J = 16.1 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H). 
 
13C NMR (75 MHz, CDCl3) δ = 166.8 (Cq), 164.2 (C q), 148.8 (Cq), 147.9 (CH), 139.7 (CH), 138.6 
(CH), 135.6 (Cq), 128.0 (CH), 128.0 (Cq), 127.4 (CH), 126.8 (CH), 126.0 (CH), 124.2 (Cq), 123.3 (CH), 
123.2 (CH), 119.8 (CH), 118.4 (CH), 110.2 (CH), 60.4 (CH2), 14.2 (CH3). 
 
IR (ATR): 2987, 1712, 1292, 1256, 1234, 1174, 1138, 783 cm-1.  
 
MS (EI) m/z (relative intensity) 318 (10) [M+], 290 (25), 274 (15), 246 (65), 225 (100), 197 (80), 168 
(20), 139 (30). 
 
HR-MS (EI) m/z for C20H17NO3 [M+]    calcd.: 319.1208. 
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Representative procedure H was followed using 2-(m-tolyloxy)pyridine (186j) (93.0 mg, 0.50 mmol), 
ethyl acrylate (63a) (250 mg, 5.0 mmol), [Ru(O2CMes)2(p-cymene)] (28.0 mg, 10.0 mol %) and CsOAc 
(288.0 mg, 1.5 mmol) purification by column chromatography (n-hexane/EtOAc: 15:1) yielded 205ja 
(80.0 mg, 56%) as a colourless solid. 
 
M.p.: 44–46 °C. 
 
1H NMR (300 MHz, CDCl3) δ = 8.15 (ddd, J = 5.0, 2.0, 0.7 Hz, 1H), 7.83 (d, J = 16.1 Hz, 1H), 7.68 
(ddd, J = 8.2, 7.2, 2.0 Hz, 1H), 7.54 (d, J = 8.1 Hz, 1H), 7.04 – 6.99 (m, 1H), 6.97 (ddd, J= 7.3, 4.9, 1.0 
Hz, 1H), 6.95 – 6.93 (m, 1H), 6.88 (d, J = 1.6 Hz, 1H), 6.41 (d, J = 16.1 Hz, 1H), 4.17 (q, J = 7.1 Hz, 
2H), 2.32 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H). 
 
13C NMR (75 MHz, CDCl3) δ = 167.0 (Cq), 163.4 (Cq), 152.8 (Cq), 147.8 (CH), 142.0 (Cq), 139.5 (CH), 
138.8 (CH), 127.8 (CH), 126.2 (CH), 124.5 (Cq), 122.8 (CH), 118.6 (CH), 118.6 (CH), 111.6 (CH), 
60.3 (CH2), 21.4 (CH3), 14.2 (CH3).  
 
IR (ATR): 2980, 1709, 1316, 1234, 1172, 1103, 1029, 781 cm-1. 
 
MS (EI) m/z (relative intensity) 282 (40) [M+ ], 254 (45), 238 (35), 210 (100), 194 (20), 182 (25), 167 
(35), 78 (35).  
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The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101a) (82.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol%), KPF6 (43.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.00 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189ab (164 mg, 81%) as a white 
solid.  
 
M.p.: = 114-115 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.02 (d, J = 8.0 Hz, 2H), 7.81 (ddt, J = 8.3, 7.2, 1.0 Hz, 2H), 
7.52 (d, J = 7.4 Hz, 1H), 7.41 (d, J = 8.0 Hz, 2H), 7.24–7.15 (m, 3H), 7.07–6.96 (m, 2H), 3.02 
(s, 3H), 2.37 (s, 3H), 2.34 (s, 3H). 
 
13C-NMR (150 MHz, CDCl3): δ = 175.0 (Cq), 165.1 (Cq), 147.7 (Cq), 144.3 (CH), 138.3 (Cq), 
137.3 (Cq), 133.7 (CH), 132.0 (Cq), 130.4 (Cq), 130.2 (CH), 129.4 (CH), 129.3 (CH), 129.2 
(CH), 128.1 (CH), 127.1 (CH), 120.4 (Cq), 44.0 (CH3), 21.7 (CH3), 19.7 (CH3). 
 
IR (ATR): 2925, 1763, 1671, 1609, 1406, 1309, 1173, 1020, 755 cm-1. 
 
MS (EI) m/z (relative intensity) 407 (60) [M+], 287 (100), 138 (50), 149 (30). 
 
HR-MS (ESI): m/z for C23H21NO4S [M+H
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The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101b) (82.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189ab (145 mg, 74%) as a white 
solid. 
 
M.p.: = 125-126 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.17 (d, J = 7.2 Hz, 2H), 7.80 (d, J = 7.5 Hz, 2H), 7.59 (ddt, 
J = 8.2, 7.2, 1.0 Hz, 2H), 7.54 (d, J = 7.4 Hz, 2H), 7.46 (dd, J = 7.6, 0.9 Hz, 2H), 7.39–7.35 
(m, 2H), 7.27 (dd, J = 8.4, 7.4 Hz, 1H), 3.06 (s, 3H), 2.42 (s, 3H). 
 
 13C-NMR (150 MHz, CDCl3): δ = 174.6 (Cq), 164.8 (Cq), 147.4 (Cq), 138.0 (Cq), 137.2 (Cq), 
133.5 (CH), 133.4 (CH), 131.8 (Cq), 130.1 (CH), 129.5 (Cq), 129.3 (CH), 129.1 (CH), 128.4 
(CH), 128.0 (CH), 126.8 (CH), 120.1 (CH), 43.9 (CH3), 19.7 (CH3).  
 
IR (neat): 2925, 1731, 1627, 1577, 1446, 1245, 1128, 1019, 835 cm-1. 
 
MS (EI) m/z (relative intensity) 393 (45) [M+], 279 (100), 178 (60), 148 (25). 
 
HR-MS (ESI): m/z for C22H19NO4S [M+H
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The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101d) (91.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189ad (156 mg, 74%) as a white 
solid. 
 
M.p.: = 110_112 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.13 (d, J = 8.7 Hz, 2H), 7.84 (d, J = 7.4 Hz, 2H), 7.57 (ddt, 
J = 8.7, 7.4, 1.2 Hz, 2H), 7.41 (dd, J = 8.5, 7.4 Hz, 2H), 7.30–7.23 (m, 2H), 7.08 (d, J = 7.4 
Hz, 1H), 7.04 (d, J = 8.2 Hz, 2H), 3.84 (s, 3H), 3.08 (s, 3H), 2.42 (s, 3H). 
 
13C-NMR (150 MHz, CDCl3): δ = 175.0 (Cq), 164.8 (Cq), 163.8 (Cq), 147.7 (Cq), 138.3 (Cq), 
137.2 (Cq), 133.7 (CH), 132.4 (CH), 132.0 (Cq), 129.4 (CH), 129.2 (CH), 128.0 (CH), 127.1 
(CH), 122.0 (Cq), 120.4 (CH), 113.8 (CH), 55.5 (CH3), 44.0 (CH3), 19.7 (CH3). 
 
IR (ATR): 2943, 1730, 1508, 1246, 1178, 1066, 917, 766 cm-1. 
 
MS (EI) m/z (relative intensity) 423 (50) [M+], 279 (100), 145 (50), 122 (20). 
 
HR-MS (ESI): m/z for C23H21NO5S [M+H
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The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101e) (82.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189ae (164 mg, 81%) as a white 
solid. 
 
M.p.: = 111-113 °C.  
 
1H-NMR (600 MHz, CDCl3): δ = 8.24 (d, J = 8.5 Hz, 2H), 7.84 (d, J = 7.3 Hz, 2H), 7.67 (d, J 
= 8.5 Hz, 2H), 7.64–7.60 (m, 2H), 7.52 (dd, J = 8.4, 1.4 Hz, 1H), 7.47 (dd, J = 8.3, 1.3 Hz, 
2H), 7.42–7.37 (m, 3H), 7.29 (dd, J = 8.4, 1.4 Hz, 1H), 7.14–7.06 (m, 2H), 3.12 (s, 3H), 2.45 
(s, 3H).  
 
13C-NMR (150 MHz, CDCl3): δ = 174.6 (Cq), 164.7 (Cq), 147.5 (Cq), 145.9 (Cq), 139.5 (Cq), 
138.1 (Cq), 137.2 (Cq), 133.5 (CH), 131.8 (Cq), 130.7 (CH), 130.0 (CH), 129.5 (CH), 129.3 
(CH), 129.0 (CH), 128.8 (CH), 128.2 (Cq), 128.0 (CH), 127.1 (CH), 126.8 (CH), 126.8 (CH), 
44.0 (CH3), 19.7 (CH3). 
 
IR (ATR): 2927, 1762, 1624, 1476, 1447, 1305, 1147, 1050, 920 cm-1. 
 
MS (EI) m/z (relative intensity) 469 (55) [M+], 286 (100), 124 (60), 146 (30). 
 
HR-MS (ESI): m/z for C28H23N2O4S [M+H
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The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101g) (82.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189ag (145 mg, 68%) as a white 
solid. 
 
M.p.: = 125-126 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.25 (d, J = 8.6 Hz, 2H), 8.21 (d, J = 8.6 Hz, 1H), 7.85–7.82 
(m, 2H), 7.61 (dt, J = 8.1, 0.8 Hz, 1H), 7.45 (dd, J = 7.4, 1.4 Hz, 2H), 7.30 (t, J = 7.4 Hz, 1H), 
7.13 (d, J = 7.4 Hz, 2H), 7.08 (d, J = 7.4 Hz, 1H), 3.21 (s, 3H), 2.45 (s, 3H). 
 
 13C-NMR (150 MHz, CDCl3): δ = 174.2 (Cq), 163.2 (Cq), 150.5 (Cq), 147.4 (Cq), 138.1 (Cq), 
137.3 (Cq), 134.9 (Cq), 133.7 (CH), 131.4 (Cq), 131.2 (CH), 129.4 (CH), 129.3 (CH), 128.4 
(CH), 126.8 (CH), 123.4 (CH), 120.0 (CH), 44.2 (CH3), 19.8 (CH3). 
 
IR (ATR): 2925, 1764, 1681, 1609, 1446, 1308, 1172, 1019, 836 cm-1. 
 
MS (EI) m/z (relative intensity) 438 (60) [M+], 288 (100), 159 (50), 119 (15). 
 
HR-MS (ESI): m/z for C22H18N2O6S [M+H
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Synthesis of N-[2-{4-(Ethoxy)benzoyloxy-6-methyl}]-S-methyl-S-phenylsulfoximine 
(189av): 
 
The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101v) (82.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189av (142 mg, 64%) as a white 
solid. 
 
M.p.: = 106-107 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.11 (d, J = 8.8 Hz, 2H), 7.83 (d, J = 7.4 Hz, 2H), 7.57 (ddt, 
J = 8.0, 1.6, 0.9, Hz, 1H), 7.44 (dd, J = 7.6, 0.6 Hz, 2H), 7.26 (t, J = 7.9 Hz, 1H), 7.08 (dd, J = 
7.7, 0.9 Hz, 1H), 7.03 (dd, J = 8.1, 2.1 Hz, 1H), 6.90 (d, J = 8.8 Hz, 2H), 4.07 (q, J = 7.0 Hz, 
2H), 3.08 (s, 3H), 2.42 (s, 3H), 1.41 (t, J = 7.0 Hz, 3H). 
 
 13C-NMR (126 MHz, CDCl3): δ = 174.8 (Cq), 164.6 (Cq), 163.1 (Cq), 147.6 (Cq), 138.2 (Cq), 
137.1 (Cq), 133.5 (CH), 132.2 (CH), 131.8 (Cq), 129.3 (CH), 129.1 (CH), 127.8 (CH), 126.7 
(CH), 121.6 (Cq), 120.3 (CH), 114.2 (CH), 63.8 (CH2), 44.0 (CH3), 20.0 (CH3), 14.7 (CH3). 
 
IR (ATR): 2936, 1745, 1607, 1462, 1348, 1264, 1130, 976 cm-1. 
 
MS (EI) m/z (relative intensity) 437 (55) [M+], 296 (100), 132 (50), 112 (35). 
 
HR-MS (ESI): m/z for C24H23NO5S [M+H















The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101d) (114.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189ad (164.0 mg, 81%) as a white 
solid. 
 
M.p.: = 88-89 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 8.00 (d, J = 8.1 Hz, 2H), 7.84 (d, J = 8.1 Hz, 2H), 7.60–7.55 
(m, 3H), 7.46 (d, J = 7.9 Hz, 2H), 7.33 (ddt, J = 8.3, 2.4, 1.2 Hz, 1H), 7.15–7.10 (m, 1H), 7.06 
(dd, J = 8.1, 1.1 Hz, 1H), 3.16 (s, 3H), 2.45 (s, 3H). 
 
 13C-NMR (126 MHz, CDCl3): δ = 174.3 (Cq), 163.7 (Cq), 147.4 (Cq), 138.0 (Cq), 137.2 (q, 
1JC-F = 238 Hz, Cq), 134.4 (q, 
2JC-F = 35 Hz, Cq), 133.5 (CH), 132.7 (Cq), 131.5 (Cq), 130.5 
(CH), 129.4 (q, 3JC-F = 10 Hz, CH), 129.2 (CH), 128.2 (CH), 126.7 (CH), 125.2 (q, 
4JC-F = 4 
Hz, CH), 120.0 (CH), 44.0 (CH3), 19.8 (CH3). 
 
19F-NMR (283 MHz, CDCl3): δ = -63.1 (s). 
 
IR (ATR): 2936, 1727, 1579, 1421, 1222, 1166, 1064, 977, 763 cm-1. 
 
MS (EI) m/z (relative intensity) 461 (70) [M+], 286 (100), 169 (50), 181 (40). 
 
HR-MS (ESI): m/z for C23H18F3NO4S [M+H
+]    calcd.: 462.0942. 
found: 462.0946.  
 
Analytical Data 
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The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101c) (82.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189ac (115 mg, 54%) as a white 
solid. 
 
M.p.: = 125-126 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.83 (dd, J = 7.4, 0.9 Hz, 1H), 8.45 (d, J = 7.2 Hz, 1H), 8.38 
(dd, J = 7.4, 0.9, Hz, 1H), 7.84 (d, J = 7.6 Hz, 2H), 7.62 (d, J = 7.2 Hz, 1H), 7.57–7.54 (m, 
1H), 7.46 (d, J = 7.2 Hz, 2H), 7.32 (dd, J = 7.4, 1.1 Hz, 1H), 7.14 (dt, J = 7.6, 0.9 Hz, 1H), 7.07 
(ddd, J = 8.1, 1.1, 0.6 Hz, 1H), 3.24 (s, 3H), 2.46 (s, 3H). 
 
 13C-NMR (150 MHz, CDCl3): δ = 174.4 (Cq), 164.2 (Cq), 147.4 (Cq), 138.1 (Cq), 137.2 (Cq), 
133.6 (CH), 131.8 (CH), 131.6 (Cq), 129.5 (CH), 129.3 (Cq), 129.2 (CH), 128.4 (CH), 128.3 
(Cq), 128.1 (CH), 126.8 (CH), 120.1 (CH), 44.1 (CH3), 19.8 (CH3). 
 
IR (ATR): 2983, 1770, 1605, 1509, 1422, 1315, cm-1. 
 
MS (EI) m/z (relative intensity) 427 (55) [M+], 246 (100), 121 (50), 182 (30). 
 
HR-MS (ESI): m/z for C19H18NO3 [M+H
+]    calcd.: 428.0616. 
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The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101t) (82.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189at (115.0 mg, 69%) as a white 
solid. 
 
M.p.: = 105_106 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.16 (d, J = 8.7 Hz, 2H), 7.78 (dd, J = 8.5, 1.3 Hz, 2H), 7.55–
7.51 (m, 1H), 7.37 (dd, J = 8.3, 0.9 Hz, 2H), 7.27 (t, J = 7.7 Hz, 1H), 7.16 (d, J = 8.7 Hz, 2H), 
7.09 (d, J = 7.7 Hz, 1H), 7.03 (dd, J = 8.3, 0.9 Hz, 1H), 3.10 (s, 3H), 2.43 (s, 3H), 2.30 (s, 3H). 
 
 13C-NMR (126 MHz, CDCl3) δ = 174.5 (Cq), 168.5 (Cq), 164.0 (Cq), 154.5 (Cq), 147.3 (Cq), 
138.0 (Cq), 137.1 (Cq), 133.6 (CH), 131.7 (Cq), 131.7 (CH), 129.3 (CH), 129.1 (CH), 128.0 
(CH), 127.0 (Cq), 126.7 (CH), 121.7 (CH), 120.1 (CH), 44.0 (CH3), 21.1 (CH3), 19.7 (CH3). 
 
IR (ATR): 2925, 1760, 1705, 1612, 1577, 1454, 1318, 1215, 1106, 990 cm-1. 
 
MS (EI) m/z (relative intensity) 451 (55) [M+], 281 (100), 197 (60), 168 (25). 
 
HR-MS (ESI): m/z for C24H21NO6S [M+H
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The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101w) (116 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189aw (131 mg, 56%) as a white 
solid. 
 
M.p.: = 106-108 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.25 (d, J = 7.8 Hz, 1H), 8.09 (dd, J = 7.8, 1.0 Hz, 1H), 7.83 
(d, J =7.8, 2H), 7.69 (dd, J = 8.0, 1.0 Hz, 1H), 7.57 (dd, J = 8.0, 1.2 Hz, 1H), 7.46 (dt, J = 7.6, 
0.9 Hz, 2H), 7.30 (dt, J = 8.3, 7.5 Hz, 2H), 7.12 (d, J = 7.6, 0.9 Hz, 1H), 7.03 (dt, J = 8.1, 0.8 
Hz, 1H), 3.16 (s, 3H), 2.45 (s, 3H). 
 
 13C-NMR (125 MHz, CDCl3): δ = 174.6 (Cq), 163.8 (Cq), 147.5 (Cq), 138.2 (Cq), 137.6 (Cq), 
136.3 (CH), 133.8 (CH), 133.1 (CH), 131.7 (Cq), 131.6 (Cq), 130.1 (CH), 129.5 (CH), 128.4 
(CH), 126.9 (CH), 122.5 (Cq), 120.2 (CH), 44.1 (CH3), 19.8 (CH3). 
 
 IR (ATR): 2926, 1731, 1519, 1447, 1280, 1194, 1129, 1066, 918, 674 cm-1. 
 
MS (EI) m/z (relative intensity) 471 (40) [79Br, M+], 373 (40) [81Br, M+], 471 (55) [M+], 269 
(100), 184 (65), 112 (45). 
 
HR-MS (ESI): m/z for C22H18BrNO4S [M+H
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Synthesis of N-[2-{4-(Benzoyloxy)benzoyloxy-6-methyl}]-S-methyl-S-phenylsulfoximine 
(189au): 
 
The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101u) (120 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189au (131 mg, 56%) as a white 
solid. 
 
M.p.: = 104-105 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.17 (d, J = 8.6, Hz, 2H), 7.84 (d, J = 8.6, Hz, 2H), 7.54 
(dd, J = 7.6, 1.0 Hz, 1H), 7.45–7.35 (m, 6H), 7.30 (ddt, J = 8.0, 2.3, 1.0 Hz, 1H), 7.14 (dd, J 
= 7.4, 0.8 Hz, 2H), 7.03–6.98 (m, 3H), 5.14 (s, 2H), 3.09 (s, 3H), 2.44 (s, 3H). 
 
 13C-NMR (126 MHz, CDCl3): δ = 174.6 (Cq), 164.4 (Cq), 162.6 (Cq), 147.4 (Cq), 137.9 (Cq), 
136.9 (Cq), 135.8 (CH), 133.4 (CH), 132.1 (Cq), 131.8 (CH), 129.1 (Cq), 128.9 (CH), 128.4 
(CH), 127.9 (CH), 127.7 (Cq), 127.2 (CH), 126.7 (CH), 121.8 (CH), 120.1 (CH), 114.5 (CH), 
70.0 (CH2), 43.8 (CH3), 19.6 (CH3). 
 
IR (ATR): 2925, 1763, 1621, 1570, 1446, 1308, 1209, 1132, 976 cm-1. 
 
MS (EI) m/z (relative intensity) 499 (55) [M+], 216 (100), 124 (60), 137 (30). 
 
HR-MS (ESI): m/z for C29H25NO5S [M+H
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Synthesis of N-[2-(4-Thienoyl-3-oxy-6-methyl)]-S-methyl-S-phenylsulfoximine (189ao): 
 
The representative procedure G was followed using sulfoximine benzamide (180a) (137 mg, 
0.50 mmol), carboxylic acid (101o) (77.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189ao (144 mg, 72%) as a colourless 
oil. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.26 (dd, J = 8.1, 1.3 Hz, 1H), 7.87–7.90 (m, 2H), 7.61 (dd, 
J = 7.3, 1.3 Hz, 1H), 7.58 (dd, J = 7.4, 1.3 Hz, 1H), 7.46–7.42 (m, 2H), 7.31 (dd, J = 7.3, 1.3 
Hz, 1H), 7.29 (d, 7.5, 2.3, 1H), 7.09 (dd, J = 7.7, 1.0 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 3.13 (s, 
3H), 2.43 (s, 3H). 
 
 13C-NMR (150 MHz, CDCl3): δ = 174.7 (Cq), 160.8 (Cq), 147.3 (Cq), 138.3 (Cq), 137.2 (Cq), 
134.1 (CH), 133.6 (CH), 133.0 (Cq), 131.8 (Cq), 129.4 (CH), 129.1 (CH), 128.2 (CH), 128.0 
(CH), 126.9 (CH), 126.2 (CH), 120.2 (CH), 44.1(CH3), 19.8 (CH3). 
 
IR (ATR): 2926, 1761, 1715, 1446, 1302, 1147, 976, 686 cm-1. 
 
MS (EI) m/z (relative intensity) 399 (50) [M+], 268 (100), 137 (50), 158 (40). 
 
HR-MS (ESI): m/z for C20H17NO4S [M+H
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Synthesis of N-[2-(4-Methylbenzoyloxy)]-S-methyl-S-phenylsulfoximine (189ba): 
 
The representative procedure G was followed using sulfoximine benzamide (180b) (130 mg, 
0.50 mmol), carboxylic acid (101a) (82.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189ba (119 mg, 61%) as a white 
solid. 
 
M.p.: = 111-113 °C. 
 
1H-NMR (500 MHz, CDCl3): δ = 8.11–8.09 (dd, J = 8.6, 2.0, Hz, 1H), 8.07 (dd, J = 7.8, 1.4 
Hz, 1H), 7.86 (dd, J = 7.8, 1.2, Hz, 1H), 7.57 (d, J = 6.9. 0.9, Hz, 1H), 7.53–7.51 (m, 1H), 7.50 
(d, 7.3, 0.9, 1H), 7.31 (ddt, 8.3, 1.7, 0.9, 3H), 7.22 (d, J = 7.1 Hz, 1H), 7.16 (dd, J = 8.1, 1.2 
Hz, 2H), 2.88 (s, 3H), 2.40 (s, 3H).  
 
13C-NMR (126 MHz, CDCl3): δ = 172.6 (Cq), 165.6 (Cq), 150.1 (Cq), 144.1 (Cq), 138.4 (Cq), 
133.5 (CH), 132.7 (CH), 131.9 (CH), 130.4 (CH), 129.5 (Cq), 129.2 (CH), 129.1 (CH), 127.3 
(Cq), 127.1 (CH), 125.9 (CH), 123.5 (CH), 44.0 (CH3), 21.7 (CH3). 
 
IR (ATR): 2926, 1737, 1603, 1503, 1413, 1369, 1268, 1159, 1066, 975 cm-1. 
 
MS (EI) m/z (relative intensity) 393 (65) [M+], 214 (100), 181 (60), 112 (25). 
 
HR-MS (ESI): m/z for C22H19NO4S [M+H
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Synthesis of N-[2-(4-Methoxybenzoyloxy)]-S-methyl-S-phenylsulfoximine (189bd): 
 
The representative procedure G was followed using sulfoximine benzamide (180b) (130 mg, 
0.50 mmol), carboxylic acid (101d) (77.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189bd (125 mg, 63%) as a white 
solid. 
 
M.p.: = 107-109 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.83 (dd, J = 8.4, 0.8 Hz, 1H), 8.46 (dd, J = 8.4, 0.8 Hz, 1H), 
8.37 (ddd, J = 8.3, 2.4, 1.1 Hz, 1H), 7.85–7.81 (m, 2H), 7.64 (d, J = 7.8, 0.9 Hz, 1H), 7.47–
7.42 (m, 2H), 7.32 (dd, J = 8.0, 1.0, Hz, 1H), 7.14 (d, J = 7.8, 0.9 Hz, 2H), 7.07 (dd, J = 7.8, 
1.0 Hz, 1H), 3.24 (s, 3H), 2.46 (s, 3H).  
 
13C-NMR (126 MHz, CDCl3): δ = 174.3 (Cq), 163.0 (Cq), 148.1 (Cq), 147.5 (Cq), 138.1 (Cq), 
137.6 (Cq), 136.0 (CH), 133.7 (CH), 131.3 (Cq), 130.0 (CH), 129.4 (CH), 128.6 (CH), 127.5 
(CH), 126.8 (CH), 125.0 (CH), 120.1 (CH), 44.2 (CH3), 20.0 (CH3). 
 
IR (ATR): 2938, 1713, 1605, 1462, 1405, 1274, 1188, 1020, 920 cm-1. 
 
MS (EI) m/z (relative intensity) 409 (55) [M+], 292 (100), 128 (60), 139 (30). 
 
HR-MS (ESI): m/z for C22H19NO5S [M+H
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Synthesis of N-[2-(4-Methylbenzoyloxy-4-methyl)]-S-methyl-S-phenylsulfoximine 
(189ca): 
 
The representative procedure G was followed using sulfoximine benzamide (180c) (130 mg, 
0.50 mmol), carboxylic acid (101a) (77.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189ca (128 mg, 63%) as a white 
solid. 
 
M.p.: = 102-103 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 8.11 (d, J = 7.4 Hz, 2H), 7.86 (d, J = 7.6 Hz, 2H), 7.57–7.54 
(m, 1H), 7.44 (dd, J = 8.1, 1.0 Hz, 2H), 7.29–7.26 (m, 3H), 7.12–7.04 (d, J = 7.6 Hz, 2H), 3.09 
(s, 3H), 2.44 (s, 3H), 2.42 (s, 3H). 
 
 13C-NMR (75 MHz, CDCl3) δ = 173.5 (Cq), 164.5 (Cq), 147.5 (Cq), 144.5 (Cq), 138.3 (Cq), 
137.2 (CH), 133.6 (CH), 131.9 (Cq), 130.7 (Cq), 130.2 (CH), 129.4 (CH), 129.3 (Cq), 129.2 
(CH), 128.1 (CH), 127.1 (CH), 126.9 (CH), 43.7 (CH3), 21.9 (CH3), 20.1 (CH3). 
 
IR (ATR): 2924, 1772, 1615, 1517, 1401, 1306, 1218, 1026, 919, 753 cm-1. 
 
MS (EI) m/z (relative intensity) 407 (40) [M+], 258 (100), 181 (65), 125 (30). 
 
HR-MS (ESI): m/z for C23H21NO4S [M+H
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Synthesis of N-[2-(4-Bromobenzoyloxy-4-methyl)]-S-methyl-S-phenylsulfoximine 
(189cw): 
 
The representative procedure G was followed using sulfoximine benzamide (180c) (137 mg, 
0.50 mmol), carboxylic acid (101w) (119 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189cw (136.0 mg, 58%) as a white 
solid. 
 
M.p.: = 103-105 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 7.92–7.89 (m, 3H), 7.70 (dd, J = 7.6, 1.0 Hz, 2H), 7.52–7.49 
(m, 3H), 7.35 (dd, J = 7.9, 1.1 Hz, 2H), 7.02 (dd, J = 7.6, 1.0 Hz, 2H), 2.95 (s, 3H), 2.41 (s, 
3H). 
 
 13C-NMR (125 MHz, CDCl3): δ = 170.6 (Cq), 164.2 (Cq), 149.1 (Cq), 144.0 (Cq), 141.5 (Cq), 
137.8 (CH), 133.4 (CH), 132.0 (CH), 131.0 (CH), 131.6 (CH), 129.1 (CH), 128.5 (Cq), 128.0 
(Cq), 126.9 (CH), 122.0 (Cq), 121.7 (CH), 43.7 (CH3), 21.5 (CH3). 
 
IR (neat): 2925, 1764, 1608, 1576, 1426, 1308, 1216, 1139, 1019, 755 cm-1. 
 
MS (EI) m/z (relative intensity) 471 (45) [79Br, M+], 373 (40) [81Br, M+], 294 (100), 261 (60), 
159 (25). 
 
HR-MS (ESI): m/z for C22H18BrNO4S [M+H
+]    calcd.: 472.0140. 
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Synthesis of N-[2-(4-Nitrobenzoyloxy-4-methyl)]-S-methyl-S-phenylsulfoximine (189cg): 
 
The representative procedure G was followed using sulfoximine benzamide (180c) (137 mg, 
0.50 mmol), carboxylic acid (101g) (100 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 5.0 
mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 10/3) yielded 189cg (140 mg, 64%) as a white solid. 
 
M.p.: = 96-97 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.26–8.24 (m, 2H), 8.22–8.19 (m, 2H), 7.83 (dt, J = 7.2, 1.3 
Hz, 2H), 7.58 (td, J = 7.4, 1.3 Hz, 1H), 7.46 (dd, J = 7.1, 1.4 Hz, 2H), 7.30 (t, J = 7.9 Hz, 1H), 
7.13 (d, J = 7.7 Hz, 1H), 7.08 (d, J = 8.1 Hz, 1H), 3.21 (s, 3H), 2.45 (s, 3H). 
 
 13C-NMR (125 MHz, CDCl3): δ = 174.3 (Cq), 163.2 (Cq), 150.5 (Cq), 147.4 (Cq), 138.1 (Cq), 
137.4 (Cq), 134.9 (Cq), 133.7 (CH), 131.4 (CH), 131.2 (Cq), 129.4 (CH), 129.3 (CH), 128.4 
(CH), 126.8 (CH), 123.4 (CH), 120.0 (CH), 44.2 (CH3), 20.0 (CH3). 
 
IR (ATR): 2928, 1734, 1605, 1510, 1447, 1280, 1218, 1096, 976, 763 cm-1. 
 
MS (EI) m/z (relative intensity) 438 (75) [M+], 229 (100), 169 (50), 118 (25). 
 
HR-MS (ESI): m/z for C22H18N2O6S [M+H
+]    calcd.: 439.0886 
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Synthesis of N-[2-(4-Methylbenzoyloxy-4-methoxy)]-S-methyl-S-phenylsulfoximine (189da): 
 
The representative procedure G was followed using sulfoximine benzamide (180d) (145 mg, 
0.50 mmol), carboxylic acid (101a) (82.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189da (129 mg, 61%) as a white 
solid. 
 
M.p.: = 110-111 °C. 
 
1H-NMR (600 MHz, CDCl3) δ = 8.08 (d, J = 8.6, 3H), 7.79 (dd, J = 7.4, 0.9 Hz, 2H), 7.36 (dd, 
J = 7.4, 1.0 Hz, 2H), 7.21 (dd, J = 7.4, 0.9 Hz, 2H), 6.89 (d, J = 7.4 Hz, 2H), 6.87 (d, J = 7.4 
Hz, 1H), 3.85 (s, 3H), 2.95 (s, 3H), 1.54 (s, 3H). 
 
 13C-NMR (150 MHz, CDCl3) δ = 171.0 (Cq), 164.4 (Cq), 163.6 (Cq), 149.1 (Cq), 138.1 (Cq), 
137.5 (Cq), 133.3 (CH), 132.4 (CH), 130.0 (Cq), 127.0 (CH), 125.0 (CH), 125.6 (Cq), 121.7 
(CH), 120.7 (CH), 120.4 (CH), 113.7 (CH), 55.5 (CH3), 44.0 (CH3), 21.0 (CH3). 
 
IR (ATR): 2936, 1745, 1624, 1530, 1416, 1350, 1254, 1116, 976, 784 cm-1. 
 
MS (EI) m/z (relative intensity) 423 (75) [M+], 159 (100), 135 (70), 128 (30). 
 
HR-MS (ESI): m/z for C23H21NO5S [M+H
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Synthesis of N-[2-(4-Methylbenzoyloxy-5-methyl)]-S-methyl-S-phenylsulfoximine 
(189ea): 
 
The representative procedure G was followed using 3 sulfoximine benzamide (180e) (137 mg, 
0.50 mmol), carboxylic acid (101a) (82.0 mg, 0.60 mmol), [{RuCl2(p-cymene)}2] (15.3 mg, 
5.0 mol %), KPF6 (46.0 mg, 50 mol %) and (NH4)2S2O8 (114 mg, 1.0 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/3) yielded 189ea (123 mg, 61%) as a white 
solid. 
 
M.p.: = 110-111 °C. 
 
1H-NMR (600 MHz, CDCl3): δ = 8.02 (d, J = 7.8 Hz, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.78 (d, J 
= 6.3 Hz, 1H), 7.75 (d, J = 8.3 Hz, 1H), 7.52 (dd, J = 8.3, 1.2 Hz,  2H), 7.37–7.30 (m, 1H), 
7.24 (s, 1H), 7.22 (J = 8.3 Hz, 2H), 7.01 (dd, J = 7.6, 0.9 Hz, 2H), 3.02 (s, 3H), 2.36 (s, 3H), 
2.34 (s, 3H).  
 
13C-NMR (125 MHz, CDCl3): δ = 174.5 (Cq), 165.1 (Cq), 147.7 (Cq), 144.2 (Cq), 138.3 (Cq), 
137.3 (Cq), 133.7 (Cq), 132.0 (CH), 130.4 (CH), 129.5 (CH), 129.0 (Cq), 129.2 (CH), 128.1 
(CH), 127.1 (CH), 126.9 (CH), 120.3 (CH), 44.0 (CH3), 21.7 (CH3), 20.0 (CH3). 
 
 IR (ATR): 2924, 1742, 1626, 1524, 1410, 1215, 1126, 1016, 830, 684 cm-1. 
 
MS (EI) m/z (relative intensity) 407 (45) [M+], 152 (100), 135 (45), 222 (35). 
 
HR-MS (ESI): m/z for C23H21NO4S [M+H
+]    calcd.: 408.1191 
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N-[2-(4-Methylbenzoyloxy-4-methoxy)]-S-methyl-S-phenylsulfoximine (189db) (211 mg, 
0.50 mmol) was dissolved in aqueous HCl (12 N, 5.0 mL) and stirred at 80 °C for 48 h. The 
reaction mixture was extracted with CH2Cl2, and aqueous layer was basified with 40% NaOH 
and extracted with CH2Cl2. The organic layer was washed with brine, dried over Na2SO4, and 
concentrated under vacuum to give sulfoximine 202 (130 mg, 74%) as a colorless liquid dried 
over Na2SO4, and concentrated under vacuum to give the corresponding 4-methoxy-2-hydroxy 
benzoic acid 190a (139 mg, 71%). 
 
M.p.: = 152-153 °C. 
 
1H-NMR (600 MHz, DMSO-d6): δ = 7.70 (dd, J = 8.6, 0.6 Hz, 1H), 6.48 (dd, J = 8.6, 2.5 Hz, 
1H), 6.46 (dd, J = 2.5, 0.6 Hz, 1H), 3.78 (s, 3H). 
 
 13C-NMR (126 MHz, DMSO-d6): δ = 171.6 (Cq), 164.9 (Cq), 163.2 (Cq), 131.4 (CH), 106.8 
(Cq), 105.5 (CH), 100.6 (CH), 55.4 (CH3). 
 
 
IR (ATR): 3415, 2976, 1356, 1271, 1139, 1093, 964 cm-1. 
 
MS (EI) m/z (relative intensity) 167 (40) [M+], 110 (100), 67 (35). 
 
HR-MS (ESI): m/z for C8H8O4 [M+H
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N-[2-(4-Methylbenzoyloxy-6-methyl)]-S-methyl-S-phenylsulfoximine (189aa) (183 mg, 0.50 
mmol) was dissolved in aqueous HCl (12 N, 5.0 mL) and stirred at 80 °C for 48 h. The reaction 
mixture was extracted with CH2Cl2, and aqueous layer was basified with 40% NaOH and 
extracted with CH2Cl2. The organic layer was washed with brine, dried over Na2SO4, and 
concentrated under vacuum to give sulfoximine 202 (130 mg, 74%) as a colorless liquid dried 
over Na2SO4, and concentrated under vacuum to give the corresponding o-hydroxy benzoic 
acid 190b (119 mg, 71%). 
 
M.p.: = 158-159 °C. 
 
1H-NMR (600 MHz, DMSO-d6): δ = 7.82 (dd, J = 8.0, 1.7 Hz, 1H), 7.47 (ddd, J = 8.0, 7.2, 1.7 
Hz, 1H), 6.93 (dd, J = 8.3, 1.1 Hz, 1H), 6.89 (ddd, J = 8.3, 7.2, 1.1 Hz, 1H). 
 
13C-NMR (126 MHz, DMSO-d6): δ = 171.7 (Cq), 161.1 (Cq), 135.4 (CH), 130.1 (CH), 119.0 
(CH), 117.0 (CH), 113.0 (Cq). 
 
 
IR (ATR): 3250, 1750, 1500, 1250, 1129, 1036, 964 cm-1. 
 
MS (EI) m/z (relative intensity) 137 (35) [M+], 105 (100), 69 (35). 
 
HR-MS (ESI): m/z for C7H6O3 [M+H
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